WO2004009618A2 - Recombinant production of mixtures of antibodies - Google Patents
Recombinant production of mixtures of antibodies Download PDFInfo
- Publication number
- WO2004009618A2 WO2004009618A2 PCT/EP2003/007690 EP0307690W WO2004009618A2 WO 2004009618 A2 WO2004009618 A2 WO 2004009618A2 EP 0307690 W EP0307690 W EP 0307690W WO 2004009618 A2 WO2004009618 A2 WO 2004009618A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibodies
- mixture
- nucleic acid
- light chain
- host cell
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 327
- 238000004519 manufacturing process Methods 0.000 title claims description 88
- 238000000034 method Methods 0.000 claims abstract description 195
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 135
- 230000027455 binding Effects 0.000 claims abstract description 99
- 238000009739 binding Methods 0.000 claims abstract description 96
- 239000000427 antigen Substances 0.000 claims abstract description 86
- 108091007433 antigens Proteins 0.000 claims abstract description 85
- 102000036639 antigens Human genes 0.000 claims abstract description 85
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 49
- 230000014509 gene expression Effects 0.000 claims description 77
- 108090000623 proteins and genes Proteins 0.000 claims description 60
- 102000004169 proteins and genes Human genes 0.000 claims description 48
- 230000009261 transgenic effect Effects 0.000 claims description 42
- 108020004707 nucleic acids Proteins 0.000 claims description 38
- 102000039446 nucleic acids Human genes 0.000 claims description 38
- 238000003556 assay Methods 0.000 claims description 37
- 241001465754 Metazoa Species 0.000 claims description 32
- 238000011282 treatment Methods 0.000 claims description 27
- 230000000694 effects Effects 0.000 claims description 24
- 238000012258 culturing Methods 0.000 claims description 23
- 108060003951 Immunoglobulin Proteins 0.000 claims description 19
- 238000002825 functional assay Methods 0.000 claims description 19
- 102000018358 immunoglobulin Human genes 0.000 claims description 19
- 238000012216 screening Methods 0.000 claims description 18
- 238000004113 cell culture Methods 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 229940072221 immunoglobulins Drugs 0.000 claims description 10
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 9
- 230000003321 amplification Effects 0.000 claims description 8
- 238000003745 diagnosis Methods 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 239000000539 dimer Substances 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 210000001525 retina Anatomy 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 description 411
- 238000001155 isoelectric focusing Methods 0.000 description 47
- 235000018102 proteins Nutrition 0.000 description 41
- 239000006228 supernatant Substances 0.000 description 37
- 238000002965 ELISA Methods 0.000 description 33
- 108090000765 processed proteins & peptides Proteins 0.000 description 32
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 30
- 239000002609 medium Substances 0.000 description 29
- 238000001890 transfection Methods 0.000 description 26
- 108020004414 DNA Proteins 0.000 description 23
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 22
- 238000002823 phage display Methods 0.000 description 22
- 239000013604 expression vector Substances 0.000 description 21
- 102000004196 processed proteins & peptides Human genes 0.000 description 21
- 241000196324 Embryophyta Species 0.000 description 20
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 description 20
- 235000021186 dishes Nutrition 0.000 description 20
- 241000700605 Viruses Species 0.000 description 19
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 19
- 238000011534 incubation Methods 0.000 description 19
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 19
- 102100039373 Membrane cofactor protein Human genes 0.000 description 18
- 238000001042 affinity chromatography Methods 0.000 description 18
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 17
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 17
- 239000002953 phosphate buffered saline Substances 0.000 description 17
- 239000013598 vector Substances 0.000 description 17
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 16
- 102000006354 HLA-DR Antigens Human genes 0.000 description 16
- 108010058597 HLA-DR Antigens Proteins 0.000 description 16
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 description 16
- 239000012737 fresh medium Substances 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 15
- 210000003719 b-lymphocyte Anatomy 0.000 description 15
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 14
- 238000010561 standard procedure Methods 0.000 description 14
- 238000001712 DNA sequencing Methods 0.000 description 13
- 150000001413 amino acids Chemical group 0.000 description 13
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 12
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 102000037865 fusion proteins Human genes 0.000 description 12
- 108020001507 fusion proteins Proteins 0.000 description 12
- 230000002068 genetic effect Effects 0.000 description 11
- 239000013642 negative control Substances 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 102000012804 EPCAM Human genes 0.000 description 10
- 101150084967 EPCAM gene Proteins 0.000 description 10
- 108010029485 Protein Isoforms Proteins 0.000 description 10
- 102000001708 Protein Isoforms Human genes 0.000 description 10
- 101150057140 TACSTD1 gene Proteins 0.000 description 10
- 108700019146 Transgenes Proteins 0.000 description 10
- 230000001143 conditioned effect Effects 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 238000004949 mass spectrometry Methods 0.000 description 10
- 235000013336 milk Nutrition 0.000 description 10
- 239000008267 milk Substances 0.000 description 10
- 210000004080 milk Anatomy 0.000 description 10
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 9
- 230000006907 apoptotic process Effects 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 8
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 8
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 8
- 241001529936 Murinae Species 0.000 description 8
- 238000002105 Southern blotting Methods 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 108090000672 Annexin A5 Proteins 0.000 description 7
- 102000004121 Annexin A5 Human genes 0.000 description 7
- 239000013613 expression plasmid Substances 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 239000000833 heterodimer Substances 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000004098 Tetracycline Substances 0.000 description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
- 229960000723 ampicillin Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 238000010899 nucleation Methods 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229960002180 tetracycline Drugs 0.000 description 6
- 229930101283 tetracycline Natural products 0.000 description 6
- 235000019364 tetracycline Nutrition 0.000 description 6
- 150000003522 tetracyclines Chemical class 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 108700012359 toxins Proteins 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 241000701022 Cytomegalovirus Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 description 5
- 102100029571 Immunoglobulin J chain Human genes 0.000 description 5
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 5
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 5
- 206010037742 Rabies Diseases 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 230000003466 anti-cipated effect Effects 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108010004729 Phycoerythrin Proteins 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 241000276498 Pollachius virens Species 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 241000711798 Rabies lyssavirus Species 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 229960001031 glucose Drugs 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 239000012678 infectious agent Substances 0.000 description 4
- 210000005075 mammary gland Anatomy 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 238000012510 peptide mapping method Methods 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000002702 ribosome display Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dithiothreitol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 244000061176 Nicotiana tabacum Species 0.000 description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 3
- 208000035415 Reinfection Diseases 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 108010052160 Site-specific recombinase Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 238000004115 adherent culture Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000005277 cation exchange chromatography Methods 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000012761 co-transfection Methods 0.000 description 3
- 238000001360 collision-induced dissociation Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002818 protein evolution Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 238000004114 suspension culture Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108030001720 Bontoxilysin Proteins 0.000 description 2
- 101710117542 Botulinum neurotoxin type A Proteins 0.000 description 2
- 102100022002 CD59 glycoprotein Human genes 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 229910052693 Europium Inorganic materials 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000009490 IgG Receptors Human genes 0.000 description 2
- 108010073807 IgG Receptors Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- 108010034949 Thyroglobulin Proteins 0.000 description 2
- 102000009843 Thyroglobulin Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 101710087237 Whey acidic protein Proteins 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000009824 affinity maturation Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000007541 cellular toxicity Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- 108020001096 dihydrofolate reductase Proteins 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 102000044446 human CD46 Human genes 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000002824 mRNA display Methods 0.000 description 2
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000017066 negative regulation of growth Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 229960002175 thyroglobulin Drugs 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- LWTDZKXXJRRKDG-KXBFYZLASA-N (-)-Phaseollin Natural products C1OC2=CC(O)=CC=C2[C@H]2[C@@H]1C1=CC=C3OC(C)(C)C=CC3=C1O2 LWTDZKXXJRRKDG-KXBFYZLASA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 101100519158 Arabidopsis thaliana PCR2 gene Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 0 C(C1)CC2C1CC*2 Chemical compound C(C1)CC2C1CC*2 0.000 description 1
- 229940124292 CD20 monoclonal antibody Drugs 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 244000228088 Cola acuminata Species 0.000 description 1
- 235000010205 Cola acuminata Nutrition 0.000 description 1
- 235000015438 Cola nitida Nutrition 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000606678 Coxiella burnetii Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 108050004280 Epsilon toxin Proteins 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 241000589601 Francisella Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000342334 Human metapneumovirus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000712890 Junin mammarenavirus Species 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241000711828 Lyssavirus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 101710202365 Napin Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 241000526636 Nipah henipavirus Species 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101800005149 Peptide B Proteins 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 240000007377 Petunia x hybrida Species 0.000 description 1
- 101710163504 Phaseolin Proteins 0.000 description 1
- 108700001094 Plant Genes Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 240000000528 Ricinus communis Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002942 anti-growth Effects 0.000 description 1
- 230000001494 anti-thymocyte effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003034 chemosensitisation Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940108471 crofab Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- -1 etc Proteins 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 238000011575 immunodeficient mouse model Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 238000010872 live dead assay kit Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 201000011475 meningoencephalitis Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 108010058731 nopaline synthase Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- LWTDZKXXJRRKDG-UHFFFAOYSA-N phaseollin Natural products C1OC2=CC(O)=CC=C2C2C1C1=CC=C3OC(C)(C)C=CC3=C1O2 LWTDZKXXJRRKDG-UHFFFAOYSA-N 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 244000045561 useful plants Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 201000006266 variola major Diseases 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Definitions
- the present invention relates to the field of medicine, more in particular to the field of production of antibodies, more in particular to the production of mixtures of antibodies.
- the essential function of the immune system is the defence against infection.
- the humoral immune system combats molecules recognized as non-self, such as pathogens, using immunoglobulines.
- immunoglobulines also called antibodies, are raised specifically against the infectious agent, which acts as an antigen, upon first contact (Roitt, Essential Immunology, Blackwell Scientific Publications, fifth edition, 1984; all references cited herein are incorporated in their entirety by reference) .
- Antibodies are multivalent molecules comprising heavy (H) chains and light (L) chains joined with interchain disulfide bonds.
- IgGl IgG2, IgG3, IgG4, IgA, IgD, IgE, and IgM.
- An IgG contains two heavy and two light chains. Each chain contains constant (C) and variable (V) regions, which can be broken down into domains designated C H if C H2 , C H3 , V, and C I , (Fig. 1) .
- Antibody binds to antigen via the variable region domains contained in the Fab portion, and after binding can interact with molecules and cells of the immune system through the constant domains, mostly through the Fc portion.
- B-lymphocytes can produce antibodies in response to exposure to biological substances like bacteria, viruses and their toxic products. Antibodies are generally epitope specific and bind strongly to substances carrying these epitopes.
- the hybridoma technique makes use of the ability of B-cells to produce monoclonal antibodies to specific antigens and to subsequently produce these monoclonal antibodies by fusing B-cells from mice exposed to the antigen of interest to immortalized murine plasma cells.
- This technology resulted in the realization that monoclonal antibodies produced by hybridoma' s could be used in research, diagnostics and therapies to treat different kinds of diseases like cancer and auto-immune related disorders.
- a therapeutic or diagnostic moiety e.g. T-cell, a cytotoxic trigger molecule or a chelator that binds a radionuclide, that is recognized by one variable region of the antibody to a cell that is recognized by the other variable region of the antibody, e.g. a tumor cell (see for bispecific antibodies Segal et al, 2001) .
- phage display libraries One very useful method known in the art to obtain fully human monoclonal antibodies with desirable binding properties employs phage display libraries. This is an in vitro, recombinant DNA-based, approach that mimics key features of the humoral immune response (see for phage display methods e.g. CF Barbas III et al, Phage Display. A laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2001) .
- phage display libraries collections of human monoclonal antibody heavy and light chain variable region genes are expressed on the surface of bacteriophage particles, usually in single chain Fv (scFv) or in Fab format.
- phage display libraries may be constructed from immunoglobulin variable regions that have been partially assembled or rearranged in vitro to introduce additional antibody diversity in the library (semi- synthetic libraries) (De Kruif et al, 1995b) .
- immunoglobulin variable regions contain stretches of synthetically produced, randomized or partially randomized DNA in those regions of the molecules that are important for antibody specificity.
- the genetic information encoding the antibodies identified by phage display can be used for cloning the antibodies in a desired format, e.g. IgG, IgA or IgM, to produce the antibody with recombinant DNA methods (Boel et al, 2000) .
- mice that comprise genetic material encoding a human immunoglobulin repertoire (Fishwild et al, 1996/ Mendez et al, 1997) . Such mice can be immunized with a target antigen, and the resulting immune response will produce fully human antibodies. The sequences of these antibodies can be used in recombinant production methods.
- polyclonal antibodies can also be used for therapeutic applications, e.g. for passive vaccination or for active immunotherapy, and currently are usually derived from pooled serum from immunized animals or from humans who recovered from the disease.
- the pooled serum is purified into the proteinaceous or gamma globulin fraction, so named because it contains predominantly IgG molecules.
- Polyclonal antibodies that are currently used for treatment include anti-rhesus polyclonal antibodies, gamma-globulin for passive immunization, anti-snake venom polyclonal (CroFab) , Thy oglobulinTM for allograft rejection, anti-digoxin to neutralize the heart drug digoxin, and anti-rabies polyclonal.
- RhoFab anti-snake venom polyclonal
- Thy oglobulinTM for allograft rejection
- anti-digoxin to neutralize the heart drug digoxin
- anti-rabies polyclonal anti-rabies polyclonal.
- an example of the higher efficacy of polyclonal antibodies compared to monoclonal antibodies can be found in the treatment of acute transplant rejection with anti- T-cell antibodies.
- the monoclonal antibodies on the market are less efficacious than a rabbit polyclonal antibody against thymocytes
- Fig. 1 Schematic representation of an antibody.
- the heavy and light chains are paired via interchain disulfide bonds (dotted lines) .
- the heavy chain can be either of the , ⁇ , ⁇ , ⁇ or ⁇ isotype.
- the light chain is either ⁇ or K.
- An antibody of IgGl isotype is shown.
- FIG. 2 Schematic representation of a bi-specific monoclonal antibody.
- a bi-specific antibody contains two different fuctional F(Ab) domains, indicated by the different patterns of the V ⁇ -V regions.
- Fig. 3 Sequence alignment of V L and V H of K53, UBS-54 and 02-237.
- DNA sequence of common V L of UBS54 and K53 is SEQ. ID. NO. 1, while the amino acid sequence is given as SEQ. ID. NO. 2.
- DNA sequences of V L of 02-237, and V H of UBS54, K53 and 02-237 are SEQ. ID. NOs . 3, 5, 7 and 9, respectively, while the amino acid sequences are given in SEQ. ID. NOs. 4, 6, 8 and 10, respectively.
- Fig. 4 Overview of plasmids pUBS3000Neo and pCD46_3000 (Neo) .
- Fig. 5 IEF of transiently expressed pUBS3000Neo, pCD46_3000 (Neo) and a combination of both.
- B The upper part shows a schematic representation of the expected molecules when a single light chain and a single heavy chain are expressed in a cell, leading to monoclonal antibodies UBS-54 or K53.
- the lower part under the arrow shows a schematic representation of the combinations produced when both heavy chains and the common light chain are co-expressed in a host cell, with theoretical amounts when both heavy chains are expressed at equal levels and pair to each other with equal efficiency.
- the common light chain is indicated with the vertically striped bars.
- Fig. 6 Schematic representation of a possible embodiment of the method according to the invention (see e.g. Examples 9) .
- Fig. 7 Sequence of v H and V of phages directed against ' CD22 (clone B28) , CD72 (clone II-2) and HLA-DR (class II; clone 1-2) .
- DNA sequences of V L of clones B28, H-2 and I- 2 are SEQ. ID. NOs. 11, 13 and 15, respectively, while the amino acid sequences are SEQ. ID. NOs. 12, 14 and 16, respectively.
- DNA sequence of the common light chain of these clones is SEQ. ID. NO. 17, while the amino acid sequence is SEQ. ID. NO. 18.
- Fig. 8 Map of pUBS54-IgA (pCRU-LOl encoding human IgAl against EPCAM) .
- Fig. 9 Dimeric bi-specific IgA with a single light chain (indicated by horizontally striped bar) .
- the method of the invention will produce a mixture of forms wherein different heavy chains can be paired, and only the most simple form is depicted in this schematic representation.
- a J-chain is shown to join the two monomers.
- Fig. 10 Pentameric multispecific IgM with a single light chain (indicated by horizontally striped bars) .
- the method of the invention will produce a mixture of many different forms wherein different heavy chains can be paired, and only the most simple form when 5 different heavy chains are expressed with a single light chain, and all 5 different heavy chains are incorporated in the pentamer and paired to the same heavy chain, is depicted in this schematic representation.
- Pentamers with less specificities can also be formed by incorporation of less than 5 different heavy chains. Especially when the J- chain is not expressed, hexamers can also be obtained.
- Fig. 11 Expression of a mixture of human IgG isotypes consisting of a common light chain, but with different binding specificities in a single cell to avoid the formation of bispecific antibodies.
- the different binding specificities are indicated by the different colours of the VH sequences.
- the common light chain is indicated with the vertically striped bars.
- the IgGl isotype is indicated with the grey Fc
- the IgG3 isotype is indicated with the black Fc part.
- Fig. 12 DNA and protein sequences of variable domains heavy and light chains of K53, UBS54 and 02-237 IgG.
- Fig. 14 BIACORE analysis of K53 and 02-237.
- Affinity purified human CD46 from LS174T cells was coupled (640 RU) to CM5 chips (BIACORE BR-1000-14) .
- Binding of 1000 (A), 500 (B) , 250 (C), 125 (D) , 63 (E) , 31 (F) , 16 (G) , 8 (H) or 0 (I) nM 02-237 or k53 purified from stable PER.C6TM derived cell lines to the CD46 was monitored using a BIACORE 3000 system at 37°C. Using this experimental set-up, a Kd of 9.1 X 10-7 and 2.2 X 10-8 was found for K53 and 02-237, respectively.
- Fig. 17 IEF analysis of purified IgG fractions.
- Ten ⁇ g purified IgG was analysed on an Isogel 3-10 gel (BMA) according to recommendations of the manufacturer. Proteins were visualized by staining with colloidal blue (Novex, cat. No LC6025) according to recommendations of the manufacturer. Clone identity is indicated on top of the IEF.
- Each gel contains a control, consisting of a 1:1:1 mixture of 02-237, K53 and UBS54.
- Fig. 18 IEF analysis of polyclonal mixtures 241, 280, 282, 361 and 402 in comparison to single K53, 02-237 and UBS54.
- Ten ⁇ g purified IgG was analysed on an Isogel 3-10 gel (BMA) according to recommendations of the manufacturer. Proteins were visualized by staining with colloidal blue (Novex, cat. No LC6025) according to recommendations of the manufacturer. IgG identity is indicated on top of the IEF.
- FIG. 19 Mass chromatograms of CDR3 peptides of K53, 02- 237, UBS54 and the two unique light chain peptides Ll- K53/UBS54 and Ll-237 in IgG fraction Polyl-280. On the right-hand side of each mass chromatogram, the isotopic pattern of the peptide is shown. The doubly charged ion at m/z 1058.98 (Mw 2115.96 Da) results from peptide Hll- K53. The doubly charged ion at m/z 1029.96 (Mw 2057.92 Da) results from peptide Hll-02-237.
- the triply charged ion at m/z 770.03 results from peptide H9-UBS54.
- the doubly charged ion at m/z 1291.08 results from peptide L1-K53/UBS54.
- the doubly charged ion at m/z 1278.11 results from peptide Ll-02-237.
- Purified IgG was dissolved in a 0.1% RapiGestTM (Waters) in 50 mM NH4HC03. The disulfides were reduced using 1 M DTT (1, 4-dithio-DL-threitol) , followed by incubation at 65°C for 30 minutes.
- the LC-system consisted of a Vydac reversed-phase C18 column, that was eluted by applying a gradient of solvent A (5/95/1 acetonitrile, water, glacial acetic acid v/v/v) and solvent B (90/10/1 acetonitrile, water, glacial acetic acid v/v/v) .
- the LC was on-line coupled to a Q-TOF2 mass spectrometer (Micromass) , equipped with an electrospray source operated at 3 kV. Mass spectra were recorded in positive ion mode from m/z 50 to 1500 at a cone voltage of 35 V.
- BIACORE analysis of polyclonal 280 Affinity purified human CD46 from LS174T cells was coupled (640 RU) to CM5 chips (BIACORE BR-1000-14) . Binding of 1000 (A), 500 (B), 250 (C), 125 (D) , 63 (E) , 31 (F) , 16 (G) , 8 (H) or 0 (I) nM Polyl-280 to CD46 was monitored using a BIACORE 3000 system at 37 °C.
- Fig. 21 IEF analysis of sub-clones from clones poly 1- 241, poly 1-280 and poly 1-402 producing a mixture of antibodies.
- Lane 2 contains isolated IgG from the parent clone poly 1-402 (as in Fig. 18) .
- Lanes 3, 4 and 5 respectively contain isolated IgG from 3 independent sub-clones derived from poly 1-402 by limiting dilution.
- Lane 6 contains a control (a 1:1:1 mixture of 02-237, K53 and UBS54) .
- Fig. 22 FACS analysis of mixtures of antibodies produced from sub-clones of poly 1-241 (A) , poly 1-280 (B) and poly 1-402 (C) .
- the present invention provides for a method of producing a mixture of antibodies in a recombinant host, the method comprising the step of: expressing in a recombinant host cell a nucleic acid sequence or nucleic acid sequences encoding at least one light chain and at least three different heavy chains that are capable of pairing with said at least one light chain.
- a further aspect of the invention is the elimination of the production of potentially nonfunctional light-heavy chain pairing by using preselected combinations of heavy and light chains. It has been recognized that phage display libraries built from a single light chain and many different heavy chains can encode antibody fragments with very distinct binding properties.
- This feature can be used to find different antibodies having the same light chain but different heavy chains, against the same target or different targets, wherein a target can be a whole antigen or an epitope thereof.
- a target can be a whole antigen or an epitope thereof.
- Such different targets may for instance be on the same surface (e.g. cell or tissue).
- Such antibody fragments obtained by phage display can be cloned into vectors for the desired format, e.g. IgG, IgA or IgM, and the nucleic acid sequences encoding these formats can be used to transfect host cells.
- H and L chains can be encoded by different constructs that, upon transfection into a cell wherein they are expressed, give rise to intact Ig molecules.
- H- and L-chains When different H chain constructs are transfected into a cell with a single L chain construct, H- and L-chains will be assembled to form all possible combinations. However, in contrast to approaches where different light chains are expressed such as for the production of bispecific antibodies, this method will result only in functional binding regions. It would be particularly useful when the host, e . g. a single cell line, is capable of expressing acceptable levels of recombinant antibodies, without the necessity to first amplify in said cell the nucleic acid sequences encoding the antibodies.
- a cell line suitable for use in the methods according to the invention is the human cell line PER.C6TM. Using this method a mixture of antibodies with defined specificities can be produced from a single cell clone in a safe, controlled, and consistent manner.
- the invention provides a method for production of a mixture of antibodies in a recombinant host, the method comprising the step of: expressing a nucleic acid sequence or nucleic acid sequences encoding at least one light chain and at least three different heavy chains that are capable of pairing with said at least one light chain in a recombinant host cell.
- the recombinant host cell comprises a nucleic acid sequence encoding a common light chain that is capable of pairing with said at least three different heavy chains, such that the produced antibodies comprise a common light chain.
- “common” also refers to functional equivalents of the light chain of which the amino acid sequence is not identical. Many variants of said light chain exist wherein mutations (deletions, substitutions, additions) are present that do not materially influence the formation of functional binding regions.
- the invention further provides a composition comprising a mixture of recombinantly produced antibodies, wherein at least three different heavy chain sequences are represented in said mixture.
- the light chains of such mixtures have a common sequence.
- the mixture of antibodies can be produced by the method according to the invention.
- the mixture of antibodies is more efficacious than the individual antibodies it comprises, more preferably, the mixture acts synergistically in a functional assay.
- the invention further provides a recombinant host cell for producing mixtures of antibodies, and methods for making such host cells. Independent clones obtained from the transfection of nucleic acid sequences encoding a light chain and more than one heavy chain may express the different antibodies in the mixture at different levels. It is another aspect of the invention to select a clone using a functional assay, for the most potent mixture of antibodies.
- the invention therefore further provides a method for identifying at least one host cell clone that produces a mixture of antibodies, wherein said mixture of antibodies has a desired effect according to a functional assay, the method comprising the steps of: (i) providing a host cell with nucleic acid sequence encoding at least one light chain and nucleic acid sequences encoding at least two different heavy chains, wherein said heavy and light chains are capable of pairing with each other/ (ii) culturing at least one clone of said host cell under conditions conducive to expression of said nucleic acid sequences/ (iii) screening said at least one clone of the host cell for production of a mixture of antibodies having the desired effect by a functional assay/ and (iv) identifying at least one clone that produces a mixture of antibodies having the desired effect.
- This method according to the invention can be performed using high- throughput procedures, if desired.
- the clones identified by the method can be used to produce antibody mixtures according to the invention.
- the invention further provides transgenic non-human animals and transgenic plants or transgenic plant cells capable of expressing mixtures of antibodies, and mixtures of antibodies produced by these.
- the invention further provides pharmaceutical compositions comprising a mixture of recombinantly produced antibodies and a suitable carrier.
- the invention further provides mixtures of antibodies for use in the treatment or diagnosis and for the preparation of a medicament for use in the treatment or diagnosis of a disease or disorder in a human or animal subject.
- the invention further provides a method for producing a mixture of antibodies comprising different isotypes from a single host cell clone.
- the invention further provides a method for indentifying a mixture of antibodies having a desired effect in a functional assay.
- the invention further provides a method for producing a mixture of antibodies that are capable of binding to a target, the method comprising the steps of: i) bringing a phage library comprising antibodies into contact with material comprising a target, ii) at least one step of selecting phages binding to said target, iii) identifying at least two phages that comprise antibodies binding to said target, wherein said at least two antibodies comprise a common light chain, iv) introducing a nucleic acid sequence encoding the light chain and a nucleic acid sequence or sequences encoding the heavy chains of said at least two antibodies into a host cell, v) culturing a clone of said host cell under conditions conducive to expression of said nucleic acid sequences.
- the light and heavy chains when paired form functional antigen binding domains.
- a functional antigen binding domain is capable of specifically binding to an antigen.
- the method for producing a mixture of antibodies according to the invention further comprises the step of recovering the antibodies from the cell or the host cell culture to obtain a mixture of antibodies suitable for further use.
- a method for production of a mixture of antibodies comprising the step of: expressing in a recombinant host cell a nucleic acid sequence encoding a common light chain and nucleic acid sequence or sequences encoding at least three different heavy chains that are capable of pairing with said common light chain, such that the antibodies that are produced comprise common light chains.
- the common light chain is identical in each light chain/heavy chain pair.
- antibody as used herein means a polypeptide containing one or more domains that bind an epitope on an antigen, where such domains are derived from or have sequence identity with the variable region of an antibody.
- the structure of an antibody is schematically represented in Fig.l.
- Examples of antibodies according to the invention include full length antibodies, antibody fragments, bispecific antibodies, immunoconjugates, and the like.
- An antibody according to the invention may be isotype IgGl, IgG2, IgG3, IgG4,
- Antibody fragments include Fv, Fab, Fab', F(ab') 2 fragments, and the like.
- Antibodies according to the invention can be of any origin, including murine, of more than one origin, i.e. chimeric, humanized, or fully human antibodies.
- Immunoconjugates comprise antigen binding domains and a non-antibody part such as a toxin, a radiolabel, an enzyme, and the like.
- An "antigen binding domain” preferably comprises variable regions of a heavy and a light chain, and is responsible for specific binding to an antigen of interest.
- Recombinant antibodies are prepared by expressing both a heavy and a light chain in a host cell. Similarly, by expressing two chains with their respective light chains (or a common light chain) , wherein each heavy chain/light chain has its own specificity, so-called “bispecific” antibodies can be prepared.
- Bispecific antibodies comprise two non-identical heavy-light chain combinations (Fig. 2), and both antigen binding regions of a bispecific antibody may recognize different antigens or different epitopes on an antigen.
- a "common light chain” according to the invention refers to light chains which may be identical or have amino acid sequence differences. Said light chains may comprise mutations which do not alter the specificity of the antibody when combined with the same heavy chain, without departing from the scope of the present invention.
- common light chains it is for instance possible within the scope of the definition of common light chains as used herein, to prepare or find light chains that are not identical but still functionally equivalent, e.g. by introducing and testing conservative amino acid changes, changes of amino acids in regions that do not or only partly contribute to binding specificity when paired with the heavy chain, and the like. It is an aspect of the present invention to use as common light chain one identical light chain to combine with different heavy chains to form antibodies with functional antigen binding domains. The use of one common light chain avoids the formation of heterodimers in which pairing of light and heavy chains results in antigen binding domains that are not functional, in other words which are not capable of binding to the target antigen or antigens.
- the host cell according to the invention is provided with nucleic acid sequences encoding for 4, 5, 6, 7, 8, 9, 10, or more heavy chains capable of pairing with the common light chain, to increase the complexity of the produced mixture of antibodies .
- “Different heavy chains” according to the invention may differ in the variable region and have the same constant region. In other embodiments, where it is clear from the context, they may have the same variable region and differ in the constant region, e.g. be of a different isotype. The use of a mixture of antibodies having different constant regions, such as the Fc-portion, may be advantageous if different arms of the immune system are to be mobilized in the treatment of the human or animal body. In yet other embodiments, also to be clear from the context, both the variable and the constant regions may differ.
- a “mixture of antibodies” according to the invention comprises at least two non-identical antibodies, but may comprise 3, 4, 5, 6, 7, 8, 9, 10, or more different antibodies, and may resemble a polyclonal or at least an oligoclonal antibody mixture with regard to complexity and number of functional antigen binding molecules.
- the mixtures produced according to the present invention usually will comprise bispecific antibodies. If desired, formation of monospecific antibodies in the mixture can be favoured over the formation of bispecific antibodies.
- n heavy chains and one common light chain are expressed according to the invention in a host cell at equal levels, the theoretical percentage of bispecific antibodies produced by the method according to the invention is (1-1/n) *100% .
- the total number of different antibodies in the mixture produced by the method according to the invention is theoretically n+ ⁇ (n 2 -n) /2 ⁇ , of which (n 2 -n/2) are bispecific antibodies. Distortion of the ratio of expression levels of the different heavy chains may lead to values deviating from the theoretical values. The amount of bispecific antibodies can also be decreased, compared to these theoretical values, if not all heavy chains pair with equal efficiency. It is for instance possible to engineer the heavy chains, e . g. by introducing specific and complementary interaction surfaces between selected heavy chains, to promote homodimer pairing over heterodimer pairing, contrary to what has been proposed by Merchant, supra . Heavy chains may also be selected so as to minimize heterodimer formation in the mixture.
- a special form of this embodiment involves heavy chains of two or more different isotypes (e.g. IgGl, IgG3, IgA) .
- heavy chains of different isotype are expressed in the same host cell in accordance with the present invention and one light chain that can pair to these heavy chains, the amount of bispecific antibodies will be reduced, possibly to very low or even to undetectable levels.
- bispecific antibodies when bispecific antibodies are less desirable, it is possible to produce a mixture of antibodies according to the invention, wherein a nucleic acid sequence encoding a common light chain and nucleic acid sequences encoding at least two different heavy chains with a different variable region capable of pairing to said common light chain are expressed in a recombinant host, and wherein said heavy chains further differ in their constant regions sufficiently to reduce or prevent pairing between the different heavy chains.
- the mixtures of antibodies according to the invention may be produced from a clone that was derived from a single host cell, i.e. from a population of cells containing the same recombinant nucleic acid sequences.
- the different heavy chains according to the invention can be encoded on separate nucleic acid molecules, but may also be present on one nucleic acid molecule comprising different regions encoding said at least three heavy chains.
- the nucleic acid molecules usually encode precursors of the light and/or heavy chains, which when expressed are secreted from the host cells, thereby becoming processed to yield the mature form.
- a “recombinant host cell” as used herein is a cell comprising one or more so-called transgenes, i.e. recombinant nucleic acid sequences not naturally present in said cell. These transgenes are expressed in said host cell to produce recombinant antibodies encoded by these nucleic acid sequences, when these cells are cultured under conditions conducive to expression of said nucleic acid sequences.
- the host cell according to the invention can be present in the form of a culture from a clone that is derived from a single host cell wherein the transgenes have been introduced.
- nucleic acid sequences encoding antibodies it is well known to those skilled in the art that sequences capable of driving such expression can be functionally linked to the nucleic acid sequences encoding the antibodies. Functionally linked is meant to describe that the nucleic acid sequences encoding the antibody fragments or precursors thereof is linked to the sequences capable of driving expression such that these sequences can drive expression of the antibodies or precursors thereof.
- Useful expression vectors are available in the art, e.g. the pcDNA vector series of Invitrogen. Where the sequence encoding the polypeptide of interest is properly inserted with reference to sequences governing the transcription and translation of the encoded polypeptide, the resulting expression cassette is useful to produce the polypeptide of interest, referred to as expression.
- Sequences driving expression may include promoters, enhancers and the like, and combinations thereof. These should be capable of functioning in the host cell, thereby driving expression of the nucleic acid sequences that are functionally linked to them.
- Promoters can be constitutive or regulated, and can be obtained from various sources, including viruses, prokaryotic, or eukaryotic sources, or artificially designed. Expression of nucleic acids of interest may be from the natural promoter or derivative thereof or from an entirely heterologous promoter.
- Some well-known and much used promoters for expression in eukaryotic cells comprise promoters derived from viruses, such as adenovirus, e.g.
- Suitable promoters can also be derived from eukaryotic cells, such as methallothionein (MT) promoters, elongation factor l (EF-l ⁇ ) promoter, actin promoter, an immunoglobulin promoter, heat shock promoters, and the like. Any promoter or enhancer/promoter capable of driving expression of the sequence of interest in the host cell is suitable in the invention.
- CMV cytomegalovirus
- IE CMV immediate early
- SV40 Simian Virus 40
- Suitable promoters can also be derived from eukaryotic cells, such as methallothionein (MT) promoters, elongation factor l (EF-l ⁇ ) promoter, actin promoter, an immunoglobulin promoter, heat shock promoters, and the like.
- MT methallothionein
- EF-l ⁇ elongation factor l
- actin promoter actin promoter
- an immunoglobulin promoter an immunoglobulin promoter
- the sequence capable of driving expression comprises a region from a CMV promoter, preferably the region comprising nucleotides -735 to +95 of the CMV immediate early gene enhancer/promoter .
- the expression sequences used in the invention may suitably be combined with elements that can stabilize or enhance expression, such as insulators, matrix attachment regions, STAR elements (WO 03/004704), and the like. This may enhance the stability and/or levels of expression. Protein production in recombinant host cells has been extensively described, e.g. in Current Protocols in
- Culturing a cell is done to enable it to metabolize, and/or grow and/or divide and/or produce recombinant proteins of interest. This can be accomplished by methods well known to persons skilled in the art, and includes but is not limited to providing nutrients for the cell. The methods comprise growth adhering to surfaces, growth in suspension, or combinations thereof. Several culturing conditions can be optimized by methods well known in the art to optimize protein production yields. Culturing can be done for instance in dishes, roller bottles or in bioreactors, using batch, fed-batch, continuous systems, hollow fiber, and the like. In order to achieve large scale
- “Host cells” may be any host cell capable of expressing recombinant DNA molecules, including bacteria such as Eschericia (e.g. E.coli), Enterobocter, Salmonalla, Bacillus, Pseudomonas, Streptomyces, yeasts such as S .
- bacteria such as Eschericia (e.g. E.coli), Enterobocter, Salmonalla, Bacillus, Pseudomonas, Streptomyces, yeasts such as S .
- filamentous fungi such as Neurospora, Aspergillus oryzae, Aspergillus nidulans and Aspergillus niger, insect cells such as Spodoptera frugiperda SF-9 or SF-21 cells, mammalian cells such as Chinese hamster ovary (CHO) cells, BHK cells, mouse cells including SP2/0 cells and NS-0 myeloma cells, primate cells such as COS and Vero cells, MDCK cells, BRL 3A cells, hybridomas, tumor-cells, immortalized primary cells, human cells such as W138, HepG2, HeLa, HEK293, HT1080 or embryonic retina cells such as PER.C6TM, and the like.
- CHO Chinese hamster ovary
- the expression system of choice will involve a mammalian cell expression vector and host so that the antibodies are appropriately glycosylated.
- a human cell line preferably PER.C6TM, can advantageously be used to obtain antibodies with a completely human glycosylation pattern.
- the conditions for growing or multiplying cells see e.g. Tissue Culture, Academic Press, Kruse and Paterson, editors (1973) ) and the conditions for expression of the recombinant product may differ somewhat, and optimization of the process is usually performed to increase the product yields and/or growth of the cells with respect to each other, according to methods generally known to the person skilled in the art.
- the antibodies are expressed in the cells according to the invention, and may be recovered from the cells or preferably from the cell culture medium, by methods generally known to persons skilled in the art. Such methods may include precipitation, centrifugation, filtration, size-exclusion chromatography, affinity chromatography, cation- and/or anion-exchange chromatography, hydrophobic interaction chromatography, and the like.
- protein A or protein G affinity chromatography can be suitably used (see e.g. US patents 4,801,687 and 5,151,504) .
- At least two antibodies from the mixture produced according to the invention comprise a heavy-light chain dimer having different specificities and/or affinities.
- the specificity determines which antigen or epitope thereof is bound by the antibody.
- the affinity is a measure for the strength of binding to a particular antigen or epitope.
- Specific binding is defined as binding with an affinity (Ka) of at least 5 * 10E4 liter/mole, more preferably 5 * 10E5, more preferably more than 5 * 10E6, still more preferably 5 * 10E7, or more.
- monoclonal antibodies may have affinities which go up to 10E10 liter per mole, or even higher.
- the mixture of antibodies produced according to the present invention may contain at least two antibodies that bind to different epitopes on the same antigen molecule and/or may contain at least two antibodies that bind to different antigen molecules present in one antigen comprising mixture.
- Such an antigen comprising mixture may be a mixture of partially or wholly purified antigens such as toxins, membrane components and proteins, viral envelope proteins, or it may be a healthy cell, a diseased cell, a mixture of cells, a tissue or mixture of tissues, a tumor, an organ, a complete human or animal subject, a fungus or yeast, a bacteria or bacterial culture, a virus or virus stock, combinations of these, and the like.
- the mixture of antibodies according to the present invention may therefore have many of the advantages of a polyclonal or oligoclonal antibody mixture.
- the host cell according to the method of the invention is capable of high-level expression of human immunoglobulin, i.e. at least 1 pg/cell/day, preferably at least 10 pg/cell/day and even more preferably at least 20 pg/cell/day or more without the need for amplification of the nucleic acid molecules encoding the heavy and light chains in said host cell.
- host cells according to the invention contain in their genome between 1 and 10 copies of each recombinant nucleic acid to be expressed. In ' the art, amplification of the copy number of the nucleic acid sequences encoding a protein of interest in e.g.
- CHO cells can be used to increase expression levels of the recombinant protein by the cells (see e.g. Bendig, 1988/ Cockett et al, 1990/ US patent 4,399,216). This is currently a widely used method. However, a significant time-consuming effort is required before a clone with a desired high copy number and high expression levels has been established, and moreover clones harbouring very high copy numbers (up to hundreds) of the expression cassette often are unstable (e.g. Kim et al., 1998). It is therefore a preferred embodiment of the present invention to use host cells that do not require such amplification strategies for high-level expression of the antibodies of interest.
- the methods of the invention include culturing the cells for at least 20, preferably 25, more preferably 30 population doublings, and in other aspects the host cells according to the invention have undergone at least 20, preferably 25, more preferably 30 population doublings and are still capable of expressing a mixture of antibodies according to the invention.
- the invention also provides a culture of cells producing a mixture of immunoglobulins from a single cell, said mixture comprising at least three different heavy chains.
- the invention also provides a culture of cells producing at least three different monospecific immunoglobulins from a single cell.
- said culture produces said mixture or said at least three different monospecific immunoglobulins in a single cell for more than 20, preferably more than 25, more preferably more than 30 population doublings.
- host cells according to the method of the invention are derived from human retina cells that have been immortalized or transformed with adenoviral El sequences.
- a particularly preferred host cell according to methods of the present invention is PER.C6TM as deposited under ECACC no. 96022940, or a derivative thereof.
- PER.C6-derived clones can be generated fast, usually contain a limited number of copies (about 1-10) of the transgene, and are capable of high-level expression of recombinant antibodies (Jones et al, 2003) . Therefore, such clones are expected to maintain a stable copy number over many generations, which is an advantage in the production of biopharmaceuticals.
- PER.C6TM cells have been extensively characterized and documented, demonstrating good process of scaling up, suspension growth and growth factor independence. Furthermore, PER.C6TM can be incorporated into a suspension in a highly reproducible manner, making it particularly suitable for large-scale production. In this regard, the PER.C6TM cell line has been characterized for bioreactor growth, where it can grow to very high densities. The use of PER.C6TM for recombinant production of antibodies has been described in detail in publication WO 00/63403 and in (Jones et al. , 2003) . It is another aspect of the present invention to provide a mixture of antibodies that is obtainable by a method according to the invention.
- mixtures of antibodies are expected to be more effective than the sole components it comprises, in analogy to polyclonal antibodies usually being more effective than monoclonal antibodies to the same target.
- Such mixtures can be prepared against a variety of target antigens or epitopes .
- It is another aspect of the present invention to provide a recombinant host cell comprising a nucleic acid sequence encoding a light chain and a nucleic acid sequence or nucleic acid sequences encoding at least three different heavy chains of an antibody, wherein said light chain and heavy chains are capable of pairing, preferably to form a functional binding domain.
- the paired heavy and light chain form functional antigen binding regions against the target antigen or target antigens.
- the host cells according to the invention are useful in the method according to the invention. They can be used to produce mixtures of antibodies according to the invention.
- compositions comprising a mixture of recombinantly produced antibodies, wherein at least three different heavy chain sequences are represented in the mixture of recombinant antibodies.
- Monoclonal antibodies are routinely produced by recombinant methods.
- the present invention discloses mixtures of antibodies useful for diagnosis or treatment in various fields.
- the compositions according to the invention comprise mixtures of at least three different heavy chains paired to light chains in the form of antibodies.
- the light chains of the antibodies in said mixtures have a common light chain.
- the mixtures may comprise bispecific antibodies.
- the mixtures may be produced from a clone that was derived from a single host cell, i.e.
- compositions according to the invention may have several of the advantages of a polyclonal antibody mixture, without the disadvantages usually inherently associated with polyclonal antibody mixtures, because of the manner in which they are produced. It is furthermore expected that the mixture of antibodies is more efficacious than separate monoclonal antibodies. Therefore the dosage, and hence the production capacity required, may be less for the mixtures of antibodies according to the invention than for monoclonal antibodies .
- 2, 3, 4, 5, 6, 7, 8, 9, 10, or more of the antibodies present in the mixture according to the invention have different specificities. Said different specificities may be directed to different epitopes on the same antigen and/or may be directed to different antigens present in one antigen comprising mixture.
- a composition according to the invention further may also comprise 2, 3, 4, 5, 6, 7, 8, 9, 10, or more antibodies having different affinities for the same epitope. Antibodies with differing affinities for the same epitope may for instance be generated by methods of affinity maturation, known to the person skilled in the art.
- the composition according to the invention has an effect that is greater than the effect of each individual monospecific antibody present in said composition. Said effect can be measured in a functional assay.
- a “functional assay” according to the present invention is an assay that can be used to determine one or more desired parameters of the antibody or the mixture of antibodies subject to the assay conditions.
- Suitable functional assays may be binding assays, apoptosis assays, antibody dependent cellular cytotoxicity (ADCC) assays, complement dependent cytotoxicity (CDC) assays, inhibition of cell growth or proliferation (cytostatic effect) assays, cell killing (cytotoxic effect) assays, cell signaling assays, assays for measuring inhibition of binding of pathogen to target cell, assays to measure the secretion of vascular endothelial growth factor (VEGF) or other secreted molecules, assays for bacteriostasis, bactericidal activity, neutralization of viruses, assays to measure the attraction of components of the immune system to the site where antibodies are bound, including in situ hybridization methods, labeling methods, and the like.
- ADCC antibody dependent cellular cytotoxicity
- CDC complement dependent cytotoxicity
- in vivo assays such as animal models, including mouse tumor models, models of autoimmune disease, virus-infected or bacteria-infected rodent or primate models, and the like, can be used for this purpose.
- the efficacy of a mixture of antibodies according to the invention can be compared to individual antibodies in such models by methods generally known to the person skilled in the art.
- said host cell comprises a nucleic acid sequence encoding a common light chain that is capable of pairing with said at least two different heavy chains, such that produced antibodies comprise common light chains, as described above.
- said culturing in step (ii) and said screening in step (iii) of the method is performed with at least two clones.
- the method may optionally include an assay for measuring the expression levels of the antibodies that are produced, which assay may be during or after step (ii) according to the method, or later in the procedure.
- assays are well known to the person skilled in the art, and include protein concentration assays, immunoglobulin specific assays such as ELISA, RIA, DELFIA, and the like.
- the host cell comprises nucleic acid sequence or sequences encoding at least 3, 4, 5, 6, 7, 8, 9, 10, or more heavy chains capable of pairing with said at least one light chain.
- Functional assays useful for the method according to the invention may be assays for apoptosis, ADCC, CDC, cell killing, inhibition of proliferation, virus neutralization, bacterial opsonization, receptor- mediated signaling, cell signaling, bactericidal activity, and the like.
- Useful screening assays for anti- cancer antibodies have for instance been described in US patent 6,180,357. Such assays may also be used to identify a clone according to the method of the present invention.
- ELISAs enzyme linked immunosorbent assays
- ELISAs enzyme linked immunosorbent assays
- cytotoxicity or cytostatic effects It is possible that upon such a different screen, other or the same clones producing mixtures of antibodies will be chosen than with the ELISA mentioned above.
- the screening for cell killing or cessation of growth of cancerous cells may be suitably used according to the invention. Cell death can be measured by various endpoints, including the absence of metabolism or the denaturation of enzymes.
- the assay is conducted by focusing on cytotoxic activity toward cancerous cells as an endpoint.
- a live/dead assay kit for example the LIVE/DEAD ® Viability/Cytotoxicity Assay Kit
- the assays may also include screening of the mixture of antibodies for specificity to the desired antigen comprising tissue.
- the antibodies according to the invention may have a limited tissue distribution. It is possible to include testing the mixtures of antibodies against a variety of cells, cell types, or tissues, to screen for mixtures of antibodies that preferably bind to cells, cell types or tissues of interest.
- the present invention also teaches ways to determine the identity of the antibodies expressed by a clone, using methods such as iso-electric focusing (IEF) , mass- spectrometry (MS), and the like. It is therefore an aspect of the invention to provide use of MS and/or IEF in selecting a clone that expresses a mixture of antibodies according to the invention.
- a screening step is usually performed to assess expression levels of the individual clones that were generated. The addition of more heavy chains to produce mixtures adds a level of complexity to the production of antibodies.
- clones When host cells are transfected with nucleic acid molecules encoding the light and heavy chains that will form the mixture of antibodies desired, independent clones may arise containing the same genetic information, but nevertheless differing in expression levels, thereby producing different ratios of the encoded antibodies, giving rise to different mixtures of antibodies from the same genetic repertoire.
- the method according to the invention is useful for identifying a clone that produces an optimal mixture for a certain purpose.
- the culturing and/or screening according to steps (ii) and (iii) respectively, may be suitably performed using high-throughput procedures, optionally in an automated fashion.
- Clones can e.g. be cultured in 96-well or other multi-well plates, e.g.
- said host cell is derived from a human embryonic retinoblast cell, that has been immortalized or transformed by adenoviral El sequences.
- said cell is derived from PER.C6TM. This cell line has already been shown to be amenable to high- throughput manipulations, including culturing (WO 99/64582) .
- said mixture of antibodies according to the method of identifying at least one host cell according to the invention comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, or more antibodies having different specificities and/or affinities .
- a potential advantage of the method will be that it will allow exploring many possible combinations simultaneously, the combinations inherently including the presence of bispecific antibodies in the produced mixture. Therefore more combinations can be tested than by just mixing purified known monoclonal antibodies, both in number of combinations and in ratios of presence of different antibodies in these combinations.
- the clone that has been identified by the method according to the invention can be used for producing a desired mixture of antibodies. It is therefore another aspect of the present invention to provide a method of producing a mixture of antibodies, the method comprising the step of: culturing a host cell clone identified by the method of identifying at least one host cell clone that produces a mixture of antibodies according to the invention, said culturing being under conditions conducive to expression of the nucleic acid molecules encoding the at least one light chain and the at least two different heavy chains.
- the produced antibodies may be recovered from the host cells and/or from the host cell culture, e.g. from the culture medium.
- the mixture of antibodies can be recovered according to a variety of techniques known to the person skilled in the art.
- Said mixtures can be used for a variety of purposes, such as in treatment or diagnosis of disease, and may replace, or be used in addition to, monoclonal or polyclonal antibodies .
- the methods according to the present invention may suitably use nucleic acid molecules for encoding the antibodies, which nucleic acid molecules have been obtained by any suitable method, including in vivo, e . g. immunization, methods or in vitro, e.g. antibody display methods (A. Pl ⁇ ckthun et al, In vitro selection and evolution of proteins. In: Adv. Prot. Chem., F.M. Richards et al, Eds, Academic Press, San Diego, 2001, vol 55: 367-403), such as phage display, ribosome display or mRNA display (C. Schaffitzel et al . , In vitro selection and evolution of protein-ligand interactions by ribosome display.
- a library of phages that express an antigen binding domain or derivative thereof on their surface is incubated with the antigen or antigen mixture of interest, after which binding of a subpopulation of the phages that display antigen binding sites binding to the desired antigen is obtained whereas the non-binding phages are discarded.
- selection steps may be repeated one, two, or more times to obtain a population of phages that are more or less specific for the antigen of interest.
- Phage display methods to obtain antibodies, parts or derivatives thereof have been extensively described in e.g. (CF Barbas III et al, Phage Display. A laboratory manual. Cold Spring Harbor Laboratory Press,
- the library used for such screening may be generated by using the genetic information of one or more light chains, combined with genetic information encoding a plurality of heavy chains.
- the library described by De Kruif et al. (1995b) comprises 7 light chains. Therefore, in a panel of phages binding to a target, which can e.g. be obtained by methods described in De Kruif et al (supra) / US patent 6,265,150/ not more than 7 different light chains will be represented, and if the panel is large enough, several phages with the same light chain coupled to unrelated heavy chains may be found. Such phages can be used to obtain the nucleic acid molecules useful in the methods according to the present invention.
- the antibody display library may be a phage display library, a ribosome display library, an mRNA display library, or a yeast display library. Step i) and ii) may optionally be repeated one
- the nucleic acid sequences encoding the antibodies obtained by the phage display, ribosome display or yeast display method may be converted to encode any desired antibody format such as IgGl, IgG2, IgG3, IgG4, IgA, IgM, IgD, IgE, before introducing them into a host cell, using standard molecular cloning methods and means known to the person skilled in the art (e.g. described in Boel et al, 2000) .
- example 1 antibodies binding to EpCAM and to CD46, described in WO 01/48485 and WO 02/18948, respectively) .
- a phage library against a target it will be also possible to start with an antibody that has already proven its merits, and use the light chain of this antibody in the preparation of a library of heavy chains combined with this particular light chain only, according to methods known to the person skilled in the art, such as phage display.
- a monoclonal antibody can be used to obtain a mixture of antibodies according to the invention, functionally resembling a polyclonal or oligoclonal antibody to the same target.
- a method reminiscent of the method described by Jespers et al (1994) to obtain a human antibody based on a functional rodent antibody can be used.
- the heavy chain of a known antibody of non-human origin is first cloned and paired as a template chain with a repertoire of human light chains for use in phage display, after which the phages are selected for binding to the antigen or mixture of antigens.
- the selected light chain is in turn paired with a repertoire of human heavy chains displayed on a phage, and the phages are selected again to find several heavy chains that when paired with the light chain are able to bind to the antigen or mixture of antigens of interest.
- the heavy and light chain coding sequences can be introduced simultaneously or consecutively into the host cell. It is also an aspect of the invention to prepare a host cell comprising a recombinant nucleic acid encoding a light chain of an antibody. Such a cell can for instance be obtained by transfection of said nucleic acid, and optionally a clone can be identified that has a high expression of the light chain. An established clone may then be used to add genetic information encoding 2, 3, 4, 5, 6, 7, 8, 9, 10, or more heavy chains of the invention by introducing the nucleic acid molecules encoding these into cells of the clone that already contains the light chain. The nucleic acid molecules encoding the heavy chains may be introduced into said host cell concomitantly.
- Suitable dominant selection markers for introducing nucleic acids into eukaryotic host cells according to the invention may be G418 or neomycin (geneticin) , hygromycin or mycophenolic acid, puromycin, and the like, for which genes encoding resistance are available on expression vectors. Further possibilities include for instance the use of vectors containing DHFR genes or glutamate synthetase to select in the presence of methotrexate in a DHFR " cell or the absence of glutamine in a glutamine auxotroph, respectively.
- selection markers that can be used more than once, e.g. when containing mutations, introns, or weakened promoters that render them concentration dependent (e.g. EP0724639; WO01/32901; US patent 5,733,779).
- a selection marker may be re-used by deleting it from the host cell after use, e.g. by site-specific recombination.
- a selectable marker located between sequences recognized by a site- specific recombinase e.g.
- lox-sites or FRT-sites is used for the generation of the first stable transfectant (see for Cre-lox site-specific recombination Wilson and Kola, 2001) .
- the selectable marker is excised from the host cell DNA by the matching site- specific recombinase, e.g. Cre or Flp.
- Cre or Flp e.g. Cre or Flp.
- a subsequent transfection can suitably use the same selection marker.
- Different host cell clones each comprising the genetic information encoding a different light chain may be prepared. If the antibodies are identified by an antibody display method, it is thus possible to prepare several host cells, each comprising one light chain present in the antibody display library.
- the nucleic acid molecules encoding the heavy chains can be introduced into the host cell containing the common light chain that is capable of pairing to the heavy chains. It is therefore an aspect of the present invention to provide a method for making a host cell for production of a mixture of antibodies, the method comprising the steps of: introducing into said host cell a nucleic acid sequence encoding a light chain and nucleic acid sequence or sequences encoding 3, 4, 5, 6, 7, 8, 9, 10, or more different heavy chains that are capable of pairing with said light chain, wherein said nucleic acid molecules are introduced consecutively or simultaneously.
- a method for making a recombinant host cell for production of a mixture of antibodies comprising the step of: introducing a nucleic acid sequence or nucleic acid sequences encoding 2, 3, 4, 5, 6, 7, 8, 9, 10, or more different heavy chains into a recombinant host cell comprising a nucleic acid sequence encoding a light chain capable of pairing with at least two of said heavy chains.
- extra copies of the nucleic acid molecules encoding the light chain may be transfected into the cell.
- methods to integrate the transgenes in predetermined positions of the genome resulting in favorable expression levels can also be used according to the invention.
- Such methods may for instance employ site-specific integration by homologous recombination (see e.g. WO 98/41645), or make use of site-specific recombinases (Gorman and Bullock, 2000) .
- Promoters in plants may also be non- tissue specific, and general gene expression elements, such as the CaMV 35S promoter and nopaline synthase polyA addition site can also be used.
- Said light chain is a common light chain according to the invention.
- the transgenic animal or plant according to the invention comprises 3, 4, 5, 6, 7, 8, 9, 10, or more heavy chain sequences.
- the art also discloses the use of transgenic animals, transgenic plants, and for instance transgenic chickens to produce proteins in the eggs, and the like to produce recombinant proteins of interest (Pollock et al, 1999/ Larrick and Thomas, 2001/ WO 91/08216) .
- These usually comprise the recombinant gene or genes encoding one or more proteins of interest in operable association with a tissue- specific promoter.
- recombinant antibodies can be produced at high levels in the milk of transgenic animals, that contain the nucleic acids encoding a heavy and a light chain behind a mammary gland specific promoter (e.g. Pollock et al, 1999/ WO 95/17085) .
- a mammary gland specific promoter e.g. Pollock et al, 1999/ WO 95/17085.
- cows, sheep, goats, pigs, rabbits, mice, and the like which can be milked to obtain antibodies.
- Useful promoters are the casein promoters, such as the ⁇ -casein promoter, the ⁇ Sl-casein promoter, the whey acidic protein (WAP) promoter, the ⁇ -lactoglobulin promoter, the -lactalbumin promoter, and the like.
- transgenic animals comprising recombinant nucleic acid molecules
- the generation of transgenic animals comprising recombinant nucleic acid molecules has been extensively documented, and may include micro-injection of oocytes (see e.g. Wilmut and Clark, 1991), nuclear transfer after transfection (e.g. Schnieke et al, 1997) , infection by recombinant viruses (e.g. US patent 6291740), and the like.
- Nuclear transfer and cloning methods for mammalian cells are known to the person skilled in the art, and are e.g. described in
- Transgenic plants or plant cells producing antibodies have also been described (Hiatt et al, 1989/ Peeters et al, 2001) , and useful plants for this purpose include corn, maize, tobacco, soybean, alfalfa, rice, and the like.
- Constitutive promoters that can for instance be used in plant cells are the CaMV 35S and 19S promoters, Agrobacterium promoters nos and ocs .
- Other useful promoters are light inducible promoters such as rbcS.
- Tissue-specific promoters can for instance be seed- specific, such as promoters from zein, napin, beta- phaseolin, ubiquitin, or tuber-specific, leaf-specific (e.g. useful in tobacco), root-specific, and the like.
- transgenic systems for producing recombinant proteins have also been described, including the use of transgenic birds to produce recombinant proteins in eggs (e.g WO 97/47739), and the use of transgenic fish (e.g. WO 98/15627), and can be used in combination with the teachings of the present invention to obtain mixtures of antibodies. It is also possible to use an in vitro transciption/translation or in vitro translation system for the expression' of mixtures of antibodies according to the present invention. It will be clear to the skilled person that the teachings of the current invention will allow producing mixtures of antibodies in systems where recombinant nucleic acid encoding the light chain and heavy chains can be introduced and expressed.
- a cell from a transgenic non-human animal or a transgenic plant according to the invention is provided.
- Such cells can be used to generate the animals or plants according to the invention, using techniques known to the person skilled in the art, such as nuclear transfer or other known methods of cloning whole organisms from single cells.
- the cells according to the invention may also be obtained by introducing the light and at least two heavy chain sequences into isolated cells of non-human animals or plants, which cells are capable of becoming part of a transgenic animal or plant. Particularly useful for such purposes are embryonic stem cells.
- plant cell cultures of cotton, corn, tomato, soybean, potato, petunia, and tobacco can be utilized as hosts, when transformed with the nucleic acid molecules encoding the light chain and the heavy chains, e.g. by use of the plant transforming bacterium Agrobacterium tumefaciens or by particle bombardment, or by infecting with recombinant plant viruses.
- It is another aspect of the present invention to provide a pharmaceutical composition comprising a mixture of recombinantly produced antibodies and a suitable carrier, wherein at least two different heavy chains are represented in said mixture of recombinantly produced antibodies.
- Pharmaceutically acceptable carriers as used herein are exemplified, but not limited to, adjuvants, solid carriers, water, buffers, or other carriers used in the art to hold therapeutic components, or combinations thereof. In particular embodiments, 3, 4, 5, 6, 7, 8, 9, 10, or more different heavy chains are represented in said mixture.
- Said mixture can be obtained by mixing recombinantly produced monoclonal antibodies, but may also be obtained by methods according to the present invention. Said mixture may therefore comprise a common light chain for said antibodies. Said mixture may comprise bispecific antibodies.
- Said mixture may be produced from a clone that was derived from a single host cell, i.e. from a population of cells containing the same recombinant nucleic acid molecules.
- recombinantly produced refers to production by host cells that produce antibodies encoded by recombinant nucleic acids introduced in such host cells or ancestors thereof. It does therefore not include the classical method of producing polyclonal antibodies, whereby a subject is immunized with an antigen or antigen comprising mixture, after which the antibodies produced by this subject are recovered from the subject, e.g. from the blood.
- the invention provides the use of a mixture of antibodies wherein at least two different heavy chains are represented, for the preparation of a medicament for use in the treatment or diagnosis of a disease or disorder in a human or animal subject.
- 2, 3, 4, 5, 6, 7, 8, 9, 10, or more heavy chains are represented in said mixture.
- Said mixtures of antibodies may be mixtures of antibodies according to the invention, or obtained by methods according to the invention.
- Antibodies present in said mixture may preferably comprise a common light chain.
- the mixtures may comprise bispecific antibodies, and may be recombinantly produced from a clone that was derived from a single host cell, i.e. from a population of cells containing the same recombinant nucleic acid molecules.
- the targets may be used to screen an antibody display library, as described supra, to obtain 2, 3, 4, 5, 6, 7, 8, 9, 10, or more antibodies comprising a common light chain that bind to the target, and produce a mixture of these according to the teachings of the present invention.
- Virtually any area of medicine where monoclonal antibodies can be used is amenable for the use of the mixtures according to the invention. This can e.g.
- Neoplastic disorders which can be treated with the mixtures according to the present invention include leukemias, lymphomas, sarcomas, carcinomas, neural cell tumors, squamous cell carcinomas, germ cell tumors, metastases, undifferentiated tumors, seminomas, melanomas, myelomas, neuroblastomas, mixed cell tumors, neoplasias caused by infectious agents, and other malignancies.
- Targets for the antibody mixtures may include, but are not limited to, the HER-2/Neu receptor, other growth factor receptors such as VEGFR1 and VEGFR2 receptor, B-cell markers such as CD19, CD20, CD22, CD37, CD72, etc, T-cell markers such as CD3, CD25, etc, other leukocyte cell surface markers such as CD33 or HLA-DR, etc, cytokines such as TNF, interleukins, receptors for these cytokines such as members of the TNF receptor family, and the like.
- the HER-2/Neu receptor other growth factor receptors such as VEGFR1 and VEGFR2 receptor
- B-cell markers such as CD19, CD20, CD22, CD37, CD72, etc
- T-cell markers such as CD3, CD25, etc
- other leukocyte cell surface markers such as CD33 or HLA-DR, etc
- cytokines such as TNF, interleukins, receptors for these cytokines such as members of the TNF receptor family, and the like
- mixtures of antibodies are superior to monoclonal antibodies in the treatment of complex antigens or antigen comprising mixtures such as bacteria or viruses. Therefore, use according to the invention can also include use against strains of bacteria and fungi, e.g. in the treatment of infectious diseases due to pathogenic bacteria such as multidrug resistant S.aureus and the like, fungi such as Candida albicans and Aspergillus species, yeast and the like.
- the mixtures according to the invention may also be used for post exposure profylaxis against viruses, such as members of the genus Lyssavirus e.g.
- rabies virus or for therapeutic or prophylactic use against viruses such as Varicella-Zoster Virus, Adenoviruses, Respiratory Syncitium Virus, Human Immunodeficiency Virus, Human Metapneumovirus, Influenzavirus, West Nile Virus, the virus causing Severe Acute Respiratory Syndrome (SARS) , and the like.
- viruses such as Varicella-Zoster Virus, Adenoviruses, Respiratory Syncitium Virus, Human Immunodeficiency Virus, Human Metapneumovirus, Influenzavirus, West Nile Virus, the virus causing Severe Acute Respiratory Syndrome (SARS) , and the like.
- Mixtures according to the inventions can also be used to protect against agents, both bacteria and viruses, and against toxic substances that are potential threats of biological warfare.
- use according to the invention can also include use against strains of bacteria such as Bacillus anthracis , Clostridium botulinum toxin, Clostridium perfringens epsilon toxin Yersinia Pestis, Francisella tulariensis, Coxiella burnetii , Brucella species, Staphylococcus enterotoxin B, or against viruses such as Variola major, alphaviruses causing meningoencephalitis syndromes (EEEV, VEEV, and WEEV) , viruses known to cause hemorrhagic fevers such as Ebola, Marburg and Junin virus or against viruses such as Nipah virus, Hantaviruses, Tickborne encephalitis virus and Yellow fever virus or against toxins e.g.
- Ricin toxin from Ricinus communis and the like Use of the mixtures according to the invention can also include use against unicellular or multicellular parasites.
- Recombinant mixtures of antibodies according to the invention may become a safe alternative to polyclonal antibodies obtained from pools of human sera for passive immunization, or from sera of hyper-immunized animals.
- the mixtures may be more efficacious than recombinant monoclonal antibodies in various therapeutic applications, including cancer, allergy, viral diseases, chronic inflammation, and the like.
- tumor- reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells (Ghetie et al, 1997) .
- target cells such as tumor cells or infectious microorganisms
- the bispecific antibodies present in mixtures according to the invention may also crosslink different receptors or other antigens on the surface of target cells, and therefore such mixtures may be very suitable for killing such cells.
- the present invention also provides methods to recombinantly produce mixtures of antibodies comprising mainly monospecific antibodies.
- Her-2 may therefore be a good target for antibody mixtures according to the present invention.
- Antibodies useful for this purpose can be obtained by methods described in the present invention, including antibody display methods.
- Human antibodies are capable of eliciting effector function via binding to immunoglobulin receptors on immune effector cells.
- Human IgG fix complement to induce CDC and interact with Fc ⁇ receptors to induce antibody dependent cell mediated cytotoxicity (ADCC) , phagocytosis, endocytosis, induction of respiratory burst and release of inflammatory mediators and cytokines.
- Human IgA interacts with Fc R, also to result in efficient activation of ADCC and phagocytosis of target cells.
- the principle of using a common light chain can also be used for the production of a mixture of isotypes from a host cell. It is therefore yet another aspect of the present invention to provide a method for producing a mixture of antibodies comprising different isotypes from a host cell, the method comprising the step of: culturing a host cell comprising a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding at least two heavy chains of different isotype that are capable of pairing with said light chain, under conditions conducive to expression of said nucleic acid sequences.
- different heavy chains may have identical variable regions, and only differ in their constant regions (i.e. be of different isotype and have the same specificity) .
- said isotypes comprise at least an IgG and an IgA and/or IgM, preferably IgGl or IgG3 and IgA.
- IgGl preferably IgGl or IgG3 and IgA.
- IgGl preferably IgGl or IgG3 and IgA.
- IgGl preferably IgGl or IgG3 and IgA.
- IgGl IgG2, IgG3 and IgG4
- bispecific antibodies will not be produced because the variable regions are the same.
- not only the constant regions of the heavy chains may differ, but also the variable regions, thereby giving rise to different specificities, paired with the same light chain.
- bispecific antibodies are not desired for a given purpose, e.g. because the mixtures of antibodies are less efficacious because of the presence of the bispecific antibodies, it is possible to use at least two heavy chains combined with the common light chain according to the invention wherein said heavy chains differ sufficient in their constant regions to reduce or prevent pairing between the different heavy chains, e.g. by using heavy chains of different isotypes, e.g. an IgGl and an IgG3 (see Fig. 11 for a schematic representation) .
- the heavy chains of different isotype will pair much less efficient, if at all, compared to the same heavy chains.
- said heavy chains are of different isotype.
- 3, 4, 5, 6, 7, 8, 9, 10, or more different heavy chains are expressed.
- Mixtures of antibodies obtainable by this method are also embodied in the present invention. Such mixtures will comprise mainly monospecific antibodies.
- the invention provides a method for producing a mixture of antibodies comprising dimeric IgA isotype ⁇ (IgA) 2 ⁇ antibodies in a recombinant host, wherein at least part of said dimeric IgA antibodies have different binding regions in each of the IgA subunits, the method comprising the step of: expressing in a recombinant host cell a nucleic acid sequence encoding a common light chain and nucleic acid sequences encoding at least two different heavy chains of IgA isotype capable of pairing to said common light chain, wherein said different heavy chains differ in their variable region. Dimerization of the IgA molecules can be enhanced by co-expressing J-chain (Yoo et al,
- the invention provides a method for producing a mixture of antibodies comprising an IgM antibody having at least two different specificities, the method comprising the step of expressing in a recombinant host cell a nucleic acid sequence encoding a common light chain and nucleic acid sequences encoding at least two different heavy chains of IgM isotype, wherein said heavy chains are capable of pairing to said common light chain and form functional antigen binding regions.
- IgM pentamer Up to five specificities can be comprised in an IgM pentamer in the presence of J-chain, and up to six in an IgM hexamer in the absence of J-chain (Yoo et al, 1999) . Therefore, in specific embodiments, 3, 4, 5, or 6 IgM heavy chains are co-expressed with the common light chain according to this aspect of the invention. See Fig. 10 for a schematic representation of one of the possible forms that can be produced and present in the mixture according to this aspect of the invention, when five different heavy chains are expressed with a common light chain.
- the invention also provides for IgA dimers, IgM pentamers or hexamers having at least two different specificities.
- These molecules can be produced from a clone of a single host cell according to the invention.
- Such molecules harbouring antigen binding regions with different specificities, can bind different epitopes on the same antigen, different antigens on one cell, or different antigens on different cells, thereby crosslinking the antigens or cells.
- said mixture is comprised in a composition according to the present invention.
- the invention also provides a method for recombinant expression of one or more proteins in a single host cell, wherein at least four different polypeptides are expressed in said single host cell.
- Each polypeptide is independently expressed, and may be under control of a heterologous promoter.
- the protein or proteins may be isolated separately or as a mixture from a culture of said host cell.
- the host cell of this embodiment is a human cell, and/or may be derived from a retina cell, more preferably a cell comprising adenovirus El sequences in its genome, most preferably a PER.C6 cell.
- Example 1 Production of a mixture of monoclonal antibodies with a common light chain and two different heavy chain variable regions in a single cell Clone UBS-54 and Clone K53 were previously isolated by selections on the colorectal cell line SW40 (Huls et al., 1999) and on a heterogeneous mixture of mononuclear cells of a patient with multiple myeloma (WO 02/18948) , respectively, with a semi-synthetic library (de Kruif et al., 1995b). Further studies revealed that clone UBS-54 and K53 bound to the EP-CAM homotypic adhesion molecule (Huls et al., 1999) and the membrane cofactor protein CD46 (WO 02/18948), respectively.
- each 80 cm 2 flask was transfected by incubation for 4 hours with 140 ⁇ l lipofectamine + 10 ⁇ g DNA (either pUBS3000Neo, pCD46_3000 (Neo) or 10 ⁇ g of both) in serum-free DMEM medium at 37 °C. After 4 hours, this was replaced with DMEM 4- 10% FBS, and the cells were grown overnight at 37°C. Cells were then washed with PBS and the medium was replaced with Excell 525 medium (JRH Bioscience) . The cells were allowed to grow at 37°C for 6 days, after which the cell culture supernatant was harvested.
- Human IgG specific ELISA analysis (described in WO 00/63403) indicated that IgG was present at approximately 10 ⁇ g/ml for all flasks containing expression plasmids. No IgGl was present in a control flask which was not transfected with expression plasmid. Human IgG from each supernatant was subsequently purified using Protein A affinity chromatography (Hightrap Protein A HP, cat.no. 1-040203) according to standard procedures, following recommendations of the manufacturer (Amersham Biosciences) . After elution, samples were concentrated in a Microcon YM30 concentrator (Amicon) and buffer exchanged to 10 mM sodium phosphate, pH 6.7.
- Protein A affinity chromatography Hightrap Protein A HP, cat.no. 1-040203
- Isoelectric focusing gels (Serva Pre-cast IEF gels, pH range 3-10, cat.no. 42866) .
- the samples were loaded on the low pH side and after focussing stained with colloidal blue (Fig. 5) .
- Lane 1 shows transiently expressed K53
- Lane 2 shows transiently expressed UBS-54
- Lane 3 shows the IgG sample of the cells in which both antibodies were co- transfected.
- K53 and UBS-54 each have a unique pi profile and the sample form the cotransfection showed other unique isoforms, with the major isoform having a pi in between those of K53 and UBS-54.
- K53 and UBS-54 have a theoretic pi of 8.24 and 7.65, respectively, whereas an isoform representing a heterodimer of one UBS-54 heavy chain and one K53 heavy chain has a theoretical pi of 8.01. Assembly of such a heterodimer can only occur when a single cell translates both the heavy chain of K53 and the heavy chain of UBS-54 and assembles these into a full length IgG molecule together with the common light chain.
- this experiment shows that it is possible to express two unique human IgG molecules in a single cell and that a heterodimer consisting of these two unique binding specificities is also efficiently formed.
- a method for producing a mixture of antibodies according to the invention, using expression in a recombinant host cell of a single light chain and three different heavy chains capable of pairing to the single light chain to form functional antibodies is exemplified herein and is schematically shown in Fig. 6.
- Phages encoding antibodies capable of binding proteins present on human B-cells, i.e. CD22, CD72 and Major Histocompatibility Complex (MHC) class II were previously isolated from a semi-synthetic phage library (de Kruif et al . , 1995/ van der Vuurst de Vries & Logtenberg, 1999) .
- V H and V L sequences of the phages clone B28 (anti-CD22) , clone 1-2 (anti-HLA-DR) and clone II-2 (anti-CD72) revealed that they all contain a unique V H sequence, but a common light chain sequence (V ⁇ 3) with an identical CDR region (Fig. 7) .
- V H and V L sequences of clones B28, 1-1 and II-2 are cloned behind the HAVT20 leader sequences of an expression plasmid comprising a heavy chain.
- An example of such a plasmid is pCRU-KOl (contains kappa heavy chain sequences, that can easily be interchanged for lambda heavy chain sequences if desired, by a person skilled in the art) , as deposited at the ECACC under number 03041601.
- the cloning gives rise to plasmids encoding a full length human IgGi with binding specificities for CD22, CD72 and HLA-DR.
- These plasmids will further be referred to as pCRU-CD22, pCRU-CD72 and pCRU-HLA-DR, respectively.
- Stable PER.C6TM derived cell lines are generated, according to methods known to the person skilled in the art (see e.g. WO 00/63403), the cell lines expressing antibodies encoded by genetic information on either pCRU- CD22, pCRU-CD72 or pCRU-HLA-DR and a cell line expressing antibodies encoded by all three plasmids. Therefore, PER.C6TM cells are seeded in DMEM plus 10% FBS in tissue culture dishes (10 cm diameter) or T80 flasks with approximately 2.5 x 10 6 cells per dish and kept overnight under their normal culture conditions (10% C0 2 concentration and 37°C) .
- transfections are performed in separate dishes at 37°C using Lipofectamine (Invitrogen Life Technologies) according to standard protocols provided by the manufacturer, with either 1-2 ⁇ g pCRU-CD22, 1-2 ⁇ g pCRU-CD72, 1-2 ⁇ g pCRU-HLA-DR or 1 ⁇ g of a mixture of pCRU-CD22, pCRU-CD72 and pCRU-HLA-DR.
- a few dishes are transfected with a LacZ control vector, while a few dishes will be not transfected and serve as negative controls.
- cells are frozen (at least 1, but usually 4 vials per sub-cultured colony) and production levels of recombinant human IgG antibody are determined in the supernatant using an ELISA specific for human IgGi (described in WO 00/63403) .
- G418 is removed from the culture medium and never re- applied again. For a representative number of colonies larger volumes will be cultured to purify the recombinant human IgGi fraction from the conditioned supernatant using Protein A affinity chromatography according to standard procedures.
- Purified human IgGi from the various clones is analyzed on SDS-PAGE, Iso-electric focusing (IEF) and binding to the targets CD22, CD72 and HLA-DR using cell transfectants expressing these human antigens on their cell surface (transfectants expressing CD72 and HLA-DR have been described by van der Vuurst-de Vries and Logtenberg, 1999/ a CD22 transfectant has been prepared according to similar standard procedures in PER.C6TM).
- Colonies obtained from the co-transfection with pCRU- CD22, pCRU-CD72 and pCRU-HLA-DR are screened by PCR on genomic DNA for the presence or absence of each of the three constructs.
- PCR products are further confirmed by DNA sequencing.
- a clonal cell line accounts for the production of each of the three binding specificities, i.e. proving that a single cell is able to produce a mixture of more than two functional human IgG's. Therefore, a limited number of colonies, which screened positive for the production of each of the three binding specificities (both by PCR at the DNA level as well as in the specified binding assays against CD22, CD72 and HLA-DR), are subjected to single cell sorting using a fluorescence activated cell sorter (FACS) (Becton & Dickinson FACS VANTAGE SE) .
- FACS fluorescence activated cell sorter
- colonies are seeded at 0.3 cells/well to guarantee clonal outgrowth.
- Clonal cell populations hereafter designated as sub- clones, are refreshed once a week with fresh medium.
- Sub- clones are grown and transferred from 96-wells via 24- and 6-wells plates to T25 flasks.
- sub- clones are frozen (at least 1, but usually 4 vials per sub-clone) and production levels of recombinant human IgGi antibody are determined in the supernatant using a human IgGi specific ELISA.
- larger volumes are cultured to purify the recombinant human IgGi fraction from the conditioned supernatant using Protein A affinity chromatography according to standard procedures.
- Purified human IgGi from the various sub-clones is subsequently analyzed as described above for human IgGi obtained from the parental clones, i.e. by SDS-PAGE, Iso- electric focusing (IEF) and binding to the targets CD22, CD72 and HLA-DR.
- Sub-clones will also be screened by PCR on genomic DNA for the presence or absence of each of the three constructs pCRU-CD22, pCRU-CD72 and pCRU-HLA-DR. The identity of the PCR products is further confirmed by DNA sequencing.
- a specific production test is performed using the human IgG specific ELISA and larger volumes are cultured to obtain the cell pellet and the supernatant.
- the cell pellet is used to assess the presence of the three constructs in the genomic DNA, either via PCR, Southern blot and/or FISH.
- the supernatant is used to purify the recombinant human IgGi fraction as described supra.
- Purified human IgGi obtained at the various population doublings is analyzed as described, i.e. by SDS-PAGE, Iso-electric focusing (IEF) and binding to the targets CD22, CD72 and HLA-DR using cell transfectants expressing these antigens.
- IEF Iso-electric focusing
- Functionality of the antibody mixture is analyzed in cell-based assays to determine whether the human IgGi mixture inhibits proliferation and/or induces apoptosis of B-cell lines, such as for example Ramos. Other cell lines can also be used.
- the antibody mixtures are analyzed for their potential to induce antibody dependent cellular toxicity and complement dependent cytotoxicity of for example Ramos cells.
- these cells are incubated in 96-well plates (0.1 - 1.0 x lOVml) with several concentrations (5 - 20 ⁇ g/ml) of the antibody mixtures against CD22, CD72 and HLA-DR for 24 hours.
- the proliferation of the cells is measured by 3 H-thymidine incorporation during another 16 hours of culture. Inhibition of growth is determined by plotting the percentage of 3 H-thymidine incorporation compared to untreated cells (taken as 100% reference value) .
- Ramos cells are stimulated in 48-well plates (0.2 - 1.0 x lOV l) with several concentrations (5 - 20 ⁇ g/ml) of the antibody mixtures against the targets CD22, CD72 and HLA- DR for 24 or 48 hours. After the incubation period the phosphatidyl serine exposure on apoptotic cells is analyzed (Koopman G et al, 1994) . Therefore, the cells are harvested, washed twice with PBS and are incubated at RT for 10 min with 100 ⁇ l FITC-labelled annexin V (Caltag) diluted 1:25 in annexin V binding buffer (Caltag) .
- PI propidium iodide
- apoptosis is induced by crosslinking the antibody mixtures against CD22, CD72 and HLA-DR on the cell surface of Ramos cells with 25 ⁇ g/ml of F(ab)2 of goat-anti-human (Fc-specific) polyclonal antibodies (Jackson Immunoresearch Laboratories, West Grove, PA) during the incubation period.
- apoptosis is induced by incubating the Ramos cells with several concentrations (5 - 20 ⁇ g/ml) of the antibody mixtures against CD22, CD72 and HLA-DR while co-incubating them with the chemosensitizing agents doxorubicin (Calbiochem) or dexamethasone (UMCU, Utrecht, the Netherlands) .
- doxorubicin Calbiochem
- UMCU dexamethasone
- Antibody Dependent Cellular Cytotoxicity of the antibody mixtures is analyzed using peripheral blood mononuclear cells as effector cells in a standard 51 Cr release assay (Huls et al, 1999) .
- peripheral blood mononuclear cells As effector cells, 1-3 x 10 6 Ramos cells are labelled with 100 ⁇ Ci (Amersham, Buckinghamshire, UK) for 1 hour at 37°C. After three washes with medium, the Ramos target cells are plated in U bottom 96 well plates at 5 x 10 3 cells/well.
- Peripheral blood mononuclear cells that are obtained from healthy donors by Ficoll-Hypaque density gradients are then added to each well at effector: target ratios ranging from 80:1 to 10:1 in triplicate.
- Complement dependent cytotoxicity is determined in a similar assay. Instead of the effector cells, now 50 ⁇ l human serum is added to the target cells. Subsequently, the assay is performed in the same manner. Alternatively, ADCC and CDC of the antibody mixtures is determined using a Europium release assay (Patel and Boyd, 1995) or using an LDH release assay (Shields et al, 2001) .
- Example 4 Use of phage display to isolate multiple phages with an identical V L sequence against a predefined target (Her-2) , and production in a recombinant host cell of a mixture of antibodies capable of binding this target.
- Phages displaying scFv fragments capable of binding multiple epitopes present on the same protein can be isolated from a semi-synthetic phage library (de Kruif et al., 1995a, b). It is possible to identify several of such phages and select the ones comprising the same light chain sequence, for further use according to the invention.
- the semi-synthetic library is formed by mixing 7 sub-libraries that each contain a different light chain (de Kruif et al, 1995a,b) . It is therefore particularly practical to use such a sub-library, containing only one light chain and many heavy chains, for screening so that multiple antibodies with an identical V L sequence are obtained, and further used for expressing the antibody mixtures according to the invention.
- phages against Her-2 several fusion proteins are generated comprising different parts of the extracellular domain of Her-2 that are fused to the CH2 and CH3 domains of human IgGl.
- a pCDNA3.1zeo expression vector (InVitrogen) has been constructed that contains in its multiple cloning region an Xhol restriction site in the hinge region in frame prior to the CH2 and CH3 domains of human IgGl.
- Her-2 cDNA clone as a template PCR fragments is generated using standard molecular biology techniques known to a person skilled in the art.
- Her-2-Ig fusionproteins are used for transient transfection of 293T cells using the lipofectamine reagent (Gibco) .
- Lipofectamine reagent Gibco
- Her-2-Ig fusion proteins containing non-overlapping fragments of the Her-2 EC domain are coated for 2 hours at 37° onto the surface of MaxisorpTM plastic tubes (Nunc) at a saturating concentration (0.5 - 5 ⁇ g/ml). The tubes are blocked for 1 h in 2% fat free milk powder dissolved in PBS (MPBS) . Simultaneously, 500 ⁇ l (approximately 10 13 cfu) of a semi-synthetic phage display library (a sub- library according to the terminology used above) in which only one Vkappal light chain is represented prepared as described by De Kruif et al (1995a, b) and references therein, is added to two volumes of 4% MPBS.
- a semi-synthetic phage display library a sub- library according to the terminology used above
- human serum is added to a final concentration of 15% and blocking is allowed to proceed for 30-60 min.
- the Her-2- Ig-coated tubes are emptied and the blocked phage library is added. The tube is sealed and rotated slowly for 1 h, followed by 2 h of incubation without rotation. The tubes are emptied and washed 10 times in PBS containing 0.1% Tween-20, followed by washing 5 times in PBS. 1 ml glycine-HCL, 0.05 M, pH 2.2 is added, and the tube is rotated slowly for 10 min. The eluted phages are added to 500 ⁇ l 1M Tris-HCl pH 7.4. To this mixture, 3.5 ml of exponentially growing XL-1 blue bacterial culture is added.
- the tubes are incubated for 30 min at 37°C without shaking. Subsequently, the bacteria are plated on 2TY agar plates containing ampicillin, tetracycline and glucose. After overnight incubation of the plates at 37 °C, the colonies are scraped from the plates and used to prepare an enriched phage library, essentially as described by De Kruif et al . (1995a). Briefly, scraped bacteria are used to inoculate 2TY medium containing ampicillin, tetracycline and glucose and are grown at 37°C to an OD 50 on of ⁇ 0.3. Helper phages are added and allowed to infect the bacteria after which the medium is changed to 2TY containing ampicillin, tetracycline and kanamycin.
- Selected phage antibodies that are obtained in the screen described above are validated by ELISA for specificity.
- Her-2-Ig fusion proteins containing non-overlapping fragments of the Her-2 EC domain are coated to Maxisorp ELISA plates. After coating, the plates are blocked in 2% MPBS. The selected phage antibodies are incubated in an equal volume of 4% MPBS. The plates are emptied, washed once in PBS, after which the blocked phages are added. Incubation is allowed to proceed for 1 h, the plates are washed in PBS 0.1% Tween- 20 and bound phages are detected using an anti-Ml3 antibody conjugated to peroxidase.
- phage antibodies are analyzed for their ability to bind BT474 human breast cancer cells that express Her-2.
- phage antibodies are first blocked in an equal volume of 4% MPBS for 15 min at 4°C prior to the staining of the BT474 cells.
- the binding of the phage antibodies to the cells is visualized using a biotinylated anti-Ml3 antibody (Santa Cruz Biotechnology) followed by streptavidin-phycoerythrin (Caltag) .
- phage antibodies recognizing multiple epitopes on Her-2 are selected using a method based upon competition of phage binding to Her-2 with binding of the well characterized murine anti-Her-2 antibodies HER50, HER66 and HER70 (Spiridon et al, 2002) .
- 2xl0 6 BT474 cells are incubated at 4°C with approximately 10 13 cfu (0.5 ml) of a semi-synthetic phage display library in which only one Vkappal light chain is represented prepared as described supra and blocked with 2 volumes of medium containing 10% of FBS. The mixture is slowly rotated at 4°C for 2 hours in a sealed tube.
- phages recognizing multiple epitopes on Her-2 are eluted by resuspending the BT474 cells in 1 ml of cold medium containing saturating concentrations (5-20 ⁇ g/ml) of the HER50, HER66 and HER70 murine anti-Her-2 antibodies.
- the cells are left on ice for 10 min, spun down and the supernatant containing the anti-Her-2 phage antibodies is used to reinfect XLl-Blue cells as described supra.
- VK1HER2-1, VK1HER2-2 and VK1HER2-3 are cloned behind the HAVT20 leader sequences of expression plasmid pCRU-KOl (ECACC deposit 03041601) , or a similar expression plasmid, to obtain plasmids encoding a full length human IgGi-kappa with binding specificities for Her-2.
- plasmids are provisionally designated as pCRU-VKlH ⁇ R2-l, PCRU-VK1HER2-2 and pCRU-VKlHER2-3, respectively.
- Stable PER.C6TM derived cell lines are generated, according to methods known to the person skilled in the art, the cell lines expressing antibodies encoded by genetic information on either pCRU-VKlHER2-l, pCRU- VK1HER2-2 or pCRU-VKlHER2-3 and a cell line expressing antibodies encoded by all three plasmids.
- PER.C6TM cells are seeded in DMEM plus 10% FBS in tissue culture dishes (10 cm diameter) or T80 flasks with approximately 2.5 x 10 6 cells per dish and kept overnight under their normal culture conditions (10% C0 2 concentration and 37°C) .
- transfections are performed in separate dishes at 37°C using Lipofectamine (Invitrogen Life Technologies) according to standard protocols provided by the manufacturer, with either 1-2 ⁇ g pCRU-VKlHER2-l, 1-2 ⁇ g pCRU-VKlHER2-2, 1-2 ⁇ g pCRU- VK1HER2-3 or 1 ⁇ g of a mixture of pCRU-VKlHER2-l, pCRU- VK1HER2-2 and pCRU-VKlHER2-3.
- a few dishes are transfected with a LacZ control vector, while a few dishes are not transfected and serve as negative controls.
- cells After 5 hours cells are washed twice with DMEM and refed with fresh medium without selection. The next day, medium is replaced with fresh medium containing 500 ⁇ g/ml G418. Cells are refreshed every 2 or 3 days with medium containing the same concentrations of G418. About 20-22 days after seeding, a large number of colonies are visible and from each transfection at least 300 are picked and grown via 96-well and/or 24-well via 6-well plates to T25 flasks. At this stage, cells are frozen (at least 1, but usually 4 vials per sub-cultured colony) and production levels of recombinant human IgG antibody are determined in the supernatant using an ELISA specific for human IgGi.
- G418 is removed from the culture medium and never re-applied again.
- larger volumes are cultured to purify the recombinant human IgGi fraction from the conditioned supernatant using Protein A affinity chromatography according to standard procedures.
- Purified human IgGi from the various clones is analyzed on SDS- PAGE, Iso-electric focusing (IEF), assayed binding to Her-2-Ig fusion proteins by ELISA, and analyzed for binding to Her-2 on the surface of BT474 cells by flow cytometry.
- IEF Iso-electric focusing
- Clones obtained from the co-transfection of pCRU-VKlHER2- 1, pCRU-VKlHER2-2 and pCRU-VKlHER2-3 are screened by PCR on genomic DNA for the presence or absence of each of the three constructs. The identity of the PCR products is further confirmed by DNA sequencing. Next, it is demonstrated that a clonal cell line accounts for the production of each of the three binding specificities.
- sub- clones are frozen (at least 1, but usually 4 vials per sub-clone) and production levels of recombinant human IgGi antibody are determined in the supernatant using a human IgGi specific ELISA.
- larger volumes are cultured to purify the recombinant human IgGi fraction from the conditioned supernatant using Protein A affinity chromatography according to standard procedures.
- Purified human IgGi from the various sub-clones is subsequently analyzed as described above for human IgGi obtained from the parental clones, i.e. by SDS-PAGE, Iso- electric focusing (IEF) and binding to Her-2.
- Sub-clones will also be screened by PCR on genomic DNA for the presence or absence of each of the three constructs pCRU- VK1HER2-1, pCRU-VKlHER2-2 and pCRU-VKlHER2-3. The identity of the PCR products is further confirmed by DNA sequencing. Other methods such as Southern blot and/or FISH can also be used to determine whether each of the three constructs are present in the clonal cell line.
- Sub-clones that are proven to be transgenic for each of the three constructs are brought into culture for an extensive period to determine whether the presence of the transgenes is stable and whether expression of the antibody mixture remains the same, not only in terms of expression levels, but also for the ratio between the various antibodies that are secreted from the cell. Therefore, the sub-clone culture is maintained for at least 25 population doubling times either as an adherent culture or as a suspension culture. At every 4-6 population doublings, a specific production test is performed using the human IgG specific ELISA and larger volumes are cultured to obtain the cell pellet and the supernatant. The cell pellet is used to assess the presence of the three constructs in the genomic DNA, either via PCR, Southern blot and/or FISH.
- the supernatant is used to purify the recombinant human IgGi fraction as described supra.
- Purified human IgGi obtained at the various population doublings is analyzed as described, i.e. by SDS-PAGE, Iso-electric focusing (IEF) and binding to Her-2 by ELISA and by flow cytometry using BT474 cells.
- Functionality of the antibody mixture of anti-Her-2 antibodies is analyzed in cell-based assays to determine whether the human IgGi mixture inhibits proliferation and/or induces apoptosis of BT474 cells.
- the antibody mixtures are analyzed for their potential to induce antibody dependent cellular toxicity and complement dependent cytotoxicity of BT474 cells.
- the functionality of the antibody mixture recognizing Her-2 can be analyzed and compared to each of the individual IgGl antibodies and to an equimolar combination of the three individual monospecific IgGl molecules.
- these cells are allowed to adhere overnight in 96-well plates (1.5 x 10 5 /well) and are subsequently incubated with several concentrations (5 - 20 ⁇ g/ml) of the antibody mixtures against Her-2 for 72 hours.
- the proliferation of the cells is measured by 3 H- thymidine incorporation during the last 6 hours of culture. Inhibition of growth is determined by plotting the percentage of 3 H-thymidine incorporation compared with untreated cells (taken as 100% reference value) .
- BT474 cells To analyze apoptosis induction of BT474 cells, these cells are allowed to adhere overnight in 48-well plates (2.5 x 10 5 /well in 1ml) and are subsequently incubated with several concentrations (5 - 20 ⁇ g/ml) of the antibody mixtures against Her-2 for 4 hours. Hereafter the cells are harvested by trypsinization, are washed twice with PBS and are incubated at RT for 10 min with 100 ⁇ l FITC-labelled annexin V (Caltag) diluted 1:25 in annexin V binding buffer (Caltag) . Prior to the analysis of the samples by flow cytometry (FACSCalibur, Becton
- PI propidium iodide
- Antibody Dependent Cellular Cytotoxicity of the antibody mixtures is analyzed using peripheral blood mononuclear cells as effector cells and BT474 cells as target cells in a standard 51 Cr release assay as descibed supra (Huls et al, 1999) .
- Complement dependent cytotoxicity is determined in a similar assay. Instead of the effector cells, now 50 ⁇ l human serum is added to the target cells. Subsequently, the assay is performed as described supra.
- ADCC and CDC of the antibody mixtures is determined using a Europium release assay (Patel and Boyd, 1995) or using an LDH release assay (Shields et al, 2001) .
- the functionality of the antibody mixtures against Her-2 is also tested using in vivo animal models, such as for instance described in Spiridon et al, 2002.
- V H and V H sequences of phages against proteins present on human B-cells i.e. CD22 clone B28), CD72 (clone II-2) and HLA-DR (clone 1-2) (Fig. 7) are cloned into expression plasmid pBCl (as provided in the pBCl Mouse Milk Expression System, Invitrogen Life Technologies) to obtain mammary-gland and lactation-specific expression of these human IgG molecules in transgenic animals, according to the manufacturers instructions.
- pBCl as provided in the pBCl Mouse Milk Expression System, Invitrogen Life Technologies
- Obtained pups are screened for the presence of each of the three constructs by PCR on DNA isolated from the tail. Pups, either male or female, confirmed for being transgenic for each of the three antibodies, are weaned and matured.
- Female transgenic mice are fertilized at the age of 6-8 weeks and milk samples are obtained at several time points after gestation. Male transgenic mice are mated with non- transgenic females and female transgenic offspring (as determined with PCR as described above) is mated and milked as described above for the female transgenic founders. Whenever needed, female or male transgenic founders are mated for another generation to be able to obtain sufficient amounts of transgenic milk for each founder line.
- Transgenic milk is analyzed for the presence of human IgG with a human IgG specific ELISA, which does not cross-react with mouse IgG or other mouse milk components.
- Human IgG is purified from transgenic mouse milk using Protein A affinity chromatography according to standard procedures. Purified human IgG is analyzed on SDS-PAGE, Isoelectric focusing and binding on the targets CD22, CD72 and HLA-DR. Functionality of the antibody mixture is analyzed as described supra.
- Example 6 Production of an IgA/IgG mixture against a predefined target in a PER.C6TM derived clone.
- V H -V L sequences of the phage UBS-54 directed against the homotypic adhesion molecule EP-CAM (Huls et al . , 1999) was not only cloned into a vector encoding the constant domains of a human IgGl with Kappa light chain (expression vector pUBS3000Neo) , but also into an expression vector encoding the constant domains of a human IgAl with Kappa light chain (expression vector pUBS54-IgA, Fig. 8) .
- expression vector pUBS54-IgA expression vector encoding the constant domains of a human IgAl with Kappa light chain
- antibodies derived from pUBS3000Neo and pUBS54-IgA are in the sequences encoding the constant domains of the heavy chain, resulting in either an IgGi or IgAi isotype.
- the Kappa light chain sequences of these two vectors are identical.
- Stable PER.C6TM derived cell lines expressing antibodies encoded by genetic information on pUBS3000Neo and pUBS54- IgA are generated by procedures well known to persons skilled in the art.
- PER.C6TM cells are seeded in DMEM plus 10% FBS in tissue culture dishes (10 cm diameter) or T80 flasks with approximately 2.5 x 10 6 cells per dish and kept overnight under their normal culture conditions (10% C0 2 concentration and 37°C) .
- transfections are performed in separate dishes at 37°C using Lipofectamine (Invitrogen Life Technologies) according to standard protocols provided by the manufacturer, with either 1-2 ⁇ g pUBS3000Neo and pUBS54- IgA.
- a few dishes are transfected with a LacZ control vector, while a few dishes are not transfected and serve as negative controls .
- cells are frozen (at least 1, but usually 4 vials per sub-cultured colony) and production levels of recombinant human IgG and human IgA antibody are determined in the supernatant using an ELISA specific for human IgGl as well as an ELISA specific for human IgA.
- G418 is removed from the culture medium and never re-applied again.
- larger volumes are cultured to purify the recombinant human IgGi and human IgA fraction from the conditioned supernatant using for instance (a combination of) Protein L or LA affinity chromatography, cation exchange chromatography, hydrophobic interaction chromatography and gel filtration.
- Purified human immunoglobulins from the various clones are analyzed on SDS-PAGE, Iso-electric focusing (IEF) and binding to the target EPCAM using cell lines having a high expression of this molecule.
- the clones will also be screened by PCR on genomic DNA for the presence or absence of pUBS3000Neo and pUBS54-IgA. The identity of the PCR products is further confirmed by DNA sequencing.
- a limited number of clones, which are screened positive for the production of both EPCAM IgGi and EPCAM IgA, are subjected to single cell sorting using a fluorescence activated cell sorter (FACS) (Becton Dickinson FACS VANTAGE SE) .
- FACS fluorescence activated cell sorter
- colonies are seeded at 0.3 cells/well to guarantee clonal outgrowth.
- Clonal cell populations, hereafter designated as sub-clones, are refreshed once a week with fresh medium.
- Sub-clones are grown and transferred from 96-wells via 24- and 6-wells plates to T25 flasks.
- sub-clones are frozen (at least 1, but usually 4 vials per sub-clone) and production levels of recombinant human IgGi and IgA antibody are determined in the supernatant using a human IgGi specific ELISA and a human IgA specific ELISA.
- larger volumes are cultured to purify the recombinant human IgGi and human IgAi fraction from the conditioned supernatant using for instance (a combination of) Protein L or LA affinity chromatography, cation exchange chromatography, hydrophobic interaction chromatography and gel filtration.
- Purified human immunoglobulins from the various clones are analyzed on SDS-PAGE, Iso-electric focusing (IEF) and binding to the target EPCAM using cell lines having a high expression of this molecule.
- Sub-clones will also be screened by PCR on genomic DNA for the presence or absence of pUBS3000Neo and pUBS54- IgA. The identity of the PCR products is further confirmed by DNA sequencing.
- Example 7 Production of a human IgG ⁇ /IgG 3 mixture against multiple targets in a clonal PER.C6TM cell line
- Phage clone UBS-54 and Clone K53 were obtained as described in Example 1.
- the V H and V L of clone UBS-54 was inserted into an expression vector containing the HAVT20 leader sequence and all the coding sequences for the constant domains of a human IgGi with a Kappa light chain by a method essentially as described (Boel et al, 2000) .
- the resulting plasmid was designated as pUBS3000Neo (Fig. 4) . It will be clear that expression vectors containing heavy chain constant domains of any desired isotype can be constructed by routine methods of molecular biology, using the sequences of these regions that are all available in the art.
- the V H and V L sequences of Phage clone K53 are cloned into an expression vector containing the HAVT20 leader sequence and all the coding sequences for the constant domains of a heavy chain of a human IgG 3 with a Kappa light chain by a method essentially as described (Boel et al, 2000) .
- This expression vector is designated as pK53IgG3.
- These plasmids are transiently expressed either alone or in combination in PER.C6TM cells.
- each 80 cm 2 flask is transfected by incubation for 4 hours with 140 ⁇ l lipofectamine + 10 ⁇ g DNA (either pUBS3000Neo, pK53lgG3 or 10 ⁇ g of both) in serum-free DMEM medium at 37 °C. After 4 hours, this is replaced with DMEM + 10% FBS, and the cells are grown overnight at 37°C. Cells are then washed with PBS and the medium is replaced with
- the pi values of the major isoforms for each sample are determined to illustrate whether there has been expression of UBS-54 IgGl, K53 IgG3 or bispecific heterodimers, depending on how the cells were transfected.
- the identification of heterodimers would indicate that single cells have translated both the IgG3 heavy chain of K53 and the IgGl heavy chain of UBS-54 and assembled these into a full length IgG molecule together with the common light chain.
- the absence of bispecific heterodimers indicates that it is possible to translate both the IgG3 heavy chain of K53 and the IgGl heavy chain of UBS-54 in single cells, but that these do not assemble into a full length IgG molecule together with the common light chain, i.e.
- PER.C6TM cells are seeded in DMEM plus 10% FBS in tissue culture dishes (10 cm diameter) or T80 flasks with approximately 2.5 x 10 6 cells per dish and kept overnight under their normal culture conditions (10% C0 2 concentration and 37°C) .
- transfections are performed in separate dishes at 37°C using Lipofectamine (Invitrogen Life Technologies) according to standard protocols provided by the manufacturer, with either 1-2 ⁇ g pUBS3000Neo, pK53IgG3 or both.
- a few dishes are transfected with a LacZ control vector, while a few dishes will be not transfected and serve as negative controls.
- cells are washed twice with DMEM and refed with fresh medium without selection.
- medium is replaced with fresh medium containing 500 ⁇ g/ml G418. Cells are refreshed every 2 or 3 days with medium containing the same concentrations of G418.
- FACS fluorescence activated cell sorter
- sub-clones are frozen (at least 1, but usually 4 vials per sub-clone) and production levels of recombinant human IgG antibody are determined in the supernatant using a human IgG specific ELISA.
- larger volumes are cultured to purify the recombinant human IgG fraction from the conditioned supernatant using Protein A affinity chromatography (Hightrap Protein A HP, cat.no. 1-040203) according to standard procedures, following recommendations of the manufacturer (Amersham Biosciences) .
- Purified human immunoglobulins from the various clones are analyzed on SDS-PAGE, Iso-electric focusing (IEF) and binding to the targets EPCAM and CD46 using cell lines having a high expression of this molecules, such as for instance LS174T cells, or transfectants expressing these molecules.
- Sub-clones are also screened by PCR on genomic DNA for the presence or absence of pUBS3000Neo and pK53lgG3. The identity of the PCR products is further confirmed by DNA sequencing.
- Example 8 Selection of phage carrying single chain Fv fragments specifically recognizing rabies virus glyco protein (RVGP) using RVGP-Ig fusion protein, and expression of mixtures of antibodies against the rabies virus .
- RVGP rabies virus glyco protein
- RVGP Rabies Virus Glycoprotein
- Several monoclonal antibodies recognizing RVGP have already been described in the art, and polyclonal antibodies have been recognized to be useful in treatment of rabies infections as well (e.g. EP0402029; EP0445625) .
- Antibody fragments are selected using antibody phage display libraries and MAbstractTM technology, essentially as described in US patent 6,265,150 and in WO 98/15833. All procedures are performed at room temperature unless stated otherwise.
- RVGP-Ig fusion protein consisting of whole RVGP fused genetically to the CH2 and CH3 domains of human IgGl is produced using vector pcDNA3.1 Zeo-CH2-CH3 expressed in PER.C6TM and coated for 2 hours at 37° onto the surface of MaxisorpTM plastic tubes (Nunc) at a concentration of 1.25 ⁇ g/ml. The tubes are blocked for 1 h in 2% fat free milk powder dissolved in PBS (MPBS) .
- MPBS fat free milk powder dissolved in PBS
- a phage display library expressing single chain Fv fragments essentially prepared as described by De Kruif et al (1995a,b) and references therein, is added to two volumes of 4% MPBS.
- selections are performed using fractions of the original library constructed using only one single variable light chain gene species (e.g. a ⁇ VK1' -library) .
- human serum is added to a final concentration of 15% and blocking is allowed to proceed for 30-60 min.
- the RVGP- Ig-coated tubes are emptied and the blocked phage library is added.
- the tube is sealed and rotated slowly for 1 h, followed by 2 h of incubation without rotation.
- the tubes are emptied and washed 10 times in PBS containing 0.1% Tween-20, followed by washing 5 times in PBS.
- 1 ml glycine-HCL, 0.05 M, pH 2.2 is added, and the tube is rotated slowly for 10 min.
- the eluted phages are added to 500 ⁇ l 1M Tris-HCl pH 7.4.
- 3.5 ml of exponentially growing XL-1 blue bacterial culture is added.
- the tubes are incubated for 30 min at 37 °C without shaking. Then, the bacteria are plated on 2TY agar plates containing ampicillin, tetracycline and glucose.
- scraped bacteria are used to inoculate 2TY medium containing ampicillin, tetracycline and glucose and grown at a temperature of 37°C to an OD 6 oonm of ⁇ 0.3.
- Helper phages are added and allowed to infect the bacteria after which the medium is changed to 2TY containing ampicillin, tetracycline and kanamycin. Incubation is continued overnight at 30°C.
- the bacteria are removed from the 2TY medium by centrifugation after which the phages are precipitated using polyethylene glycol 6000/NaCl. Finally, the phages are dissolved in a small volume of PBS-1% BSA, filter- sterilized and used for a next round of selection. The selection/re-infection procedure is performed twice. After the second round of selection, individual E. coli colonies are used to prepare monoclonal phage antibodies. Essentially, individual colonies are grown to log-phase and infected with helper phages after which phage antibody production is allowed to proceed overnight. Phage antibody containing supernatants are tested in ELISA for binding activity to human RVGP-Ig coated 96 wells plates.
- Selected phage antibodies that are obtained in the screen described above, are validated in ELISA for specificity.
- human RVGP-Ig is coated to Maxisorp ELISA plates. After coating, the plates are blocked in 2% MPBS. The selected phage antibodies are incubated in an equal volume of 4% MPBS. The plates are emptied, washed once in PBS, after which the blocked phages are added. Incubation is allowed to proceed for 1 h, the plates are washed in PBS 0.1% Tween-20 and bound phages are detected using an anti-M13 antibody conjugated to peroxidase. As a control, the procedure is performed simultaneously using a control phage antibody directed against thyroglobulin (De Kruif et al. 1995a, b), which serves as a negative control.
- the phage antibodies that bind to human RVGP-Ig are subsequently tested for binding to human serum IgG to exclude the possibility that they recognized the Fc part of the fusion protein.
- phage antibodies are analyzed for their ability to bind PER.C6TM cells that express RVGP
- PER.C6TM cells are transfected with a plasmid carrying a cDNA sequence encoding RVGP or with the empty vector and stable transfectants are selected using standard techniques known to a person skilled in the art (e.g. Coligan, J.E. etal. (2001) Current protocols in protein science, volume I. John Wiley & Sons, Inc. New York) .
- phage antibodies are first blocked in an equal volume of 4% MPBS for 15 min at 4°C prior to the staining of the RVGP- and control transfected PER.C6TM cells.
- the blocked phages are added to a mixture of unlabelled control transfected PER.C6TM cells and RGVP transfected PER.C6TM cells that have been labelled green using a lipophylic dye (PKH67, Sigma) .
- PHL67 lipophylic dye
- the binding of the phage antibodies to the cells is visualized using a biotinylated anti-M13 antibody (Santa Cruz Biotechnology) followed by streptavidin- phycoerythrin (Caltag) .
- Anti RVGP scFv selectively stains the PER.C6TM RVGP transfectant while they do not bind the control transfectant.
- RVGP-transfected PER.C6TM cells An alternative way of screening for phages carrying single chain Fv fragments specifically recognizing human RVGP, is by use of RVGP-transfected PER.C6TM cells.
- PER.C6TM cells expressing membrane bound RVGP are produced as described supra. Phage selection experiments are performed as described supra, using these cells as target. A fraction of the phage library comprised of scFv-phage particles using only one single scFv species (500 ⁇ l, approximately 10 13 cfu) is blocked with 2 ml RPMI/10%FCS/1%NHS for 15' at RT . Untransfected PER.C6TM cells ( ⁇ 10*10 6 cells) are added to the PER.C6-RVGP cells ( ⁇ 1.0*10 6 cells). This mixture is added to the blocked light chain restricted phage-library and incubated for 2,5 hr while slowly rotating at 4°C.
- the cells are washed twice and were resuspended in 500 ⁇ l RPMI/10%FCS and incubated with a murine anti-RVGP antibody (Becton Dickinson) followed by a phycoerythrin (PE) -conjugated anti-mouse-IgG antibody (Calltag) for 15' on ice.
- the cells are washed once and transferred to a 4 ml tube. Cell sorting is performed on a FACSvantage fluorescence-activated cell sorter (Becton Dickinson) and RVGP (PE positive) cells are sorted.
- the sorted cells are spun down, the supernatant is saved and the bound phages are eluted from the cells by resuspending the cells in 500 ⁇ l 50mM Glycin pH2.2 followed by incubation for 5 min. at room temperature. The mixture is neutralized with 250 ⁇ l 1M Tris-HCl pH 7.4 and added to the rescued supernatant.
- phages are used to prepare an enriched phage library as described above.
- the selection/re-infection procedure is performed twice. After the second round of selection, monoclonal phage antibodies are prepared and tested for binding to RVGP- PER.C6TM cells and untransfected PER.C6TM cells as described supra.
- Phages that are positive on RVGP- transfected cells are subsequently tested for binding to the RVGP-IgG fusion protein in ELISA as described supra.
- the selected scFv fragments are cloned in a human IgGl format, according to methods known in the art (e.g. Boel et al, 2000) .
- the VL fragment shared by the selected scFv is PCR amplified using oligo's that add appropriate restriction sites. A similar procedure is used for the VH genes.
- modified genes are cloned in expression pCRU-KOl (ECACC deposit 03041601) , which results in expression vectors encoding a complete hulgGI heavy chain and a complete human light chain gene having the same specificity as the original phage clone.
- pCRU-RVGP-1 pCU-RVGP-2
- pCRU-RVGP-3 pCRU-RVGP-3
- these three vectors may lack DNA encoding the V L region, which can then be encoded in a fourth, separate expression vector not encoding a heavy chain. It is also possible to have V L sequences present in all three or two of the three vectors comprising the different V H sequences.
- Stable PER.C6TM derived cell lines are generated, according to methods known to the person skilled in the art (see e.g. WO 00/63403), the cell lines expressing antibodies encoded by genetic information on either pCRU- RVGP-1, pCRU-RVGP-2 or pCRU-RVGP-3 and a cell line expressing antibodies encoded by all three plasmids. Therefore, PER.C6TM cells are seeded in DMEM plus 10% FBS in tissue culture dishes (10 cm diameter) or T80 flasks with approximately 2.5 x 10 6 cells per dish and kept overnight under their normal culture conditions (10% C0 2 concentration and 37°C) .
- transfections are performed in separate dishes at 37°C using Lipofectamine (Invitrogen Life Technologies) according to standard protocols provided by the manufacturer, with either 1-2 ⁇ g pCRU-RVGP-1, 1-2 ⁇ g pCRU-RVGP-2, 1-2 ⁇ g pCRU-RVGP-3 or 1 ⁇ g of a mixture of pCRU-RVGP-1, pCRU-RVGP-2 and pCRU- RVGP-3.
- a few dishes are transfected with a LacZ control vector, while a few dishes will not be transfected and serve as negative controls.
- cells are washed twice with DMEM and refed with fresh medium without selection.
- medium are replaced with fresh medium containing 500 ⁇ g/ml G418.
- Cells are refreshed every 2 or 3 days with medium containing the same concentrations of G418.
- a large number of colonies are visible and from each transfection at least 300 are picked and grown via 96-well and/or 24-well via 6-well plates to T25 flasks.
- cells are frozen (at least 1, but usually 4 vials per sub-cultured colony) and production levels of recombinant human IgG antibody are determined in the supernatant using an ELISA specific for human IgG x (described in WO 00/63403) .
- G418 is removed from the culture medium and never re- applied again.
- a limited number of colonies, which screened positive for the production of each of the three binding specificities are subjected to single cell sorting using a fluorescence activated cell sorter (FACS) (Becton & Dickinson FACS VANTAGE SE) .
- FACS fluorescence activated cell sorter
- colonies are seeded at 0.3 cells/well to guarantee clonal outgrowth.
- Clonal cell populations, hereafter designated as sub-clones, are refreshed once a week with fresh medium. Sub-clones are grown and transferred from 96-wells via 24- and 6-wells plates to T25 flasks.
- sub-clones are frozen (at least 1, but usually 4 vials per sub-clone) and production levels of recombinant human IgGi antibody are determined in the supernatant using a human IgGi specific ELISA.
- larger volumes are cultured to purify the recombinant human IgGi fraction from the conditioned supernatant using Protein A affinity chromatography according to standard procedures.
- Purified human IgGi from the various sub-clones is subsequently analyzed as described above for human IgGi obtained from the parental clones, i.e. by SDS-PAGE, Isoelectric focusing (IEF) and binding to the target RVGP.
- IEF Isoelectric focusing
- Sub-clones are also screened by PCR on genomic DNA for the presence or absence of each of the three constructs pCRU-RVGP-1, pCRU-RVGP-2 and pCRU-RVGP-3. The identity of the PCR products is further confirmed by DNA sequencing. Other methods such as Southern blot and/or FISH can also be used to determine whether each of the three constructs are present in the clonal cell line.
- Sub-clones that are proven to be transgenic for each of the three constructs are brought into culture for an extensive period to determine whether the presence of the transgenes is stable and whether expression of the antibody mixture remains the same, not only in terms of expression levels, but also for the ratio between the various antibody isoforms that are secreted from the cell. Therefore, the sub-clone culture is maintained for at least 25 population doubling times either as an adherent culture or as a suspension culture. At every 4-6 population doublings, a specific production test is performed using the human IgG specific ELISA and larger volumes are cultured to obtain the cell pellet and the supernatant. The cell pellet is used to assess the presence of the three constructs in the genomic DNA, either via PCR, Southern blot and/or FISH.
- the supernatant is used to purify the recombinant human IgGi fraction as described supra.
- Purified human IgGi obtained at the various population doublings is analyzed as described, i.e. by SDS-PAGE, Iso-electric focusing (IEF) and binding to the target RVGP.
- the efficacy of the antibody mixtures against rabies is tested in in vitro cell culture assays where the decrease in spread of rabies virus is measured, as well as in in vivo animal models infected by rabies. Such models are known to the person skilled in the art, and are e.g. described in EP0402029.
- Example 9 Production of a mixture of antibodies with a common light chain and three different heavy chain variable regions in a single cell.
- a method for producing a mixture of antibodies according to the invention, using expression in a recombinant host cell of a single light chain and three different heavy chains capable of pairing to the single light chain to form functional antibodies, is exemplified herein and is schematically shown in Fig. 6.
- Human IgG' s UBS54 and K53 against the EP-CAM homotypic adhesion molecule (Huls et al., 1999) and the membrane cofactor protein CD46 (WO 02/18948), respectively, are described in Example 1.
- Another clone that was identified to bind to cofactor protein CD46 was clone 02-237 (sequence of VH provided in Fig. 12) .
- DNA sequencing of this clone revealed that it contained the same light chain as UBS54 and K53, but a unique heavy chain variable sequence (see alignment in Fig. 3) .
- the CDR3 of the heavy chain of 02-237 differs at 4 positions from that of K53 (see alignment in Fig. 13) .
- the heavy and light chain variable sequences of phage 02-237 were cloned into the expression plasmid pCRU-KOl, (pCRU-KOl is deposited at the European Collection of Cell Cultures (ECACC) under number 03041601) , which contains the heavy and light chain constant domains for an IgGl antibody.
- the resulting plasmid was designated pgG102-237. Due to the cloning strategy followed, the resulting N-terminus of the light chain of 02-237 as encoded by pgG102-237 differed slightly from the N-terminus of UBS54 and K53 as present by pUBS3000Neo, pCD46_3000 (Neo) , respectively
- Plasmid pgG102-237 was transiently produced in human 293 (T) cells or stably in PER.C6 cells. It appeared that purified 02-237 IgG had a much higher affinity for purified CD46 (Fig. 14) than K53 IgG, i.e. the affinity had increased from 9.1 X 10 "7 M to 2.2 X 10 "8 M for K53 and 02-237, respectively. Also, 02-237 bound much better to CD46 on human coloncarcinoma LS174T cells than K53 (Fig. 15) .
- Stable PER.C6TM derived cell lines expressing a combination of the plasmids pUBS3000Neo, pCD46_3000 (Neo) and pgG102-237 encoding human IgG 02-237 were generated according to methods known as such to the person skilled in the art (see e.g. WO 00/63403). Therefore, PER.C6TM cells were seeded in DMEM plus 10% FBS in tissue culture dishes (10 cm diameter) with approximately 2.5 x 10 6 cells per dish and kept overnight under their normal culture conditions (10% C02 concentration and 37°C) .
- transfections were performed in separate dishes at 37°C using Lipofectamine (Invitrogen Life Technologies) according to standard protocols provided by the manufacturer, with 2 ⁇ g of an equimolar mixture of pUBS3000Neo, pCD46_3000 (Neo) and pgG102-237. As negative control for selection, a few dishes were not transfected. After 4 to 5 hours, cells were washed twice with DMEM and refed with fresh medium without selection. The next day, medium was replaced with fresh medium containing 500 ⁇ g/ml G418. Cells were refreshed every 2 or 3 days with medium containing the same concentrations of G418.
- the 30 best producing colonies were frozen down in vials and the 19 highest producing clones were selected for purification of the IgG (Table 1) . They were sub-cultured in T80 flasks and human IgG from each clone was subsequently purified using Protein A affinity chromatography. Therefore, 15-25 ml of conditioned medium was loaded on a 5 ml Protein A FF Sepharose column (Amersha Biosciences) . The column was washed with 4 mM phosphate buffered saline, pH 7.4 (PBS) before elution with 0.1 M citrate pH 3.0.
- PBS phosphate buffered saline
- the eluted fraction was subsequently desalted on a Sephadex G25 Fine HiPrep Desalting column (Amersham Biotech) to PBS.
- the concentration of the purified IgG fraction was determined by absorbance measurement at 280 nm using a coefficient of 1.4 for a 0.1% (w/v) solution (Table 1).
- the purified IgG samples were analysed on non-reduced and reduced SDS-PAGE and IEF.
- Non-reduced SDS-PAGE (Fig. 16A) showed that all IgG samples migrated comparable to the control K53 or 02-237, as an assembled, intact IgG molecule of approximately 150 kDa.
- reduced SDS-PAGE (Fig. 16B) , the IgG samples migrated as heavy and light chains of about 50 and 25 kDa, respectively, comparable to the heavy and light chain of the control K53 or 02- 237.
- the purified IgG fractions were first compared to a mixture of equal amounts of K53, UBS54 and 02-237 (Fig. 17) .
- some of the samples contained isoforms with a unique pi profile, when compared to the mixture containing purified K53, UBS54 and 02-237.
- Some major unique isoforms have a pi in between the pi of K53 and 02-237 on one hand and UBS54 on the other hand. This is also anticipated on the basis of theoretic pi when calculated with the ProtParam tool provided on the Expasy homepage (http://www.expasy.ch/ Appel et al., 1994).
- K53, 02-237 and UBS54 have a theoretic pi of 8.24, 8.36 and 7.65, respectively, whereas an isoform representing a heterodimer of one UBS54 heavy chain and one K53 heavy chain has a theoretical pi of 8.01. Assembly of such a heterodimer can only occur when a single cell translates both the heavy chain of K53 and the heavy chain of UBS54 and assembles these into a full length IgG molecule together with the common light chain.
- these results suggest that certain clones at least express two functional antibodies.
- samples of the most interesting clones were run in parallel with K53, UBS54 and 02-237, either alone or in a mixture (Fig. 18) .
- Polyl-280 was analysed by BIACORE for binding to CD46 (Fig. 20).
- the affinity of polyl-280 for CD46 was 2.1 X 10 "8 M, which shows that the IgG mixture contains CD46 binding molecules having the same affinity as 02-237 IgG alone.
- this experiment shows that it is possible to express a mixture of functional IgG molecules comprising three unique heavy chains in a single cell and that next to the homodimers, heterodimers consisting of two binding specificities are also formed.
- the frequency of clones expressing three different heavy chains suggests that it will also be possible to obtain clones expressing at least 4, 5 or more heavy chains, using the same procedure.
- a clone expressing at least 3 heavy chains according to the invention can be used to introduce more heavy chains in a separate round of transfection, for instance by using a different selection marker.
- clones 241, 280 and 402 which were screened positive for the production of each of the three IgG's, both by IEF and MS, were subjected to limiting dilution, i.e. seeded at 0.3 cells/well in 96-wells plate to guarantee clonal outgrowth.
- sub-clones Clonal cell populations, hereafter designated as sub- clones, were refreshed once a week with fresh medium. Sub-clones were grown and transferred from 96-wells via 24- and 6-wells plates, T25, T80 and T175 flasks. At the T80 stage, sub-clones were frozen. Production levels of recombinant human IgGi antibody were determined in the supernatant using a human IgGi specific ELISA. For each parental clone, 3 sub-clones were chosen and cultured in a few T175 flasks to obtain sufficient conditioned medium for purification using Protein A affinity chromatography as described above.
- clone 402 is stably producing a mixture of antibodies.
- cDNA of EpCAM, CD46 and control antigen CD38 were cloned into expression vectors pcDNA (Invitrogen) . These vectors were transfected into CHO (dhfr-) cells using Fugene (Roche) according to the protocol supplied by the manufacturer. Cells were cultured in Iscove's medium containing 10% FBS and HT supplement (Gibco) . After culturing for 2 days, cells were harvested by trypsinization and suspended in PBS-1%BSA (PBSB) for use in FACS analysis.
- PBSB PBS-1%BSA
- Purified IgGl of the clones producing the mixtures of antibodies and control IgGl samples of anti-GBSIII, an anti-CD72 antibody (02-004), as well as antibodies from anti-EpCAM clone UBS54 and anti-CD46 clones K53 and 02- 237 were diluted in PBSB to a concentration of 20 ⁇ g IgGl /ml. 20 ⁇ l of each was added to 200.000 transfected cells and incubated on ice for 1 hour. Thereafter, cells were washed once in ice-cold PBSB. Bound IgG was then detected using incubation with goat-anti-human IgG-biotin followed by streptavidin-PE.
- Table II Tryptic peptides of the variable domains of the light chain of K53/UBS54 and 02-237.
- Table III Tryptic peptides of variable domains of heavy chains of K53, 02-237 and UBS54.
- amino acid residue 1 is a pyroglutamic acid
- Flavell DJ Noss A, Pulford KA, Ling N, Flavell SU. 1997.
- Systemic therapy with 3BIT a triple combination cocktail of anti-CDl9, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice. Cancer Res 57: 4824-4829.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (24)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT03764997T ATE514717T1 (en) | 2002-07-18 | 2003-07-15 | RECOMBINANT PRODUCTION OF ANTIBODIES MIXTURES |
SI200332045T SI1523496T1 (en) | 2002-07-18 | 2003-07-15 | Recombinant production of mixtures of antibodies |
DK03764997.7T DK1523496T3 (en) | 2002-07-18 | 2003-07-15 | Recombinant preparation of mixture of antibodies |
EP03764997A EP1523496B1 (en) | 2002-07-18 | 2003-07-15 | Recombinant production of mixtures of antibodies |
CA2492377A CA2492377C (en) | 2002-07-18 | 2003-07-15 | Recombinant production of mixtures of antibodies |
EP10186063.3A EP2314629B2 (en) | 2002-07-18 | 2003-07-15 | Recombinant production of mixtures of antibodies |
AU2003250074A AU2003250074B2 (en) | 2002-07-18 | 2003-07-15 | Recombinant production of mixtures of antibodies |
JP2004522465A JP4836451B2 (en) | 2002-07-18 | 2003-07-15 | Recombinant production of antibody mixtures |
CNB038170779A CN100480260C (en) | 2002-07-18 | 2003-07-15 | Recombinant production of mixtures of antibodies |
ES03764997T ES2368733T3 (en) | 2002-07-18 | 2003-07-15 | RECOMBINANT PRODUCTION OF MIXTURES OF ANTIBODIES. |
NZ537277A NZ537277A (en) | 2002-07-18 | 2003-07-15 | Recombinant production of mixtures of antibodies |
US10/644,256 US8236561B2 (en) | 1999-04-15 | 2003-08-20 | Efficient production of IgA in recombinant mammalian cells |
US11/039,767 US7262028B2 (en) | 2002-07-18 | 2005-01-18 | Recombinant production of mixtures of antibodies |
HK05103474.4A HK1070902A1 (en) | 2002-07-18 | 2005-04-22 | Recombinant production of mixtures of antibodies |
US11/593,280 US7932360B2 (en) | 2002-07-18 | 2006-11-06 | Recombinant production of mixtures of antibodies |
US11/593,279 US7429486B2 (en) | 2002-07-18 | 2006-11-06 | Recombinant production of mixtures of antibodies |
US12/221,021 US7927834B2 (en) | 2002-07-18 | 2008-07-29 | Recombinant production of mixtures of antibodies |
AU2010249150A AU2010249150B9 (en) | 2002-07-18 | 2010-12-02 | Recombinant production of mixtures of antibodies |
US12/932,719 US9303081B2 (en) | 2002-07-18 | 2011-03-04 | Recombinant production of mixtures of antibodies |
US13/795,637 US20130243773A1 (en) | 2002-07-18 | 2013-03-12 | Recombinant production of mixtures of antibodies |
US15/090,505 US10934571B2 (en) | 2002-07-18 | 2016-04-04 | Recombinant production of mixtures of antibodies |
US15/158,543 USRE47770E1 (en) | 2002-07-18 | 2016-05-18 | Recombinant production of mixtures of antibodies |
US15/842,303 US20180094289A1 (en) | 2002-07-18 | 2017-12-14 | Recombinant production of mixtures of antibodies |
US15/855,258 US20180112247A1 (en) | 2002-07-18 | 2017-12-27 | Recombinant production of mixtures of antibodies |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39706602P | 2002-07-18 | 2002-07-18 | |
US60/397,066 | 2002-07-18 | ||
EP02077953 | 2002-07-18 | ||
EP02077953.4 | 2002-07-18 | ||
EPPCT/EP03/50201 | 2003-05-27 | ||
EPPCT/EP03/50201 | 2003-05-27 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EPPCT/EP03/50201 Continuation | 1999-04-15 | 2003-05-27 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/549,463 Continuation-In-Part US6855544B1 (en) | 1999-04-15 | 2000-04-14 | Recombinant protein production in a human cell |
EP10186063.3A Previously-Filed-Application EP2314629B2 (en) | 2002-07-18 | 2003-07-15 | Recombinant production of mixtures of antibodies |
US11/039,767 Continuation US7262028B2 (en) | 2002-07-18 | 2005-01-18 | Recombinant production of mixtures of antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004009618A2 true WO2004009618A2 (en) | 2004-01-29 |
WO2004009618A3 WO2004009618A3 (en) | 2004-11-04 |
Family
ID=43768900
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/007690 WO2004009618A2 (en) | 1999-04-15 | 2003-07-15 | Recombinant production of mixtures of antibodies |
Country Status (15)
Country | Link |
---|---|
US (9) | US7262028B2 (en) |
EP (2) | EP1523496B1 (en) |
JP (4) | JP4836451B2 (en) |
CN (3) | CN101537180B (en) |
AT (1) | ATE514717T1 (en) |
AU (2) | AU2003250074B2 (en) |
CA (3) | CA2872136C (en) |
CY (1) | CY1111886T1 (en) |
DK (2) | DK1523496T3 (en) |
ES (2) | ES2368733T3 (en) |
HK (1) | HK1070902A1 (en) |
NZ (1) | NZ537277A (en) |
PT (2) | PT1523496E (en) |
SI (1) | SI1523496T1 (en) |
WO (1) | WO2004009618A2 (en) |
Cited By (140)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004106375A1 (en) | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
EP1508576A1 (en) * | 2003-08-20 | 2005-02-23 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
WO2005118644A3 (en) * | 2004-05-27 | 2006-03-09 | Crucell Holland Bv | Binding molecules capable of neutralizing rabies virus and uses thereof |
US20060159673A1 (en) * | 2003-01-21 | 2006-07-20 | Tetsuo Kojima | Methods of screening light chain of antibody |
US20070111312A1 (en) * | 2005-11-16 | 2007-05-17 | Cevec Pharmaceuticals Gmbh | Method for the production of permanent human cell lines |
WO2007065433A2 (en) | 2005-12-05 | 2007-06-14 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
WO2007048077A3 (en) * | 2005-10-21 | 2007-07-05 | Gtc Biotherapeutics Inc | Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use |
JP2008506960A (en) * | 2004-07-20 | 2008-03-06 | シムフォゲン・アクティーゼルスカブ | Method for structural characterization of recombinant polyclonal proteins or polyclonal cell lines |
EP1972639A2 (en) | 2007-03-07 | 2008-09-24 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
EP1975184A2 (en) | 2007-03-26 | 2008-10-01 | Albrecht Moritz | Serine or threonine phosphorylation sites |
EP1983002A2 (en) | 2007-04-19 | 2008-10-22 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
EP1983003A2 (en) | 2007-04-19 | 2008-10-22 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
WO2009002380A2 (en) * | 2007-06-26 | 2008-12-31 | The Trustees Of The University Of Pennsylvania | Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies |
EP2062920A2 (en) | 2007-11-21 | 2009-05-27 | Peter Hornbeck | Protein phosphorylation by basophilic serine/threonine kinases in insulin signalling pathways |
WO2009129814A1 (en) * | 2008-04-23 | 2009-10-29 | Symphogen A/S | Methods for manufacturing a polyclonal protein |
EP2123679A2 (en) | 2007-05-01 | 2009-11-25 | Peter Hornbeck | Tyrosine phosphorylation sites |
EP2159291A1 (en) | 2008-09-01 | 2010-03-03 | Agendia B.V. | Means and method for determining tumor cell percentage in a sample |
WO2010084197A1 (en) * | 2009-01-26 | 2010-07-29 | Genmab A/S | Methods for producing mixtures of antibodies |
WO2010093928A2 (en) | 2009-02-12 | 2010-08-19 | Cell Signaling Technology, Inc. | Mutant ros expression in human cancer |
US7807789B2 (en) | 2004-12-21 | 2010-10-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in EGFR-signaling pathways |
US7887805B2 (en) | 2007-03-01 | 2011-02-15 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
US7888480B2 (en) | 2005-08-31 | 2011-02-15 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
US7935790B2 (en) | 2004-10-04 | 2011-05-03 | Cell Singaling Technology, Inc. | Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways |
US7939636B2 (en) | 2006-08-11 | 2011-05-10 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in c-Src signaling pathways |
US7959922B2 (en) | 2006-12-05 | 2011-06-14 | Crucell Holland B.V. | Liquid anti-rabies antibody formulations |
US7973134B2 (en) | 2004-07-07 | 2011-07-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways |
US7977462B2 (en) | 2007-04-19 | 2011-07-12 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
EP2359834A1 (en) | 2006-03-15 | 2011-08-24 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
JP2011525808A (en) * | 2008-06-27 | 2011-09-29 | メルス・ベー・フェー | Antibody-producing non-human mammal |
EP2380907A1 (en) | 2006-09-05 | 2011-10-26 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
WO2011133886A3 (en) * | 2010-04-23 | 2011-12-22 | Genentech, Inc. | Production of heteromultimeric proteins |
WO2012019132A2 (en) | 2010-08-06 | 2012-02-09 | Cell Signaling Technology, Inc. | Anaplastic lymphoma kinase in kidney cancer |
US8148088B2 (en) | 2008-07-18 | 2012-04-03 | Abgent | Regulation of autophagy pathway phosphorylation and uses thereof |
US8198415B2 (en) | 2004-07-20 | 2012-06-12 | Symphogen A/S | Anti-rhesus D recombinant polyclonal antibody |
EP2453236A3 (en) * | 2006-02-17 | 2012-08-22 | Atsuo Sekiyama | Biological load indicator and method of measuring biological load |
WO2012122512A1 (en) | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Recombinant production of mixtures of single chain antibodies |
US8268756B2 (en) | 2004-01-20 | 2012-09-18 | Merus B.V. | Mixture of binding proteins |
EP2505654A1 (en) * | 2010-02-08 | 2012-10-03 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
WO2012162373A1 (en) | 2011-05-23 | 2012-11-29 | Cell Signaling Technology, Inc. | Ros kinase in lung cancer |
AU2011218688B2 (en) * | 2004-05-27 | 2013-01-10 | Crucell Holland B.V. | Binding molecules capable of neutralizing rabies virus and uses thereof |
WO2012148873A3 (en) * | 2011-04-25 | 2013-02-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing antibodies having a common light chain |
WO2013022782A1 (en) * | 2011-08-05 | 2013-02-14 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
WO2013067054A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Antibodies and methods of treating cancer |
WO2013067057A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Anti-gpr49 antibodies |
WO2013067060A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Anti-gpr49 antibodies |
WO2013067055A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
EP2604625A1 (en) | 2011-09-26 | 2013-06-19 | Merus B.V. | Generation of binding molecules |
WO2013157953A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
WO2013158859A1 (en) | 2012-04-18 | 2013-10-24 | Cell Signaling Technology, Inc. | Egfr and ros1 in cancer |
US8663640B2 (en) | 2008-08-29 | 2014-03-04 | Symphogen A/S | Methods using recombinant anti-epidermal growth factor receptor antibody compositions |
WO2014044892A1 (en) * | 2012-09-21 | 2014-03-27 | Consejo Superior De Investigaciones Científicas (Csic) | Method for the production of complex repertoires of recombinant molecules |
WO2014051433A1 (en) * | 2012-09-27 | 2014-04-03 | Merus B.V. | BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS |
NL2012424A (en) * | 2013-03-13 | 2014-09-16 | Regeneron Pharma | Common light chain mouse. |
EP2824183A1 (en) * | 2005-04-08 | 2015-01-14 | Chugai Seiyaku Kabushiki Kaisha | Antibody substituting for function of blood coagulation factor VIII |
AU2012201010B2 (en) * | 2005-10-21 | 2015-01-22 | Genzyme Corporation | Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use |
WO2015130172A1 (en) | 2014-02-28 | 2015-09-03 | Merus B.V. | Antibodies that bind egfr and erbb3 |
WO2015130173A1 (en) | 2014-02-28 | 2015-09-03 | Merus B.V. | Antibody that binds erbb-2 and erbb-3 |
US9163232B2 (en) | 2003-01-07 | 2015-10-20 | Symphogen A/S | Method for manufacturing recombinant polyclonal proteins |
CN105189755A (en) * | 2013-01-15 | 2015-12-23 | 加利福尼亚大学董事会 | Adenoviruses and their use |
AU2013204140B2 (en) * | 2012-03-06 | 2016-01-28 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
US9301510B2 (en) | 2012-03-16 | 2016-04-05 | Regeneron Pharmaceuticals, Inc. | Mice that produce antigen-binding proteins with pH-dependent binding characteristics |
WO2016054315A1 (en) | 2014-10-01 | 2016-04-07 | Medimmune, Llc | Method of conjugating a polypeptide |
US9332742B2 (en) | 2012-03-16 | 2016-05-10 | Regeneron Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
US9334334B2 (en) | 2012-03-16 | 2016-05-10 | Regeneron Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
EP3023502A1 (en) | 2008-04-10 | 2016-05-25 | Cell Signaling Technology, Inc. | Compositions and methods for detecting egfr mutations in cancer |
EP2915819A4 (en) * | 2012-11-05 | 2016-07-20 | Zenyaku Kogyo Kk | Antibody and antibody composition production method |
EP3072963A1 (en) | 2007-10-18 | 2016-09-28 | Cell Signaling Technology, Inc. | Translocation and mutant ros kinase in human non-small cell lung carcinoma |
WO2017010874A1 (en) | 2015-07-10 | 2017-01-19 | Merus N.V. | Human cd3 binding antibody |
US9648856B2 (en) | 2012-03-16 | 2017-05-16 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing pH-sensitive immunoglobulin sequences |
US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
WO2017132298A1 (en) | 2016-01-27 | 2017-08-03 | Medimmune, Llc | Methods for preparing antibodies with a defined glycosylation pattern |
US9765133B2 (en) | 2008-06-27 | 2017-09-19 | Merus N.V. | Antibody producing non-human mammals |
EP3142750A4 (en) * | 2014-05-13 | 2017-10-18 | The Trustees Of The University Of Pennsylvania | Compositions comprising aav expressing dual antibody constructs and uses thereof |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US9828429B2 (en) | 2007-09-26 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US9862778B2 (en) | 2011-10-11 | 2018-01-09 | Genentech, Inc. | Assembly of bispecific antibodies |
US9914771B2 (en) | 2009-04-27 | 2018-03-13 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
WO2018056821A1 (en) | 2016-09-23 | 2018-03-29 | Merus N.V. | Binding molecules that modulate a biological activity expressed by a cell |
US9969814B2 (en) | 2010-02-08 | 2018-05-15 | Regeneron Pharmaceuticals, Inc. | Methods for making fully human bispecific antibodies using a common light chain |
US9975966B2 (en) | 2014-09-26 | 2018-05-22 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing theraputic agent |
US9982013B2 (en) | 2009-06-26 | 2018-05-29 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
WO2018098553A1 (en) * | 2016-12-01 | 2018-06-07 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Production of ricin antibodies in plant |
US10011858B2 (en) | 2005-03-31 | 2018-07-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
US10071158B2 (en) | 2005-04-26 | 2018-09-11 | Lindis Biotech Gmbh | Combination of the application of antibodies for immunostimulation together with glucocorticoids |
WO2018182421A1 (en) | 2017-03-31 | 2018-10-04 | Merus N.V. | Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour |
WO2018212656A1 (en) | 2017-05-17 | 2018-11-22 | Merus N.V. | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer |
WO2018229612A1 (en) | 2017-06-12 | 2018-12-20 | Novartis Ag | Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies |
WO2019009728A1 (en) | 2017-07-06 | 2019-01-10 | Merus N.V. | Antibodies that modulate a biological activity expressed by a cell |
WO2019009726A1 (en) | 2017-07-06 | 2019-01-10 | Merus N.V. | Binding molecules that modulate a biological activity expressed by a cell |
WO2019009727A1 (en) | 2017-07-06 | 2019-01-10 | Merus N.V. | Bispecific anti pd1-anti tim3 antibodies |
US10358500B2 (en) | 2014-04-04 | 2019-07-23 | Bionomics Inc. | Humanized antibodies that bind LGR5 |
WO2019156199A1 (en) | 2018-02-09 | 2019-08-15 | 小野薬品工業株式会社 | Bispecific antibody |
WO2019190327A2 (en) | 2018-03-30 | 2019-10-03 | Merus N.V. | Multivalent antibody |
US10450381B2 (en) | 2010-11-17 | 2019-10-22 | Chugai Seiyaku Kabushiki Kaisha | Methods of treatment that include the administration of bispecific antibodies |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
WO2019243626A1 (en) | 2018-06-22 | 2019-12-26 | Genmab A/S | Method for producing a controlled mixture of two or more different antibodies |
US10584181B2 (en) | 2009-12-04 | 2020-03-10 | Genentech, Inc. | Methods of making and using multispecific antibody panels and antibody analog panels |
WO2020141974A1 (en) | 2018-12-31 | 2020-07-09 | Merus N.V. | Truncated multivalent multimers |
WO2020141973A1 (en) | 2018-12-31 | 2020-07-09 | Merus N.V. | Mixed binding domains |
US10745487B2 (en) | 2016-03-22 | 2020-08-18 | Bionomics Limited | Method of treating cancer by administering an anti-LGR5 monoclonal antibody |
EP3699200A1 (en) | 2013-07-15 | 2020-08-26 | Cell Signaling Technology, Inc. | Anti-mucin 1 binding agents and uses thereof |
US10759870B2 (en) | 2017-09-29 | 2020-09-01 | Chugai Seiyaku Kabushiki Kaisha | Multispecific antigen-binding molecules having blood coagulation factor VIII (FVIII) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ingredient |
WO2020204708A1 (en) | 2019-03-29 | 2020-10-08 | Merus N.V. | Cd3 binding molecules |
WO2020204152A1 (en) | 2019-04-04 | 2020-10-08 | 小野薬品工業株式会社 | Bispecific antibody |
US10808043B2 (en) | 2015-01-08 | 2020-10-20 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | Bispecific antibody or antibody mixture with common light chains |
US10822399B2 (en) | 2014-02-10 | 2020-11-03 | Igm Biosciences, Inc. | IgA multi-specific binding molecules |
WO2020226502A2 (en) | 2019-05-09 | 2020-11-12 | Merus N.V. | Variant domains for multimerizing proteins and separation thereof |
US10881085B2 (en) | 2014-03-21 | 2021-01-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
WO2021006199A1 (en) | 2019-07-05 | 2021-01-14 | 小野薬品工業株式会社 | Treatment of hematologic cancer with pd-1/cd3 dual specificity protein |
WO2021020416A1 (en) | 2019-07-30 | 2021-02-04 | 小野薬品工業株式会社 | Bispecific antibody |
EP3772518A1 (en) | 2019-08-07 | 2021-02-10 | Merus N.V. | Modified human variable domains |
WO2021032966A1 (en) | 2019-08-21 | 2021-02-25 | Cambridge Enterprise Limited | Detection of a-beta oligomers |
US10934571B2 (en) | 2002-07-18 | 2021-03-02 | Merus N.V. | Recombinant production of mixtures of antibodies |
US10941190B2 (en) | 2014-05-06 | 2021-03-09 | Genentech, Inc. | Production of heteromultimeric proteins using mammalian cells |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
WO2021133167A1 (en) | 2019-12-24 | 2021-07-01 | Merus N.V. | Tgf-beta-rii binding proteins |
US11051497B2 (en) | 2011-09-19 | 2021-07-06 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
WO2021154073A1 (en) | 2020-01-29 | 2021-08-05 | Merus N.V. | Means and method for modulating immune cell engaging effects. |
US11111314B2 (en) | 2015-03-19 | 2021-09-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
US11124576B2 (en) | 2013-09-27 | 2021-09-21 | Chungai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
US11150254B2 (en) | 2014-09-26 | 2021-10-19 | Chugai Seiyaku Kabushiki Kaisha | Method for measuring reactivity of FVIII |
EP3912998A2 (en) | 2015-10-23 | 2021-11-24 | Merus N.V. | Binding molecules that inhibit cancer growth |
WO2021235936A1 (en) | 2020-05-21 | 2021-11-25 | Merus N.V. | Methods and means for the production of ig-like molecules |
US11214623B2 (en) | 2014-09-26 | 2022-01-04 | Chugai Seiyaku Kabushiki Kaisha | Antibody capable of neutralizing substance having activity alternative to function of coagulation factor VIII (FVIII) |
WO2022023559A1 (en) | 2020-07-31 | 2022-02-03 | Curevac Ag | Nucleic acid encoded antibody mixtures |
US11297810B2 (en) | 2013-03-18 | 2022-04-12 | Kymab Limited | Animal models and therapeutic molecules |
US11297811B2 (en) | 2012-03-28 | 2022-04-12 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
US11352438B2 (en) | 2016-09-06 | 2022-06-07 | Chugai Seiyaku Kabushiki Kaisha | Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X |
WO2022128546A1 (en) | 2020-12-16 | 2022-06-23 | Merus N.V. | Multispecific antibodies for the treatment of cancer |
US11399522B2 (en) | 2013-10-01 | 2022-08-02 | Kymab Limited | Animal models and therapeutic molecules |
RU2787781C2 (en) * | 2012-08-03 | 2023-01-12 | Регенерон Фармасьютикалз, Инк. | Mice with humanized universal light chain |
US11564380B2 (en) | 2009-07-08 | 2023-01-31 | Kymab Limited | Animal models and therapeutic molecules |
US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
WO2023146394A1 (en) | 2022-01-25 | 2023-08-03 | Merus N.V. | Combination therapy for the treatment of cancer |
EP4223319A2 (en) | 2017-05-26 | 2023-08-09 | MedImmune, LLC | Method and molecules |
US11773170B2 (en) | 2017-08-09 | 2023-10-03 | Merus N.V. | Antibodies that bind EGFR and cMET |
US11780925B2 (en) | 2017-03-31 | 2023-10-10 | Merus N.V. | ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene |
US11820810B2 (en) | 2013-05-02 | 2023-11-21 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
Families Citing this family (150)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994128A (en) | 1995-06-15 | 1999-11-30 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US6783980B2 (en) * | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
ATE299938T1 (en) * | 1997-05-02 | 2005-08-15 | Genentech Inc | A METHOD FOR PRODUCING MULTI-SPECIFIC ANTIBODIES THAT POSSESS HETEROMULTIMER AND COMMON COMPONENTS |
US20030207346A1 (en) * | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US8236561B2 (en) * | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
US7297680B2 (en) * | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
US20050164386A1 (en) * | 1999-04-15 | 2005-07-28 | Uytdehaag Alphonsus G. | Overexpression of enzymes involved in post-translational protein modifications in human cells |
US6855544B1 (en) * | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
US7521220B2 (en) * | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
US7192759B1 (en) * | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
CA2756610C (en) * | 2001-10-29 | 2015-08-25 | Crucell Holland B.V. | Methods for producing proteins having n-linked glycans comprising (sialyl-) lewis x or lacdinac structures |
EP2290100B1 (en) * | 2002-11-01 | 2014-02-19 | Iris International, Inc. | Kits for displacement Sandwich Immuno-PCR |
GB0230201D0 (en) * | 2002-12-27 | 2003-02-05 | Domantis Ltd | Retargeting |
WO2004104046A1 (en) * | 2003-05-23 | 2004-12-02 | Crucell Holland B.V. | Production of recombinant igm in per.c6 cells |
WO2006137933A2 (en) * | 2004-11-03 | 2006-12-28 | Leucadia Technologies, Inc. | Microbubbles for affinity separation |
DK1842226T3 (en) | 2004-11-03 | 2010-10-18 | Iris Molecular Diagnostics Inc | Homogeneous analyte detection |
US20070111237A1 (en) * | 2005-09-14 | 2007-05-17 | Maurizio Zanetti | Process for identifying antigenized antibodies using ribosome cell free expression system |
PL2064325T3 (en) | 2006-09-01 | 2012-05-31 | Therapeutic Human Polyclonals Inc | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
NL1033696C2 (en) * | 2007-04-16 | 2008-10-20 | Friesland Brands Bv | Obtaining an antigen specific antibody from milk derived from a non-human mammal that has not been immunized with the antigen prior to collecting the milk for delivering an antibody of a ruminant |
NZ581316A (en) * | 2007-05-25 | 2012-02-24 | Symphogen As | Method for manufacturing a recombinant polyclonal protein |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof |
KR20100122932A (en) * | 2008-02-21 | 2010-11-23 | 아이리스 인터내셔널 인크. | Method for early determination of recurrence after therapy for prostate cancer |
EP2098536A1 (en) | 2008-03-05 | 2009-09-09 | 4-Antibody AG | Isolation and identification of antigen- or ligand-specific binding proteins |
CN102076355B (en) | 2008-04-29 | 2014-05-07 | Abbvie公司 | Dual varistructure domain immunoglobulins and uses thereof |
KR20110016958A (en) | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | Dual variable domain immunoglobulins and uses thereof |
ES2533952T3 (en) | 2009-02-09 | 2015-04-16 | Morphosys Ag | Production of oligoclonal mixtures of immunoglobulins in individual cells |
US8835610B2 (en) | 2009-03-05 | 2014-09-16 | Abbvie Inc. | IL-17 binding proteins |
MY159837A (en) | 2009-08-29 | 2017-02-15 | Abbvie Inc | Therapeutic dll4 binding proteins |
EP2542582A4 (en) | 2010-03-02 | 2013-12-04 | Abbvie Inc | Therapeutic dll4 binding proteins |
EP2571532B1 (en) | 2010-05-14 | 2017-05-03 | Abbvie Inc. | Il-1 binding proteins |
UY33492A (en) | 2010-07-09 | 2012-01-31 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
EP2947151A1 (en) | 2010-08-02 | 2015-11-25 | Regeneron Pharmaceuticals, Inc. | Binding proteins comprising vl domains |
MX341579B (en) | 2010-08-03 | 2016-08-25 | Abbvie Inc * | Dual variable domain immunoglobulins and uses thereof. |
CA2808482C (en) * | 2010-08-16 | 2021-10-26 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
TW201211252A (en) | 2010-08-26 | 2012-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
SG188328A1 (en) | 2010-09-03 | 2013-04-30 | Stem Centrx Inc | Novel modulators and methods of use |
RU2627171C2 (en) | 2010-12-21 | 2017-08-03 | Эббви Инк. | Il-1 alpha and beta bispecific immunoglobulins with double variable domains and their application |
JP6223829B2 (en) | 2011-01-03 | 2017-11-01 | エーブイエム・バイオテクノロジー・エルエルシー | Individual production of biologics and methods for reprogramming somatic cells |
DE14176593T1 (en) | 2011-02-25 | 2015-03-05 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
US9561274B2 (en) | 2011-06-07 | 2017-02-07 | University Of Hawaii | Treatment and prevention of cancer with HMGB1 antagonists |
US9244074B2 (en) | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
UA117901C2 (en) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Antibody variants and uses thereof |
HUE042192T2 (en) | 2011-09-23 | 2019-06-28 | Oncomed Pharm Inc | Vegf/dll4 binding agents and uses thereof |
SI2627773T1 (en) | 2011-10-17 | 2017-12-29 | Regeneron Pharmaceuticals, Inc., | Restricted immunoglobulin heavy chain mice |
AR088514A1 (en) | 2011-10-24 | 2014-06-18 | Abbvie Inc | BISPECIFIC IMMUNOLIGANTS DIRECTED AGAINST TNF |
EP2771360A1 (en) | 2011-10-24 | 2014-09-03 | AbbVie Inc. | Immunobinders directed against sclerostin |
EP2793567B1 (en) | 2011-12-20 | 2019-02-27 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
US10745468B2 (en) | 2011-12-22 | 2020-08-18 | Kota Biotherapeutics, Llc | Compositions and methods for modified B cells expressing reassigned biological agents |
US9175072B2 (en) | 2011-12-22 | 2015-11-03 | Elwha Llc | Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen |
US8962315B2 (en) * | 2011-12-22 | 2015-02-24 | Elwha Llc | Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen |
US10233424B2 (en) | 2011-12-22 | 2019-03-19 | Elwha Llc | Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin |
JP2015508994A (en) | 2011-12-30 | 2015-03-26 | アッヴィ・インコーポレイテッド | Dual variable domain immunoglobulins against IL-13 and / or IL-17 |
US20130171059A1 (en) | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
KR102023401B1 (en) * | 2012-05-10 | 2019-11-04 | 바이오아트라, 엘엘씨 | Multi-specific monoclonal antibodies |
NZ717848A (en) | 2012-06-12 | 2019-03-29 | Regeneron Pharma | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
EP2869845B1 (en) | 2012-07-06 | 2019-08-28 | Genmab B.V. | Dimeric protein with triple mutations |
EP3632462A1 (en) | 2012-07-06 | 2020-04-08 | Genmab B.V. | Dimeric protein with triple mutations |
WO2014011955A2 (en) | 2012-07-12 | 2014-01-16 | Abbvie, Inc. | Il-1 binding proteins |
CN102851338A (en) | 2012-07-25 | 2013-01-02 | 苏州康宁杰瑞生物科技有限公司 | Method for preparing homodimer protein mixture by using charge repulsive interaction |
AU2013337775B2 (en) | 2012-11-01 | 2017-03-30 | Abbvie Inc. | Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof |
JP2016501881A (en) | 2012-12-04 | 2016-01-21 | アッヴィ・インコーポレイテッド | Bispecific binding protein that permeates the blood-brain barrier (BBB) |
US9856319B2 (en) | 2012-12-28 | 2018-01-02 | Abbvie Inc. | Monovalent binding proteins |
US20140219913A1 (en) | 2012-12-28 | 2014-08-07 | Abbvie, Inc. | Dual Specific Binding Proteins Having a Receptor Sequence |
KR20220156667A (en) | 2013-01-10 | 2022-11-25 | 젠맵 비. 브이 | Human igg1 fc region variants and uses thereof |
CN104994730B (en) | 2013-02-20 | 2018-12-28 | 瑞泽恩制药公司 | The non-human animal of immunoglobulin heavy chain with modification |
TW201512219A (en) | 2013-03-15 | 2015-04-01 | Abbvie Inc | Dual specific binding proteins directed against IL-1[beta] and/or IL-17 |
US20140271457A1 (en) | 2013-03-15 | 2014-09-18 | Abbvie Inc. | Dual Specific Binding Proteins Directed Against TNF |
IL290613B1 (en) | 2013-07-05 | 2024-07-01 | Genmab As | Humanized or chimeric cd3 antibodies |
US20150125397A1 (en) | 2013-10-06 | 2015-05-07 | Abbvie Inc. | Dual specific binding proteins directed against immune cell receptors and autoantigens |
JP2016540761A (en) | 2013-12-02 | 2016-12-28 | アッヴィ・インコーポレイテッド | Compositions and methods for treating osteoarthritis |
ES2762640T3 (en) | 2014-03-21 | 2020-05-25 | Regeneron Pharma | VL antigen binding proteins exhibiting different binding characteristics |
WO2015153765A1 (en) | 2014-04-01 | 2015-10-08 | Adimab, Llc | Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use |
AU2015240595B2 (en) | 2014-04-03 | 2020-02-27 | Igm Biosciences, Inc. | Modified J-chain |
SG11201610777VA (en) | 2014-07-11 | 2017-01-27 | Genmab As | Antibodies binding axl |
AR101262A1 (en) | 2014-07-26 | 2016-12-07 | Regeneron Pharma | PURIFICATION PLATFORM FOR Bispecific Antibodies |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
AU2016209324B2 (en) | 2015-01-20 | 2020-02-27 | Igm Biosciences, Inc. | Tumor necrosis factor (TNF) superfamily receptor binding molecules and uses thereof |
PT3265575T (en) | 2015-03-04 | 2021-06-16 | Igm Biosciences Inc | Cd20 binding molecules and uses thereof |
TW201710286A (en) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | Binding proteins against VEGF, PDGF, and/or their receptors |
EP3730520A1 (en) | 2015-07-10 | 2020-10-28 | Genmab A/S | Axl-specific antibody-drug conjugates for cancer treatment |
CN114989302A (en) | 2015-07-15 | 2022-09-02 | 根马布股份公司 | Humanized or chimeric CD3 antibodies |
MX2018002493A (en) * | 2015-08-27 | 2018-06-07 | Crystal Bioscience Inc | Transgenic animal for production of antibodies having a common light chain. |
US11639389B2 (en) | 2015-09-30 | 2023-05-02 | Igm Biosciences, Inc. | Binding molecules with modified J-chain |
EP3824903A1 (en) | 2015-09-30 | 2021-05-26 | IGM Biosciences Inc. | Binding molecules with modified j-chain |
WO2017165464A1 (en) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
CA3025162A1 (en) | 2016-05-26 | 2017-11-30 | Qilu Puget Sound Biotherapeutics Corporation | Mixtures of antibodies |
UA128304C2 (en) | 2016-07-14 | 2024-06-05 | Ґенмаб А/С | Multispecific antibodies against cd40 and cd137 |
SG11201903693QA (en) | 2016-11-01 | 2019-05-30 | Genmab Bv | Polypeptide variants and uses thereof |
CA3050988A1 (en) * | 2017-02-02 | 2018-08-09 | Merck Patent Gmbh | Preferred pairing of antibody domains |
KR20240101717A (en) | 2017-02-10 | 2024-07-02 | 젠맵 비. 브이 | Polypeptide variants and uses thereof |
WO2018151820A1 (en) | 2017-02-16 | 2018-08-23 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
WO2018162749A1 (en) | 2017-03-09 | 2018-09-13 | Genmab A/S | Antibodies against pd-l1 |
JP7330942B2 (en) | 2017-03-31 | 2023-08-22 | ジェンマブ ホールディング ビー.ブイ. | Bispecific Anti-CD37 Antibodies, Monoclonal Anti-CD37 Antibodies, and Methods of Using Them |
JP2020522254A (en) | 2017-05-31 | 2020-07-30 | エルスター セラピューティクス, インコーポレイテッド | Multispecific molecules that bind myeloproliferative leukemia (MPL) proteins and uses thereof |
GB201710984D0 (en) * | 2017-07-07 | 2017-08-23 | Kymab Ltd | Cells, vertebrates, populations & methods |
KR20200064062A (en) | 2017-08-04 | 2020-06-05 | 젠맵 에이/에스 | Binders that bind to PD-L1 and CD137 and uses thereof |
EP3731867A4 (en) * | 2017-12-19 | 2022-04-06 | Surrozen Operating, Inc. | Anti-lrp5/6 antibodies and methods of use |
CN118271444A (en) | 2017-12-19 | 2024-07-02 | 瑟罗泽恩奥普瑞汀公司 | WNT-substituted molecules and uses thereof |
US20210107988A1 (en) | 2018-01-24 | 2021-04-15 | Genmab B.V. | Polypeptide variants and uses thereof |
MA52152A (en) | 2018-03-12 | 2021-01-20 | Genmab As | ANTIBODY |
WO2019178364A2 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
EP3768707A4 (en) * | 2018-03-19 | 2022-01-26 | The Invention Science Fund II, LLC | Compositions and methods for modified b cells expressing reassigned biological agents |
WO2019211472A1 (en) | 2018-05-03 | 2019-11-07 | Genmab B.V. | Antibody variant combinations and uses thereof |
US20210371539A1 (en) | 2018-06-22 | 2021-12-02 | Genmab Holding B.V. | Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof |
DE202019005887U1 (en) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
JP7534281B2 (en) | 2018-07-13 | 2024-08-14 | ジェンマブ エー/エス | Trogocytosis-mediated therapy using CD38 antibodies |
SG11202012993SA (en) | 2018-07-13 | 2021-02-25 | Genmab As | Variants of cd38 antibody and uses thereof |
MA53812A (en) | 2018-10-04 | 2021-08-11 | Genmab Holding B V | PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTI-CD37 ANTIBODIES |
SG11202104300PA (en) | 2018-11-06 | 2021-05-28 | Genmab As | Antibody formulation |
CA3125380A1 (en) | 2019-02-18 | 2020-08-27 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with humanized immunoglobulin locus |
AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
CA3130754A1 (en) | 2019-02-21 | 2020-08-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
WO2020172601A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
GB2598218B (en) | 2019-02-21 | 2024-05-08 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
EP3927745A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
US20220315661A1 (en) | 2019-05-09 | 2022-10-06 | Genmab B.V. | Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer |
US20220411529A1 (en) | 2019-11-06 | 2022-12-29 | Genmab B.V. | Antibody variant combinations and uses thereof |
JP7183143B2 (en) | 2019-12-23 | 2022-12-05 | 日立Astemo株式会社 | engine controller |
EP4084821A4 (en) | 2020-01-03 | 2024-04-24 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
BR112022013553A2 (en) | 2020-01-16 | 2022-09-06 | Genmab As | PHARMACEUTICAL COMPOSITION, ANTIBODY, AND METHOD TO TREAT A DISEASE |
WO2021155916A1 (en) | 2020-02-04 | 2021-08-12 | BioNTech SE | Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137 |
TW202200624A (en) | 2020-03-18 | 2022-01-01 | 丹麥商珍美寶股份有限公司 | Antibodies |
US11707487B2 (en) | 2020-04-13 | 2023-07-25 | Affyimmune Therapeutics, Inc. | EpCAM antibody and CAR-T cells |
WO2021217085A1 (en) | 2020-04-24 | 2021-10-28 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
CN115667532A (en) * | 2020-06-02 | 2023-01-31 | 百奥赛图(北京)医药科技股份有限公司 | Genetically modified non-human animals with a common light chain immunoglobulin locus |
US20230293680A1 (en) | 2020-07-23 | 2023-09-21 | Genmab B.V. | A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma |
AU2021322046A1 (en) | 2020-08-06 | 2023-02-02 | BioNTech SE | Binding agents for coronavirus S protein |
AU2021333779A1 (en) | 2020-08-26 | 2023-04-13 | Marengo Therapeutics, Inc. | Methods of detecting TRBC1 or TRBC2 |
AU2021331076A1 (en) | 2020-08-26 | 2023-04-06 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
CN116249718A (en) | 2020-08-26 | 2023-06-09 | 马伦戈治疗公司 | Multifunctional molecules binding to calreticulin and uses thereof |
MX2023002545A (en) | 2020-09-10 | 2023-03-14 | Genmab As | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma. |
MX2023002546A (en) | 2020-09-10 | 2023-03-14 | Genmab As | Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia. |
EP4221742A1 (en) | 2020-10-02 | 2023-08-09 | Genmab A/S | Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3 |
EP4305056A1 (en) | 2021-03-12 | 2024-01-17 | Genmab A/S | Non-activating antibody variants |
GB2623199A (en) | 2021-04-08 | 2024-04-10 | Marengo Therapeutics Inc | Multifunctional molecules binding to TCR and uses thereof |
KR20240004949A (en) | 2021-05-07 | 2024-01-11 | 젠맵 에이/에스 | Pharmaceutical composition comprising a bispecific antibody that binds B7H4 and CD3 |
JP2024523438A (en) | 2021-06-21 | 2024-06-28 | ジェンマブ エー/エス | Combination Dosing Regimen of CD137-Binding Agent and PD-L1-Binding Agent |
TW202328192A (en) | 2021-09-06 | 2023-07-16 | 荷蘭商珍美寶公司 | Antibodies capable of binding to cd27, variants thereof and uses thereof |
PE20241175A1 (en) | 2021-10-08 | 2024-05-28 | Genmab As | ANTIBODIES BINDING TO CD30 AND CD3 |
WO2023174521A1 (en) | 2022-03-15 | 2023-09-21 | Genmab A/S | Binding agents binding to epcam and cd137 |
WO2023218046A1 (en) | 2022-05-12 | 2023-11-16 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
WO2023218051A1 (en) | 2022-05-12 | 2023-11-16 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
WO2024013723A1 (en) | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
WO2024094660A1 (en) | 2022-10-31 | 2024-05-10 | Genmab A/S | Cd38 antibodies and uses thereof |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0120694A2 (en) | 1983-03-25 | 1984-10-03 | Celltech Limited | Processes for the production of multichain polypeptides or proteins |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0314161A1 (en) | 1987-10-28 | 1989-05-03 | Bristol-Myers Squibb Company | Human immunoglobulines produced by recombinant DNA techniques |
EP0402029A2 (en) | 1989-06-08 | 1990-12-12 | The Wistar Institute | Monoclonal antibodies for post exposure treatment of rabies |
EP0445625A1 (en) | 1990-03-03 | 1991-09-11 | BEHRINGWERKE Aktiengesellschaft | Human monoclonal antibody against rabies virus, its production and use |
EP0481790A2 (en) | 1990-10-17 | 1992-04-22 | The Wellcome Foundation Limited | Antibody production |
WO1995020401A1 (en) | 1994-01-31 | 1995-08-03 | Trustees Of Boston University | Polyclonal antibody libraries |
EP0724639A1 (en) | 1991-03-29 | 1996-08-07 | Genentech, Inc. | Methods for selection of recombinant host cells expressing high levels of a desired protein |
US5733779A (en) | 1992-11-13 | 1998-03-31 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
WO1998015833A1 (en) | 1996-10-08 | 1998-04-16 | Universiteit Utrecht | Methods and means for selecting peptides and proteins having specific affinity for a target |
US5772997A (en) | 1988-01-12 | 1998-06-30 | Genentech, Inc. | Monoclonal antibodies directed to the HER2 receptor |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
WO1998041645A1 (en) | 1997-03-14 | 1998-09-24 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
WO2000063403A2 (en) | 1999-04-15 | 2000-10-26 | Crucell Holland B.V. | Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein |
WO2001032901A1 (en) | 1999-11-01 | 2001-05-10 | Chiron Corporation | Expression vectors, transfection systems, and method of use thereof |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
WO2002018948A2 (en) | 2000-08-28 | 2002-03-07 | Crucell Holland B.V. | Differentially expressed epitopes and uses thereof |
WO2003004704A2 (en) | 2001-07-04 | 2003-01-16 | Chromagenics B.V. | Method of selecting dna sequence with transcription modulating activity using a vector comprising an element with a gene transcription repressing activity |
Family Cites Families (191)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5180502A (en) | 1974-12-28 | 1976-07-14 | Seirei Ind | TSUMEJIKUFURIKAESHIKISEIGYAKUTENKONSOCHI |
US4634665A (en) * | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) * | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4599311A (en) * | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
AU600885B2 (en) | 1984-05-25 | 1990-08-30 | Zymogenetics Inc. | Stable DNA constructs |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4868103A (en) * | 1986-02-19 | 1989-09-19 | Enzo Biochem, Inc. | Analyte detection by means of energy transfer |
ATE87659T1 (en) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | BINDING MOLECULES WITH SINGLE POLYPEPTIDE CHAIN. |
US4801687A (en) | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
US4937190A (en) * | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
US5202238A (en) * | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
ES2035317T5 (en) * | 1987-11-09 | 1998-03-16 | Becton Dickinson Co | METHOD FOR ANALYZING HEMATOPOYETIC CELLS IN A SAMPLE. |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
EP1997891A1 (en) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
GB8909218D0 (en) | 1989-04-22 | 1989-06-07 | Medical Res Council | Improvements in or relating to enhancers |
WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
US5030002A (en) | 1989-08-11 | 1991-07-09 | Becton, Dickinson And Company | Method and apparatus for sorting particles with a moving catcher tube |
US5959177A (en) † | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5151504A (en) | 1989-11-17 | 1992-09-29 | E. R. Squibb & Sons, Inc. | Method for purification of monoclonal antibodies |
RU2095414C1 (en) † | 1989-12-01 | 1997-11-10 | Джен Фарминг Ойроп БВ | Transgene for preparing the recombinant polypeptide in transgenic cow milk, a method of obtaining the transgenic cow (variants), milk from transgenic cow, food composition |
WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
DK0585287T3 (en) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Process for producing specific binding pair elements |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
JPH0568599A (en) | 1990-07-31 | 1993-03-23 | Wistar Inst | Genetic engineering-made antibody |
IE76732B1 (en) * | 1990-08-07 | 1997-11-05 | Becton Dickinson Co | One step test for absolute counts |
US6255458B1 (en) † | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
ES2287206T3 (en) | 1991-03-01 | 2007-12-16 | Dyax Corporation | PROCESS FOR THE DEVELOPMENT OF MINI-PROTEINS OF UNION. |
DK1471142T3 (en) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimeric receptor libraries using phagemids |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
DE4122599C2 (en) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid for screening antibodies |
ES2199216T3 (en) | 1991-07-15 | 2004-02-16 | The Wellcome Foundation Limited | ANTIBODY PRODUCTION. |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0552108B1 (en) * | 1992-01-17 | 1999-11-10 | Lakowicz, Joseph R. | Energy transfer phase-modulation fluoro-immunoassay |
US5667988A (en) * | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
US7067284B1 (en) * | 1992-01-27 | 2006-06-27 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
SE9201984D0 (en) * | 1992-06-29 | 1992-06-29 | Pharmacia Biosensor Ab | IMPROVEMENT IN OPTICAL ASSAYS |
AU687010B2 (en) * | 1992-07-17 | 1998-02-19 | Dana-Farber Cancer Institute | Method of intracellular binding of target molecules |
JPH07509137A (en) | 1992-07-24 | 1995-10-12 | セル ジェネシス,インク. | Production of xenoantibodies |
DE4228162C1 (en) | 1992-08-25 | 1994-01-13 | Rajewsky Klaus Dr | Method for replacing homologous gene segments from mammals in the germline of non-human mammals |
EP1167384B1 (en) | 1992-10-28 | 2006-12-13 | Genentech, Inc. | HVEGF Receptor as Vascular endothelial cell growth factor antagonists |
WO1994023046A1 (en) | 1993-04-07 | 1994-10-13 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Dna sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells |
US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
CA2168202A1 (en) | 1993-07-30 | 1995-03-16 | Joseph Dougherty | Efficient gene transfer into primary lymphocytes |
US5693506A (en) † | 1993-11-16 | 1997-12-02 | The Regents Of The University Of California | Process for protein production in plants |
US5827690A (en) † | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
EP0739412B1 (en) † | 1993-12-23 | 2002-02-27 | Infigen, Inc. | ungulate EMBRYONIC STEM CELLS AS NUCLEAR DONORS AND NUCLEAR TRANSFER TECHNIQUES TO PRODUCE CHIMERIC AND TRANSGENIC ANIMALS |
FR2717187B1 (en) | 1994-03-10 | 1996-05-31 | Transgene Sa | Combined use of two expression cassettes for the production of a protein of interest. |
US6080560A (en) † | 1994-07-25 | 2000-06-27 | Monsanto Company | Method for producing antibodies in plant cells |
JPH08116978A (en) | 1994-10-18 | 1996-05-14 | Nisshinbo Ind Inc | Preparation of antibody fab library |
AU722668B2 (en) * | 1994-12-30 | 2000-08-10 | King's College London | Methods for producing immunoglobulins containing protection proteins in plants and their use |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US5885827A (en) | 1996-01-23 | 1999-03-23 | The Regents Of The Universtiy Of California | Eukaryotic high rate mutagenesis system |
US6300065B1 (en) | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
US6825396B2 (en) | 1996-06-12 | 2004-11-30 | Board Of Trustees Operating Michigan State University | Methods for tissue specific synthesis of protein in eggs of transgenic hens |
GB9621113D0 (en) | 1996-10-10 | 1996-11-27 | Univ Southampton | Transgenic fish |
JP2001505055A (en) | 1996-12-02 | 2001-04-17 | ウエイク・フオレスト・ユニバーシテイ | Inactivation of HIV co-receptors as a treatment for HIV infection |
JP4215172B2 (en) | 1996-12-03 | 2009-01-28 | アムジェン フレモント インク. | Transgenic mammal having human Ig locus comprising a plurality of V {lower H} and V {lower κ} regions, and antibodies produced therefrom |
EP0971946B1 (en) * | 1997-01-21 | 2006-07-05 | The General Hospital Corporation | Selection of proteins using rna-protein fusions |
WO1998039416A1 (en) † | 1997-03-06 | 1998-09-11 | Infigen, Inc. | Method of cloning animals |
US5830698A (en) * | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
US6080912A (en) | 1997-03-20 | 2000-06-27 | Wisconsin Alumni Research Foundation | Methods for creating transgenic animals |
CN1203922A (en) * | 1997-03-21 | 1999-01-06 | 三共株式会社 | Humanized anti-human fas antibody |
EP1787999B1 (en) | 1997-04-07 | 2010-08-04 | Genentech, Inc. | Anti-VEGF antibodies |
ATE299938T1 (en) | 1997-05-02 | 2005-08-15 | Genentech Inc | A METHOD FOR PRODUCING MULTI-SPECIFIC ANTIBODIES THAT POSSESS HETEROMULTIMER AND COMMON COMPONENTS |
US20020062010A1 (en) * | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US20030207346A1 (en) * | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
JP2002512624A (en) | 1997-05-21 | 2002-04-23 | バイオベーション リミテッド | Method for producing non-immunogenic protein |
GB2345063B (en) | 1997-09-23 | 2002-07-24 | Oxford Biomedica Ltd | Method |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
CN1203178C (en) | 1997-10-27 | 2005-05-25 | 尤尼利弗公司 | Multivalent antigen-binding proteins |
EP0968694B1 (en) | 1997-11-26 | 2004-05-06 | Mitsubishi Precision Co., Ltd. | Information guidance system |
US6074385A (en) | 1998-02-03 | 2000-06-13 | Kiefer Corp. | Hair follicle devitalization by induced heating of magnetically susceptible particles |
IL138579A0 (en) | 1998-03-30 | 2001-10-31 | Res Dev Foundation | Corticotropin releasing factor receptor 1-deficient mice |
US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
CN1241574A (en) * | 1998-07-02 | 2000-01-19 | 中国人民解放军第四军医大学 | Liver cancer-resisting monoclone antibody HAb25 and its single stranded antibody and bifunctional antibody |
GB9823930D0 (en) † | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
JP2002536968A (en) | 1999-01-29 | 2002-11-05 | イムクローン システムズ インコーポレイティド | Antibodies specific for KDR and uses thereof |
EP2067788B1 (en) | 1999-05-18 | 2015-07-22 | Dyax Corp. | Fab fragment libraries and methods for their use |
US6472147B1 (en) | 1999-05-25 | 2002-10-29 | The Scripps Research Institute | Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
PT1189641E (en) | 1999-06-25 | 2009-11-04 | Genentech Inc | Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies |
WO2001019394A2 (en) | 1999-09-15 | 2001-03-22 | Therapeutic Human Polyclonals, Inc. | Immunotherapy with substantially human polyclonal antibody preparations purified from genetically engineered birds |
US6180357B1 (en) | 1999-10-08 | 2001-01-30 | Arius Research, Inc. | Individualized patient-specific anti-cancer antibodies |
AU7676300A (en) * | 1999-10-12 | 2001-04-23 | Cambridge Antibody Technology Limited | Human anti-adipocyte monoclonal antibodies and their use |
GB9928787D0 (en) * | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
DE60033455T2 (en) | 1999-12-27 | 2007-11-29 | Crucell Holland B.V. | Human monoclonal antibody to Ep-CAM and its use in cancer therapy |
AU2001245358A1 (en) † | 2000-02-29 | 2001-09-12 | Auburn University | Production of antibodies in transgenic plastids |
JP2004506408A (en) | 2000-04-26 | 2004-03-04 | イルーシス セラポーティクス,インコーポレーテッド | Bispecific molecules and their uses |
US6890532B2 (en) | 2000-05-16 | 2005-05-10 | Thomas Jefferson University | Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods |
KR20080074231A (en) | 2000-06-29 | 2008-08-12 | 아보트 러보러터리즈 | Dual specificity antibodies and methods of making and using |
CN1334343A (en) * | 2000-07-14 | 2002-02-06 | 中国医学科学院肿瘤医院肿瘤研究所 | Antibody for suppressing tumor growth, its derivative and its application |
EP1188771A1 (en) | 2000-09-15 | 2002-03-20 | U-BISys B.V. | Libraries of human heavy chain variable fragments in a functional format |
US7737258B2 (en) | 2000-10-18 | 2010-06-15 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
DE60131456T2 (en) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | TRANCHROMOSOMAL TRANSGEN RODENTS FOR THE MANUFACTURE OF HUMAN ANTIBODIES |
FR2817875B1 (en) | 2000-12-07 | 2005-03-18 | Technopharm | PROCESS FOR THE PREPARATION OF A HUMAN MONOCLONAL ANTIBODY, FRAGMENTS THEREOF OR ANTIBODIES COMPRISING SUCH FRAGMENTS, THE ANTIBODIES THUS OBTAINED AND THEIR USE |
JP2004525624A (en) | 2001-01-25 | 2004-08-26 | エボルバ バイオテック アクティーゼルスカブ | Cell collection library |
WO2002074969A2 (en) | 2001-01-26 | 2002-09-26 | University Of Lausanne | Matrix attachment regions and methods for use thereof |
WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
JP2005508608A (en) | 2001-03-22 | 2005-04-07 | アボット ゲーエムベーハー ウント カンパニー カーゲー | Transgenic animals expressing antibodies specific to the gene of interest and uses thereof |
GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
US7595378B2 (en) * | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
US7247301B2 (en) * | 2001-06-13 | 2007-07-24 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
AU2002345421B2 (en) | 2001-06-15 | 2006-11-16 | Crucell Holland B.V. | Chimaeric phages |
DE60237282D1 (en) | 2001-06-28 | 2010-09-23 | Domantis Ltd | DOUBLE-SPECIFIC LIGAND AND ITS USE |
ATE557040T1 (en) | 2001-08-21 | 2012-05-15 | Univ Jefferson | RECOMBINANT ANTIBODIES AND COMPOSITIONS AND METHODS FOR THE PRODUCTION AND USE THEREOF |
US20030077739A1 (en) | 2001-08-27 | 2003-04-24 | Genentech, Inc. | System for antibody expression and assembly |
JP2005535282A (en) | 2001-11-16 | 2005-11-24 | アイデック ファーマシューティカルズ コーポレイション | Polycistronic expression of antibodies |
CA2468878A1 (en) | 2001-11-30 | 2003-06-05 | Crucell Holland B.V. | Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their productionor generation |
CA2468583C (en) | 2001-11-30 | 2012-05-01 | C. Roger Mackenzie | Self-assembling multimeric binding complexes derived from ab5 toxin family members |
US20050037427A1 (en) | 2001-12-10 | 2005-02-17 | Erwin Houtzager | Structure for presenting desired peptide sequences |
US20030215914A1 (en) | 2001-12-10 | 2003-11-20 | Erwin Houtzager | Structure for presenting desired peptide sequences |
US7244592B2 (en) * | 2002-03-07 | 2007-07-17 | Dyax Corp. | Ligand screening and discovery |
GB2387030A (en) | 2002-03-26 | 2003-10-01 | Thales Plc | Compensation of mutual coupling in array antenna systems |
JP4753578B2 (en) | 2002-06-03 | 2011-08-24 | ジェネンテック, インコーポレイテッド | Synthetic antibody phage library |
ITGE20020049A1 (en) | 2002-06-05 | 2003-12-05 | Ali Spa | PISTON DEVICE FOR THE DISPENSING OF DOSED QUANTITIES OF PASTY SUBSTANCES, SUCH AS ICE CREAM, APPLICABLE TO MACHINES FOR THEIR FA |
CA2489475C (en) | 2002-06-14 | 2011-03-29 | Chromagenics B.V. | A method for simultaneous production of multiple proteins; vectors and cells for use therein |
WO2003106674A2 (en) | 2002-06-14 | 2003-12-24 | Chromagenics B.V. | Means and methods for regulating gene expression |
AU2002368062A1 (en) | 2002-06-26 | 2004-01-19 | Imclone Systems Incorporated | Bispecific antibodies that bind to vegf receptors |
US20080241166A1 (en) | 2002-06-28 | 2008-10-02 | Domantis Limited | Ligands that bind a receptor |
WO2004007860A1 (en) | 2002-07-10 | 2004-01-22 | Agostino Di Trapani | Building block |
DK1523496T3 (en) | 2002-07-18 | 2011-10-17 | Merus B V | Recombinant preparation of mixture of antibodies |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
EA013225B1 (en) | 2003-01-07 | 2010-04-30 | Симфоген А/С | Method for manufacturing cell line producing recombinant polyclonal protein, method for manufacture of polyclonal protein, cell line producing recombinant polyclonal protein, library of vectors, cells population |
EP1439234A1 (en) | 2003-01-08 | 2004-07-21 | ARTEMIS Pharmaceuticals GmbH | Targeted transgenesis using the rosa26 locus |
ES2408582T3 (en) | 2003-05-30 | 2013-06-21 | Merus B.V. | Fab library for the preparation of a mixture of antibodies |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
CA2529001A1 (en) | 2003-06-10 | 2004-12-16 | Catchmabs B.V. | Binding peptides: methods for their generation and use |
WO2005012360A2 (en) | 2003-07-22 | 2005-02-10 | Crucell Holland B.V. | Binding molecules against sars-coronavirus and uses thereof |
JP4712724B2 (en) | 2003-12-23 | 2011-06-29 | クルセル ホランド ベー ヴェー | Human binding molecule for CD1a |
WO2005068622A2 (en) | 2004-01-20 | 2005-07-28 | Merus B.V. | Mixtures of binding proteins |
EA010785B1 (en) | 2004-05-27 | 2008-10-30 | Круселл Холланд Б.В. | Binding molecules capable of neutralizing rabies virus and uses thereof |
US7728114B2 (en) | 2004-06-03 | 2010-06-01 | Novimmune S.A. | Anti-CD3 antibodies and methods of use thereof |
WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
JP4487068B2 (en) | 2004-10-12 | 2010-06-23 | 国立大学法人 岡山大学 | Method for producing mutant protein by controlling gene mutation function of cell |
EP2279749B1 (en) | 2004-10-12 | 2015-06-10 | Crucell Holland B.V. | Binding molecules for detection of aml |
WO2006051091A1 (en) | 2004-11-11 | 2006-05-18 | Crucell Holland B.V. | Compositions against sars-coronavirus and uses thereof |
JP5620626B2 (en) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | Polypeptide production method by association control |
CA2604440A1 (en) | 2005-04-29 | 2006-11-09 | Inserm (Institut De La Sante Et De La Recherche Medicale) | Transgenic animals and methods of making recombinant antibodies |
EP1879921B1 (en) | 2005-05-12 | 2011-04-27 | Crucell Holland B.V. | Host cell specific binding molecules capable of neutralizing viruses and uses thereof |
US20090130652A1 (en) | 2005-06-23 | 2009-05-21 | Crucell Holland B.V. | Optimization of West Nile Virus Antibodies |
US8642513B2 (en) | 2005-09-15 | 2014-02-04 | Crucell Holland B.V. | Method for preparing immunoglobulin libraries |
PL1999154T3 (en) | 2006-03-24 | 2013-03-29 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
WO2007117410A2 (en) | 2006-03-31 | 2007-10-18 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
ES2398076T3 (en) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies against the human IL-6 receptor |
WO2007141274A2 (en) | 2006-06-06 | 2007-12-13 | Crucell Holland B.V. | Human binding molecules having killing activity against staphylococci and uses thereof |
KR20200058579A (en) | 2006-06-06 | 2020-05-27 | 얀센 백신스 앤드 프리벤션 비.브이. | Human binding molecules having killing activity against enterococci and uses thereof |
WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
EP2059532B1 (en) | 2006-09-07 | 2012-12-26 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
MX2009003393A (en) | 2006-10-02 | 2009-05-11 | Regeneron Pharma | High affinity human antibodies to human il-4 receptor. |
US8290739B2 (en) | 2006-10-20 | 2012-10-16 | Amfit, Inc. | Method for determining relative mobility of regions of an object |
NO347649B1 (en) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Human antibody or antibody fragment that specifically binds human delta-like ligand 4 (hDII4), nucleic acid molecule that codes for such and vector and host-vector systems, as well as method for production, composition and use. |
WO2008119353A1 (en) | 2007-03-29 | 2008-10-09 | Genmab A/S | Bispecific antibodies and methods for production thereof |
ITMI20071522A1 (en) | 2007-07-27 | 2009-01-28 | Areta Internat S R L | IDIOTYPIC VACCINE |
EP3124497B1 (en) | 2007-09-14 | 2020-04-15 | Adimab, LLC | Rationally designed, synthetic antibody libraries and uses therefor |
US8536310B2 (en) | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
HUE028536T2 (en) | 2008-01-07 | 2016-12-28 | Amgen Inc | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
CA2715043C (en) | 2008-02-05 | 2021-02-16 | Zymeworks Inc. | Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics |
EP3456190B1 (en) | 2008-06-27 | 2021-11-24 | Merus N.V. | Antibody producing transgenic murine animal |
WO2010084197A1 (en) | 2009-01-26 | 2010-07-29 | Genmab A/S | Methods for producing mixtures of antibodies |
ES2708124T3 (en) | 2009-04-27 | 2019-04-08 | Oncomed Pharm Inc | Procedure for preparing heteromultimeric molecules |
NZ596032A (en) | 2009-05-11 | 2013-09-27 | Crucell Holland Bv | Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof |
MY164121A (en) | 2009-06-26 | 2017-11-30 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
RU2724663C2 (en) | 2010-02-08 | 2020-06-25 | Ридженерон Фармасьютикалз, Инк. | Mouse with common light chain |
US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
EP2603526A1 (en) | 2010-08-13 | 2013-06-19 | Medimmune Limited | Monomeric polypeptides comprising variant fc regions and methods of use |
CA2808482C (en) | 2010-08-16 | 2021-10-26 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
EP2635607B1 (en) | 2010-11-05 | 2019-09-04 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
DE14176593T1 (en) | 2011-02-25 | 2015-03-05 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
EA028804B1 (en) | 2011-03-25 | 2018-01-31 | Гленмарк Фармасьютикалс С.А. | Hetero-dimeric immunoglobulins |
JP2013004215A (en) | 2011-06-14 | 2013-01-07 | Hitachi Ltd | Lithium-ion secondary battery |
JP2016184957A (en) | 2012-02-09 | 2016-10-20 | シャープ株式会社 | Information processing device and information processing method |
EP3594232A1 (en) | 2012-04-20 | 2020-01-15 | Merus N.V. | Methods and means for the production of ig-like molecules |
EP3470431A1 (en) | 2012-09-27 | 2019-04-17 | Merus N.V. | Bispecific igg antibodies as t cell engagers |
-
2003
- 2003-07-15 DK DK03764997.7T patent/DK1523496T3/en active
- 2003-07-15 WO PCT/EP2003/007690 patent/WO2004009618A2/en active Application Filing
- 2003-07-15 CA CA2872136A patent/CA2872136C/en not_active Expired - Lifetime
- 2003-07-15 ES ES03764997T patent/ES2368733T3/en not_active Expired - Lifetime
- 2003-07-15 ES ES10186063T patent/ES2442615T5/en not_active Expired - Lifetime
- 2003-07-15 AT AT03764997T patent/ATE514717T1/en active
- 2003-07-15 AU AU2003250074A patent/AU2003250074B2/en not_active Expired
- 2003-07-15 PT PT03764997T patent/PT1523496E/en unknown
- 2003-07-15 EP EP03764997A patent/EP1523496B1/en not_active Expired - Lifetime
- 2003-07-15 DK DK10186063.3T patent/DK2314629T4/en active
- 2003-07-15 NZ NZ537277A patent/NZ537277A/en not_active IP Right Cessation
- 2003-07-15 CA CA2965865A patent/CA2965865C/en not_active Expired - Lifetime
- 2003-07-15 CN CN200910132819.2A patent/CN101537180B/en not_active Expired - Lifetime
- 2003-07-15 JP JP2004522465A patent/JP4836451B2/en not_active Expired - Lifetime
- 2003-07-15 CN CN201610051739.4A patent/CN105884893A/en active Pending
- 2003-07-15 CN CNB038170779A patent/CN100480260C/en not_active Expired - Lifetime
- 2003-07-15 CA CA2492377A patent/CA2492377C/en not_active Expired - Lifetime
- 2003-07-15 SI SI200332045T patent/SI1523496T1/en unknown
- 2003-07-15 EP EP10186063.3A patent/EP2314629B2/en not_active Expired - Lifetime
- 2003-07-15 PT PT101860633T patent/PT2314629E/en unknown
-
2005
- 2005-01-18 US US11/039,767 patent/US7262028B2/en not_active Expired - Lifetime
- 2005-04-22 HK HK05103474.4A patent/HK1070902A1/en not_active IP Right Cessation
-
2006
- 2006-11-06 US US11/593,279 patent/US7429486B2/en not_active Expired - Lifetime
- 2006-11-06 US US11/593,280 patent/US7932360B2/en active Active
-
2008
- 2008-07-29 US US12/221,021 patent/US7927834B2/en not_active Expired - Lifetime
-
2010
- 2010-12-02 AU AU2010249150A patent/AU2010249150B9/en not_active Expired
-
2011
- 2011-03-04 US US12/932,719 patent/US9303081B2/en not_active Expired - Lifetime
- 2011-05-30 JP JP2011121054A patent/JP6049239B2/en not_active Expired - Lifetime
- 2011-09-23 CY CY20111100924T patent/CY1111886T1/en unknown
-
2013
- 2013-03-12 US US13/795,637 patent/US20130243773A1/en not_active Abandoned
-
2014
- 2014-07-03 JP JP2014137927A patent/JP6166693B2/en not_active Expired - Fee Related
-
2016
- 2016-04-04 US US15/090,505 patent/US10934571B2/en not_active Expired - Lifetime
- 2016-09-21 JP JP2016184803A patent/JP2016220696A/en active Pending
-
2017
- 2017-12-14 US US15/842,303 patent/US20180094289A1/en not_active Abandoned
- 2017-12-27 US US15/855,258 patent/US20180112247A1/en not_active Abandoned
Patent Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0120694A2 (en) | 1983-03-25 | 1984-10-03 | Celltech Limited | Processes for the production of multichain polypeptides or proteins |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0314161A1 (en) | 1987-10-28 | 1989-05-03 | Bristol-Myers Squibb Company | Human immunoglobulines produced by recombinant DNA techniques |
US5772997A (en) | 1988-01-12 | 1998-06-30 | Genentech, Inc. | Monoclonal antibodies directed to the HER2 receptor |
EP0402029A2 (en) | 1989-06-08 | 1990-12-12 | The Wistar Institute | Monoclonal antibodies for post exposure treatment of rabies |
EP0445625A1 (en) | 1990-03-03 | 1991-09-11 | BEHRINGWERKE Aktiengesellschaft | Human monoclonal antibody against rabies virus, its production and use |
EP0481790A2 (en) | 1990-10-17 | 1992-04-22 | The Wellcome Foundation Limited | Antibody production |
EP0724639A1 (en) | 1991-03-29 | 1996-08-07 | Genentech, Inc. | Methods for selection of recombinant host cells expressing high levels of a desired protein |
US5733779A (en) | 1992-11-13 | 1998-03-31 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
WO1995020401A1 (en) | 1994-01-31 | 1995-08-03 | Trustees Of Boston University | Polyclonal antibody libraries |
US6335163B1 (en) | 1994-01-31 | 2002-01-01 | The Trustees Of Boston University | Polyclonal antibody libraries |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
WO1998015833A1 (en) | 1996-10-08 | 1998-04-16 | Universiteit Utrecht | Methods and means for selecting peptides and proteins having specific affinity for a target |
WO1998041645A1 (en) | 1997-03-14 | 1998-09-24 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
WO2000063403A2 (en) | 1999-04-15 | 2000-10-26 | Crucell Holland B.V. | Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein |
WO2001032901A1 (en) | 1999-11-01 | 2001-05-10 | Chiron Corporation | Expression vectors, transfection systems, and method of use thereof |
WO2002018948A2 (en) | 2000-08-28 | 2002-03-07 | Crucell Holland B.V. | Differentially expressed epitopes and uses thereof |
WO2003004704A2 (en) | 2001-07-04 | 2003-01-16 | Chromagenics B.V. | Method of selecting dna sequence with transcription modulating activity using a vector comprising an element with a gene transcription repressing activity |
Non-Patent Citations (7)
Title |
---|
"Antibodies: A Laboratory Manual", 1988 |
"Current Protocols in Molecular Biology", 1987 |
"Methods in Enzymology", ACADEMIC PRESS, INC. |
"PCR2: A Practical Approach", 1995 |
A. PLÜCKTHUN ET AL.: "Adv. Prot. Chem.", vol. 55, 2001, ACADEMIC PRESS, article "In vitro selection and evolution of proteins", pages: 367 - 403 |
C. SCHAFFITZEL ET AL.: "Protein-Protein Interactions. A Molecular Cloning Manual", COLD SPRING HARBOR, article "In vitro selection and evolution of protein-ligand interactions by ribosome display" |
SAMBROOK; FRITSCH; MANIATIS: "Molecular Cloning: A Laboratory Manual", 1989 |
Cited By (289)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10934571B2 (en) | 2002-07-18 | 2021-03-02 | Merus N.V. | Recombinant production of mixtures of antibodies |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
US9163232B2 (en) | 2003-01-07 | 2015-10-20 | Symphogen A/S | Method for manufacturing recombinant polyclonal proteins |
US20060159673A1 (en) * | 2003-01-21 | 2006-07-20 | Tetsuo Kojima | Methods of screening light chain of antibody |
US8337841B2 (en) * | 2003-01-21 | 2012-12-25 | Chugai Seiyaku Kabushiki Kaisha | Methods of screening for antibody light chains |
US10605808B2 (en) | 2003-05-30 | 2020-03-31 | Merus N.V. | Antibody producing non-human animals |
EP1639009B1 (en) * | 2003-05-30 | 2013-02-27 | Merus B.V. | Fab library for the preparation of a mixture of antibodies |
US10670599B2 (en) | 2003-05-30 | 2020-06-02 | Merus N.V. | Method for selecting a single cell expressing a heterogeneous combination of antibodies |
WO2004106375A1 (en) | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
US9738701B2 (en) | 2003-05-30 | 2017-08-22 | Merus N.V. | Method for selecting a single cell expressing a heterogeneous combination of antibodies |
EP1508576A1 (en) * | 2003-08-20 | 2005-02-23 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
US8268756B2 (en) | 2004-01-20 | 2012-09-18 | Merus B.V. | Mixture of binding proteins |
US9012371B2 (en) | 2004-01-20 | 2015-04-21 | Merus B.V. | Mixtures of binding proteins |
US7740852B2 (en) | 2004-05-27 | 2010-06-22 | Crucell Holland B.V. | Binding molecules capable of neutralizing rabies virus and uses thereof |
US9005624B2 (en) | 2004-05-27 | 2015-04-14 | Crucell Holland B.V. | Binding molecules capable of neutralizing rabies virus and uses thereof |
AU2011218688B2 (en) * | 2004-05-27 | 2013-01-10 | Crucell Holland B.V. | Binding molecules capable of neutralizing rabies virus and uses thereof |
EA010785B1 (en) * | 2004-05-27 | 2008-10-30 | Круселл Холланд Б.В. | Binding molecules capable of neutralizing rabies virus and uses thereof |
US8148497B2 (en) | 2004-05-27 | 2012-04-03 | Crucell Holland B.V. | Binding molecules capable of neutralizing rabies virus and uses thereof |
US7579446B2 (en) | 2004-05-27 | 2009-08-25 | Crucell Holland B.V. | Binding molecules capable of neutralizing rabies virus and uses thereof |
EP2314620A1 (en) * | 2004-05-27 | 2011-04-27 | Crucell Holland B.V. | Binding molecules capable of neutralizing rabies virus and uses thereof |
WO2005118644A3 (en) * | 2004-05-27 | 2006-03-09 | Crucell Holland Bv | Binding molecules capable of neutralizing rabies virus and uses thereof |
US7973134B2 (en) | 2004-07-07 | 2011-07-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways |
US9029091B2 (en) | 2004-07-20 | 2015-05-12 | Symphogen A/S | Procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line |
US8198415B2 (en) | 2004-07-20 | 2012-06-12 | Symphogen A/S | Anti-rhesus D recombinant polyclonal antibody |
EP1787126B1 (en) * | 2004-07-20 | 2009-09-23 | Symphogen A/S | A procedure for characterization of a polyclonal cell line |
US8288109B2 (en) | 2004-07-20 | 2012-10-16 | Symphogen A/S | Procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line |
EP2053408A3 (en) * | 2004-07-20 | 2009-07-29 | Symphogen A/S | A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line |
EP2053408A2 (en) | 2004-07-20 | 2009-04-29 | Symphogen A/S | A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line |
JP2008506960A (en) * | 2004-07-20 | 2008-03-06 | シムフォゲン・アクティーゼルスカブ | Method for structural characterization of recombinant polyclonal proteins or polyclonal cell lines |
US7935790B2 (en) | 2004-10-04 | 2011-05-03 | Cell Singaling Technology, Inc. | Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways |
US7807789B2 (en) | 2004-12-21 | 2010-10-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in EGFR-signaling pathways |
US10011858B2 (en) | 2005-03-31 | 2018-07-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
US11168344B2 (en) | 2005-03-31 | 2021-11-09 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
EP2824183A1 (en) * | 2005-04-08 | 2015-01-14 | Chugai Seiyaku Kabushiki Kaisha | Antibody substituting for function of blood coagulation factor VIII |
US10576149B2 (en) | 2005-04-26 | 2020-03-03 | Lindis Biotech Gmbh | Combination of the application of antibodies for immunostimulation together with glucocorticoids |
US10071158B2 (en) | 2005-04-26 | 2018-09-11 | Lindis Biotech Gmbh | Combination of the application of antibodies for immunostimulation together with glucocorticoids |
US7888480B2 (en) | 2005-08-31 | 2011-02-15 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
KR101507027B1 (en) * | 2005-10-21 | 2015-03-31 | 엘에프비 유에스에이, 인크. | Antibodies with enhanced antibody-dependent cellular cytotoxicity activity, methods of their production and use |
AU2012201010B2 (en) * | 2005-10-21 | 2015-01-22 | Genzyme Corporation | Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use |
CN101484470B (en) * | 2005-10-21 | 2014-07-23 | 阿伊沃生物制剂有限公司 | Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use |
EP2388273A1 (en) * | 2005-10-21 | 2011-11-23 | GTC Biotherapeutics, Inc. | Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use |
EP2388272A1 (en) * | 2005-10-21 | 2011-11-23 | GTC Biotherapeutics, Inc. | Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use |
WO2007048077A3 (en) * | 2005-10-21 | 2007-07-05 | Gtc Biotherapeutics Inc | Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use |
AU2006304886B2 (en) * | 2005-10-21 | 2012-04-12 | Genzyme Corporation | Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use |
US8936908B2 (en) * | 2005-11-16 | 2015-01-20 | Cevec Pharmaceuticals Gmbh | Method for the production of permanent human cell lines |
US9315773B2 (en) * | 2005-11-16 | 2016-04-19 | Cevec Pharmaceuticals Gmbh | Method for the production of permanent human cell lines |
US20070111312A1 (en) * | 2005-11-16 | 2007-05-17 | Cevec Pharmaceuticals Gmbh | Method for the production of permanent human cell lines |
US20150203813A1 (en) * | 2005-11-16 | 2015-07-23 | Cevec Pharmaceuticals Gmbh | Method for the production of permanent human cell lines |
WO2007065433A2 (en) | 2005-12-05 | 2007-06-14 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
EP2314619A1 (en) | 2005-12-05 | 2011-04-27 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
EP2453236A3 (en) * | 2006-02-17 | 2012-08-22 | Atsuo Sekiyama | Biological load indicator and method of measuring biological load |
EP2359834A1 (en) | 2006-03-15 | 2011-08-24 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
EP4316465A2 (en) | 2006-03-15 | 2024-02-07 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
EP3124029A1 (en) | 2006-03-15 | 2017-02-01 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
EP3167888A1 (en) | 2006-03-15 | 2017-05-17 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US10934344B2 (en) | 2006-03-31 | 2021-03-02 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
US7939636B2 (en) | 2006-08-11 | 2011-05-10 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in c-Src signaling pathways |
EP2913342A1 (en) | 2006-09-05 | 2015-09-02 | Alexion Pharmaceuticals, Inc. | Compositions for use in the treatment of antibody mediated neuropathies |
EP3199549A1 (en) | 2006-09-05 | 2017-08-02 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
EP2380907A1 (en) | 2006-09-05 | 2011-10-26 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
US7959922B2 (en) | 2006-12-05 | 2011-06-14 | Crucell Holland B.V. | Liquid anti-rabies antibody formulations |
US8414896B2 (en) | 2007-03-01 | 2013-04-09 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
US7887805B2 (en) | 2007-03-01 | 2011-02-15 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
EP1972639A2 (en) | 2007-03-07 | 2008-09-24 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
EP1975184A2 (en) | 2007-03-26 | 2008-10-01 | Albrecht Moritz | Serine or threonine phosphorylation sites |
EP2145902A2 (en) | 2007-04-19 | 2010-01-20 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
EP1983002A2 (en) | 2007-04-19 | 2008-10-22 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
EP1983003A2 (en) | 2007-04-19 | 2008-10-22 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
US7977462B2 (en) | 2007-04-19 | 2011-07-12 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
EP2123679A2 (en) | 2007-05-01 | 2009-11-25 | Peter Hornbeck | Tyrosine phosphorylation sites |
WO2009002380A2 (en) * | 2007-06-26 | 2008-12-31 | The Trustees Of The University Of Pennsylvania | Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies |
WO2009002380A3 (en) * | 2007-06-26 | 2009-02-19 | Univ Pennsylvania | Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies |
US8846867B2 (en) | 2007-06-26 | 2014-09-30 | The Trustees Of The University Of Pennsylvania | Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies |
US11248053B2 (en) | 2007-09-26 | 2022-02-15 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US9828429B2 (en) | 2007-09-26 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
EP3741851A1 (en) | 2007-10-18 | 2020-11-25 | Cell Signaling Technology, Inc. | Translocation and mutant ros kinase in human non-small cell lung carcinoma |
EP3072963A1 (en) | 2007-10-18 | 2016-09-28 | Cell Signaling Technology, Inc. | Translocation and mutant ros kinase in human non-small cell lung carcinoma |
EP2062920A2 (en) | 2007-11-21 | 2009-05-27 | Peter Hornbeck | Protein phosphorylation by basophilic serine/threonine kinases in insulin signalling pathways |
EP3023502A1 (en) | 2008-04-10 | 2016-05-25 | Cell Signaling Technology, Inc. | Compositions and methods for detecting egfr mutations in cancer |
WO2009129814A1 (en) * | 2008-04-23 | 2009-10-29 | Symphogen A/S | Methods for manufacturing a polyclonal protein |
EP3456190B1 (en) | 2008-06-27 | 2021-11-24 | Merus N.V. | Antibody producing transgenic murine animal |
US11237165B2 (en) | 2008-06-27 | 2022-02-01 | Merus N.V. | Antibody producing non-human animals |
US11559049B2 (en) | 2008-06-27 | 2023-01-24 | Merus N.V. | Antibody producing non-human animals |
US9951124B2 (en) | 2008-06-27 | 2018-04-24 | Merus N.V. | Antibody producing non-human mammals |
US9944695B2 (en) | 2008-06-27 | 2018-04-17 | Merus N.V. | Antibody producing non-human mammals |
JP2011525808A (en) * | 2008-06-27 | 2011-09-29 | メルス・ベー・フェー | Antibody-producing non-human mammal |
US11925174B2 (en) | 2008-06-27 | 2024-03-12 | Merus N.V. | Antibody producing non-human animals |
US11785924B2 (en) | 2008-06-27 | 2023-10-17 | Merus N.V. | Antibody producing non-human animals |
US9765133B2 (en) | 2008-06-27 | 2017-09-19 | Merus N.V. | Antibody producing non-human mammals |
US10966411B2 (en) | 2008-06-27 | 2021-04-06 | Merus N.V. | Antibody producing non-human mammals |
US8148088B2 (en) | 2008-07-18 | 2012-04-03 | Abgent | Regulation of autophagy pathway phosphorylation and uses thereof |
US8663640B2 (en) | 2008-08-29 | 2014-03-04 | Symphogen A/S | Methods using recombinant anti-epidermal growth factor receptor antibody compositions |
EP2159291A1 (en) | 2008-09-01 | 2010-03-03 | Agendia B.V. | Means and method for determining tumor cell percentage in a sample |
US8658371B2 (en) | 2008-09-01 | 2014-02-25 | Agendia B.V. | Means and method for determining tumor cell percentage in a sample |
WO2010084197A1 (en) * | 2009-01-26 | 2010-07-29 | Genmab A/S | Methods for producing mixtures of antibodies |
EP3266795A1 (en) | 2009-02-12 | 2018-01-10 | Cell Signaling Technology, Inc. | Method for detecting a fig-ros fusion polynucleotide |
WO2010093928A2 (en) | 2009-02-12 | 2010-08-19 | Cell Signaling Technology, Inc. | Mutant ros expression in human cancer |
EP2881402A1 (en) | 2009-02-12 | 2015-06-10 | Cell Signaling Technology, Inc. | Mutant ROS expression in human liver cancer |
US9914771B2 (en) | 2009-04-27 | 2018-03-13 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
EP2424567B1 (en) * | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
US9982013B2 (en) | 2009-06-26 | 2018-05-29 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
US11168111B2 (en) | 2009-06-26 | 2021-11-09 | Regeneran Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
US11564380B2 (en) | 2009-07-08 | 2023-01-31 | Kymab Limited | Animal models and therapeutic molecules |
US11606941B2 (en) | 2009-07-08 | 2023-03-21 | Kymab Limited | Animal models and therapeutic molecules |
US11812731B2 (en) | 2009-07-08 | 2023-11-14 | Kymab Ltd. | Animal models and therapeutic molecules |
US10584181B2 (en) | 2009-12-04 | 2020-03-10 | Genentech, Inc. | Methods of making and using multispecific antibody panels and antibody analog panels |
US10986820B2 (en) | 2010-02-08 | 2021-04-27 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
US10143186B2 (en) | 2010-02-08 | 2018-12-04 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
EP2505654B2 (en) † | 2010-02-08 | 2020-05-13 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
EP3095871A1 (en) * | 2010-02-08 | 2016-11-23 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
US9969814B2 (en) | 2010-02-08 | 2018-05-15 | Regeneron Pharmaceuticals, Inc. | Methods for making fully human bispecific antibodies using a common light chain |
US11026407B2 (en) | 2010-02-08 | 2021-06-08 | Regeneran Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
EP3540066A1 (en) * | 2010-02-08 | 2019-09-18 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US10412940B2 (en) | 2010-02-08 | 2019-09-17 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US10167344B2 (en) | 2010-02-08 | 2019-01-01 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
EP2505654B1 (en) | 2010-02-08 | 2016-08-24 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
EP2505654A1 (en) * | 2010-02-08 | 2012-10-03 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
EP2501817B1 (en) * | 2010-02-08 | 2015-08-26 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
RU2624027C2 (en) * | 2010-04-23 | 2017-06-30 | Дженентек, Инк. | Heteromultimeric proteins production |
EP2560683B1 (en) | 2010-04-23 | 2016-12-14 | F. Hoffmann-La Roche AG | Production of heteromultimeric proteins |
CN105001330A (en) * | 2010-04-23 | 2015-10-28 | 弗·哈夫曼-拉罗切有限公司 | Production of heteromultimeric proteins |
EP2560683B2 (en) † | 2010-04-23 | 2022-07-20 | F. Hoffmann-La Roche AG | Production of heteromultimeric proteins |
US9637557B2 (en) | 2010-04-23 | 2017-05-02 | Genentech, Inc. | Production of heteromultimeric proteins |
WO2011133886A3 (en) * | 2010-04-23 | 2011-12-22 | Genentech, Inc. | Production of heteromultimeric proteins |
WO2012019132A2 (en) | 2010-08-06 | 2012-02-09 | Cell Signaling Technology, Inc. | Anaplastic lymphoma kinase in kidney cancer |
US10450381B2 (en) | 2010-11-17 | 2019-10-22 | Chugai Seiyaku Kabushiki Kaisha | Methods of treatment that include the administration of bispecific antibodies |
WO2012122512A1 (en) | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Recombinant production of mixtures of single chain antibodies |
WO2012148873A3 (en) * | 2011-04-25 | 2013-02-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing antibodies having a common light chain |
RU2614859C2 (en) * | 2011-04-25 | 2017-03-29 | Регенерон Фармасьютикалс, Инк. | Animals different to human animal expressing antibodies with common light chain |
AU2012249953B2 (en) * | 2011-04-25 | 2016-01-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing antibodies having a common light chain |
CN103596424A (en) * | 2011-04-25 | 2014-02-19 | 瑞泽恩制药公司 | Non-human animals expressing antibodies having a common light chain |
EP2989893A1 (en) * | 2011-04-25 | 2016-03-02 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing antibodies having a common light chain |
EP3492918A1 (en) | 2011-05-23 | 2019-06-05 | Cell Signaling Technology, Inc. | Ros kinase in lung cancer |
WO2012162373A1 (en) | 2011-05-23 | 2012-11-29 | Cell Signaling Technology, Inc. | Ros kinase in lung cancer |
EP3182128A1 (en) | 2011-05-23 | 2017-06-21 | Cell Signaling Technology, Inc. | Ros kinase in lung cancer |
EP3572517A1 (en) * | 2011-08-05 | 2019-11-27 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
US11357217B2 (en) | 2011-08-05 | 2022-06-14 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
WO2013022782A1 (en) * | 2011-08-05 | 2013-02-14 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
RU2664232C2 (en) * | 2011-08-05 | 2018-08-15 | Регенерон Фармасьютикалз, Инк. | Humanised universal light chain mice |
US10130081B2 (en) | 2011-08-05 | 2018-11-20 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
EP3865581A1 (en) * | 2011-08-05 | 2021-08-18 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
EP3311661B1 (en) | 2011-09-19 | 2022-04-20 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US11051497B2 (en) | 2011-09-19 | 2021-07-06 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
EP2604625A1 (en) | 2011-09-26 | 2013-06-19 | Merus B.V. | Generation of binding molecules |
US9908946B2 (en) | 2011-09-26 | 2018-03-06 | Merus N.V. | Generation of binding molecules |
US11408095B2 (en) | 2011-09-26 | 2022-08-09 | Merus N.V. | Generation of binding molecules |
US9145588B2 (en) | 2011-09-26 | 2015-09-29 | Merus Biopharmaceuticals B.V. | Generation of binding molecules |
EP3263597A1 (en) | 2011-09-26 | 2018-01-03 | Merus N.V. | Generation of binding molecules |
EP4086282A1 (en) | 2011-09-26 | 2022-11-09 | Merus N.V. | Generation of binding molecules |
US10647781B2 (en) | 2011-09-26 | 2020-05-12 | Merus N.V. | Generation of binding molecules |
US10626189B2 (en) | 2011-10-11 | 2020-04-21 | Genentech, Inc. | Assembly of bispecific antibodies |
US11725065B2 (en) | 2011-10-11 | 2023-08-15 | Genentech, Inc. | Assembly of bispecific antibodies |
US9862778B2 (en) | 2011-10-11 | 2018-01-09 | Genentech, Inc. | Assembly of bispecific antibodies |
WO2013067054A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Antibodies and methods of treating cancer |
WO2013067060A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Anti-gpr49 antibodies |
WO2013067057A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Anti-gpr49 antibodies |
WO2013067055A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
US10196442B2 (en) | 2011-11-01 | 2019-02-05 | Bionomics Inc. | Methods of inhibiting growth of a colon cancer tumor in a subject by administering monoclonal antibodies to G protein-coupled receptor 49 (GPR49) |
US10598653B2 (en) | 2011-11-01 | 2020-03-24 | Bionomics Inc. | Methods of blocking cancer stem cell growth |
AU2016202488C1 (en) * | 2012-03-06 | 2018-10-18 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
AU2016202488B2 (en) * | 2012-03-06 | 2018-04-05 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
AU2013204140B2 (en) * | 2012-03-06 | 2016-01-28 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
US9301510B2 (en) | 2012-03-16 | 2016-04-05 | Regeneron Pharmaceuticals, Inc. | Mice that produce antigen-binding proteins with pH-dependent binding characteristics |
US9801362B2 (en) | 2012-03-16 | 2017-10-31 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing pH-sensitive immunoglobulin sequences |
US11224207B2 (en) | 2012-03-16 | 2022-01-18 | Regeneran Pharmaceuticals, Inc. | Non-human animals expressing pH-sensitive immunoglobulin sequences |
US11192947B2 (en) | 2012-03-16 | 2021-12-07 | Regeneran Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified non-human animals for generating same |
US9334334B2 (en) | 2012-03-16 | 2016-05-10 | Regeneron Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
US9648856B2 (en) | 2012-03-16 | 2017-05-16 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing pH-sensitive immunoglobulin sequences |
US9422370B2 (en) | 2012-03-16 | 2016-08-23 | Regeneron Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
US9332742B2 (en) | 2012-03-16 | 2016-05-10 | Regeneron Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
US11297811B2 (en) | 2012-03-28 | 2022-04-12 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
WO2013158859A1 (en) | 2012-04-18 | 2013-10-24 | Cell Signaling Technology, Inc. | Egfr and ros1 in cancer |
EP3336181A1 (en) | 2012-04-18 | 2018-06-20 | Cell Signaling Technology, Inc. | Egfr and ros1 in cancer |
WO2013157954A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
US9248182B2 (en) | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
US11926859B2 (en) | 2012-04-20 | 2024-03-12 | Merus N.V. | Methods and means for the production of Ig-like molecules |
WO2013157953A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
EA035344B1 (en) * | 2012-04-20 | 2020-05-29 | Мерюс Н.В. | Method for producing two antibodies from a single host cell |
US9358286B2 (en) | 2012-04-20 | 2016-06-07 | Merus B.V. | Methods and means for the production of IG-like molecules |
EP3594232A1 (en) | 2012-04-20 | 2020-01-15 | Merus N.V. | Methods and means for the production of ig-like molecules |
EP3594233A1 (en) | 2012-04-20 | 2020-01-15 | Merus N.V. | Methods and means for the production of ig-like molecules |
AU2018201325B2 (en) * | 2012-04-20 | 2020-02-06 | Merus N.V. | Methods and means for the production of Ig-like molecules |
US9758805B2 (en) | 2012-04-20 | 2017-09-12 | Merus N.V. | Methods and means for the production of Ig-like molecules |
US10752929B2 (en) | 2012-04-20 | 2020-08-25 | Merus N.V. | Methods and means for the production of ig-like molecules |
US9248181B2 (en) | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
US10337045B2 (en) | 2012-04-20 | 2019-07-02 | Merus N.V. | Methods and means for the production of Ig-like molecules |
AU2013249985B2 (en) * | 2012-04-20 | 2017-11-23 | Merus N.V. | Methods and means for the production of Ig-like molecules |
US10329596B2 (en) | 2012-04-20 | 2019-06-25 | Merus N.V. | Methods and means for the production of Ig-like molecules |
RU2787781C2 (en) * | 2012-08-03 | 2023-01-12 | Регенерон Фармасьютикалз, Инк. | Mice with humanized universal light chain |
WO2014044892A1 (en) * | 2012-09-21 | 2014-03-27 | Consejo Superior De Investigaciones Científicas (Csic) | Method for the production of complex repertoires of recombinant molecules |
US12060418B2 (en) | 2012-09-27 | 2024-08-13 | Merus N.V. | Bispecific IgG antibodies as T cell engagers |
US10358492B2 (en) | 2012-09-27 | 2019-07-23 | Merus N.V. | Bispecific IgG antibodies as T cell engagers |
EP3470431A1 (en) | 2012-09-27 | 2019-04-17 | Merus N.V. | Bispecific igg antibodies as t cell engagers |
WO2014051433A1 (en) * | 2012-09-27 | 2014-04-03 | Merus B.V. | BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS |
KR20150076178A (en) | 2012-09-27 | 2015-07-06 | 메뤼스 베.페. | Bispecific igg antibodies as t cell engagers |
EP2915819A4 (en) * | 2012-11-05 | 2016-07-20 | Zenyaku Kogyo Kk | Antibody and antibody composition production method |
US10344099B2 (en) | 2012-11-05 | 2019-07-09 | Zenyaku Kogyo Kabushikikaisha | Antibody and antibody composition production method |
CN105189755A (en) * | 2013-01-15 | 2015-12-23 | 加利福尼亚大学董事会 | Adenoviruses and their use |
NL2012424A (en) * | 2013-03-13 | 2014-09-16 | Regeneron Pharma | Common light chain mouse. |
WO2014160179A1 (en) * | 2013-03-13 | 2014-10-02 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
US11297810B2 (en) | 2013-03-18 | 2022-04-12 | Kymab Limited | Animal models and therapeutic molecules |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US11820810B2 (en) | 2013-05-02 | 2023-11-21 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
EP3699200A1 (en) | 2013-07-15 | 2020-08-26 | Cell Signaling Technology, Inc. | Anti-mucin 1 binding agents and uses thereof |
US11124576B2 (en) | 2013-09-27 | 2021-09-21 | Chungai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
US11399522B2 (en) | 2013-10-01 | 2022-08-02 | Kymab Limited | Animal models and therapeutic molecules |
US10822399B2 (en) | 2014-02-10 | 2020-11-03 | Igm Biosciences, Inc. | IgA multi-specific binding molecules |
US11279770B2 (en) | 2014-02-28 | 2022-03-22 | Merus N.V. | Antibody that binds ErbB-2 and ErbB-3 |
WO2015130172A1 (en) | 2014-02-28 | 2015-09-03 | Merus B.V. | Antibodies that bind egfr and erbb3 |
WO2015130173A1 (en) | 2014-02-28 | 2015-09-03 | Merus B.V. | Antibody that binds erbb-2 and erbb-3 |
US10844127B2 (en) | 2014-02-28 | 2020-11-24 | Merus N.V. | Antibodies that bind EGFR and ErbB3 |
US11820825B2 (en) | 2014-02-28 | 2023-11-21 | Merus N.V. | Methods of treating a subject having an EGFR-positive and/or ErbB-3-positive tumor |
EP3786186A1 (en) | 2014-02-28 | 2021-03-03 | Merus N.V. | Antibodies that bind egfr and erbb3 |
EP3470435A1 (en) | 2014-02-28 | 2019-04-17 | Merus N.V. | Antibody that binds erbb-2 and erbb-3 |
EP3805268A1 (en) | 2014-02-28 | 2021-04-14 | Merus N.V. | Antibody that binds erbb-2 and erbb-3 |
US10881085B2 (en) | 2014-03-21 | 2021-01-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
US10358500B2 (en) | 2014-04-04 | 2019-07-23 | Bionomics Inc. | Humanized antibodies that bind LGR5 |
US12030926B2 (en) | 2014-05-06 | 2024-07-09 | Genentech, Inc. | Production of heteromultimeric proteins using mammalian cells |
US10941190B2 (en) | 2014-05-06 | 2021-03-09 | Genentech, Inc. | Production of heteromultimeric proteins using mammalian cells |
US10385119B2 (en) | 2014-05-13 | 2019-08-20 | Trustees Of The University Of Pennsylvania | Compositions comprising AAV expressing dual antibody constructs and uses thereof |
IL248508B (en) * | 2014-05-13 | 2022-10-01 | Univ Pennsylvania | Compositions comprising aav expressing dual antibody constructs and uses thereof |
EP3142750A4 (en) * | 2014-05-13 | 2017-10-18 | The Trustees Of The University Of Pennsylvania | Compositions comprising aav expressing dual antibody constructs and uses thereof |
US10975140B2 (en) | 2014-05-13 | 2021-04-13 | The Trustees Of The University Of Pennsylvania | Compositions comprising AAV expressing dual antibody constructs and uses thereof |
US10138295B2 (en) | 2014-05-13 | 2018-11-27 | The Trustees Of The University Of Pennsylvania | Compositions comprising AAV expressing dual antibody constructs and uses thereof |
US10647758B2 (en) | 2014-05-13 | 2020-05-12 | The Trustees Of The University Of Pennsylvania | Compositions comprising AAV expressing dual antibody constructs and uses thereof |
IL248508B2 (en) * | 2014-05-13 | 2023-02-01 | Univ Pennsylvania | Compositions comprising aav expressing dual antibody constructs and uses thereof |
US11214623B2 (en) | 2014-09-26 | 2022-01-04 | Chugai Seiyaku Kabushiki Kaisha | Antibody capable of neutralizing substance having activity alternative to function of coagulation factor VIII (FVIII) |
US9975966B2 (en) | 2014-09-26 | 2018-05-22 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing theraputic agent |
US11150254B2 (en) | 2014-09-26 | 2021-10-19 | Chugai Seiyaku Kabushiki Kaisha | Method for measuring reactivity of FVIII |
US11001643B2 (en) | 2014-09-26 | 2021-05-11 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
WO2016054315A1 (en) | 2014-10-01 | 2016-04-07 | Medimmune, Llc | Method of conjugating a polypeptide |
US11396557B2 (en) | 2015-01-08 | 2022-07-26 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | Bispecific antibody or antibody mixture with common light chains |
US10808043B2 (en) | 2015-01-08 | 2020-10-20 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | Bispecific antibody or antibody mixture with common light chains |
US11111314B2 (en) | 2015-03-19 | 2021-09-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
EP3345928A1 (en) | 2015-07-10 | 2018-07-11 | Merus N.V. | Human cd3 binding antibody |
WO2017010874A1 (en) | 2015-07-10 | 2017-01-19 | Merus N.V. | Human cd3 binding antibody |
US10266593B2 (en) | 2015-07-10 | 2019-04-23 | Merus N.V. | Human CD3 binding antibody |
US11739148B2 (en) | 2015-07-10 | 2023-08-29 | Merus N.V. | Human CD3 binding antibody |
US9914777B2 (en) | 2015-07-10 | 2018-03-13 | Merus N.V. | Human CD3 binding antibody |
EP3757129A1 (en) | 2015-07-10 | 2020-12-30 | Merus N.V. | Human cd3 binding antibody |
EP3912998A2 (en) | 2015-10-23 | 2021-11-24 | Merus N.V. | Binding molecules that inhibit cancer growth |
US11939394B2 (en) | 2015-10-23 | 2024-03-26 | Merus N.V. | Binding molecules that inhibit cancer growth |
US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
WO2017132298A1 (en) | 2016-01-27 | 2017-08-03 | Medimmune, Llc | Methods for preparing antibodies with a defined glycosylation pattern |
US10745487B2 (en) | 2016-03-22 | 2020-08-18 | Bionomics Limited | Method of treating cancer by administering an anti-LGR5 monoclonal antibody |
US11352438B2 (en) | 2016-09-06 | 2022-06-07 | Chugai Seiyaku Kabushiki Kaisha | Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X |
US11685786B2 (en) | 2016-09-23 | 2023-06-27 | Merus N.V. | Binding molecules that bind CD137 and PD-L1 |
WO2018056821A1 (en) | 2016-09-23 | 2018-03-29 | Merus N.V. | Binding molecules that modulate a biological activity expressed by a cell |
EP4342912A2 (en) | 2016-09-23 | 2024-03-27 | Merus N.V. | Binding molecules that modulate a biological activity expressed by a cell |
WO2018098553A1 (en) * | 2016-12-01 | 2018-06-07 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Production of ricin antibodies in plant |
US11447789B2 (en) | 2016-12-01 | 2022-09-20 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Production in plants of ricin antibodies that bind to ricin B chain |
WO2018182421A1 (en) | 2017-03-31 | 2018-10-04 | Merus N.V. | Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour |
US11780925B2 (en) | 2017-03-31 | 2023-10-10 | Merus N.V. | ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene |
WO2018212656A1 (en) | 2017-05-17 | 2018-11-22 | Merus N.V. | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer |
EP4223319A2 (en) | 2017-05-26 | 2023-08-09 | MedImmune, LLC | Method and molecules |
WO2018229612A1 (en) | 2017-06-12 | 2018-12-20 | Novartis Ag | Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies |
WO2019009728A1 (en) | 2017-07-06 | 2019-01-10 | Merus N.V. | Antibodies that modulate a biological activity expressed by a cell |
US11732043B2 (en) | 2017-07-06 | 2023-08-22 | Merus N.V. | Antibodies that modulate a biological activity expressed by a cell |
WO2019009727A1 (en) | 2017-07-06 | 2019-01-10 | Merus N.V. | Bispecific anti pd1-anti tim3 antibodies |
WO2019009726A1 (en) | 2017-07-06 | 2019-01-10 | Merus N.V. | Binding molecules that modulate a biological activity expressed by a cell |
US11667714B2 (en) | 2017-07-06 | 2023-06-06 | Merus N.V. | Binding molecules that modulate a biological activity expressed by a cell |
US11753470B2 (en) | 2017-07-06 | 2023-09-12 | Merus N.V. | Bispecific anti PD1-anti TIM3 antibodies |
US11773170B2 (en) | 2017-08-09 | 2023-10-03 | Merus N.V. | Antibodies that bind EGFR and cMET |
US10759870B2 (en) | 2017-09-29 | 2020-09-01 | Chugai Seiyaku Kabushiki Kaisha | Multispecific antigen-binding molecules having blood coagulation factor VIII (FVIII) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ingredient |
WO2019156199A1 (en) | 2018-02-09 | 2019-08-15 | 小野薬品工業株式会社 | Bispecific antibody |
WO2019190327A2 (en) | 2018-03-30 | 2019-10-03 | Merus N.V. | Multivalent antibody |
US11952424B2 (en) | 2018-03-30 | 2024-04-09 | Merus N.V. | Multivalent antibody |
WO2019243626A1 (en) | 2018-06-22 | 2019-12-26 | Genmab A/S | Method for producing a controlled mixture of two or more different antibodies |
WO2020141974A1 (en) | 2018-12-31 | 2020-07-09 | Merus N.V. | Truncated multivalent multimers |
WO2020141973A1 (en) | 2018-12-31 | 2020-07-09 | Merus N.V. | Mixed binding domains |
WO2020204708A1 (en) | 2019-03-29 | 2020-10-08 | Merus N.V. | Cd3 binding molecules |
WO2020204152A1 (en) | 2019-04-04 | 2020-10-08 | 小野薬品工業株式会社 | Bispecific antibody |
WO2020226502A2 (en) | 2019-05-09 | 2020-11-12 | Merus N.V. | Variant domains for multimerizing proteins and separation thereof |
WO2021006199A1 (en) | 2019-07-05 | 2021-01-14 | 小野薬品工業株式会社 | Treatment of hematologic cancer with pd-1/cd3 dual specificity protein |
WO2021020416A1 (en) | 2019-07-30 | 2021-02-04 | 小野薬品工業株式会社 | Bispecific antibody |
EP3772518A1 (en) | 2019-08-07 | 2021-02-10 | Merus N.V. | Modified human variable domains |
WO2021025555A1 (en) | 2019-08-07 | 2021-02-11 | Merus N.V. | Modified human variable domains |
WO2021032966A1 (en) | 2019-08-21 | 2021-02-25 | Cambridge Enterprise Limited | Detection of a-beta oligomers |
EP4269433A2 (en) | 2019-12-24 | 2023-11-01 | Merus N.V. | Tgf-beta-rii binding proteins |
WO2021133167A1 (en) | 2019-12-24 | 2021-07-01 | Merus N.V. | Tgf-beta-rii binding proteins |
WO2021154073A1 (en) | 2020-01-29 | 2021-08-05 | Merus N.V. | Means and method for modulating immune cell engaging effects. |
WO2021235936A1 (en) | 2020-05-21 | 2021-11-25 | Merus N.V. | Methods and means for the production of ig-like molecules |
WO2022023559A1 (en) | 2020-07-31 | 2022-02-03 | Curevac Ag | Nucleic acid encoded antibody mixtures |
WO2022128546A1 (en) | 2020-12-16 | 2022-06-23 | Merus N.V. | Multispecific antibodies for the treatment of cancer |
WO2023146394A1 (en) | 2022-01-25 | 2023-08-03 | Merus N.V. | Combination therapy for the treatment of cancer |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10934571B2 (en) | Recombinant production of mixtures of antibodies | |
AU2017279594B2 (en) | Recombinant production of mixtures of antibodies | |
USRE47770E1 (en) | Recombinant production of mixtures of antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003764997 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 537277 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003250074 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2492377 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038170779 Country of ref document: CN Ref document number: 2004522465 Country of ref document: JP Ref document number: 11039767 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2003764997 Country of ref document: EP |